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Abstract
Introduction Survivors of critical illness suffer physical, psychological, and
social problems. The factors hindering recovery and the best rehabilitation
interventions remain illusive. Critical illness is associated with inflammation that
persists in some individuals and this might affect recovery. The hypotheses for the
thesis are 1. Persistent inflammation is common after critical illness. 2. Persistent
inflammation is associated with functional recovery. 3. Persistent inflammation is
associated with critical illness-induced viral reactivation. 4. Biomarkers may help
predict functional disability. The main part of the project was based on 197 of the
240 patients enrolled in the RECOVER trial who also consented to take part in an
inflammation sub study.
Systematic Review Aims: Prevalence of systemic inflammation in ICU
survivors; association of inflammation with physical recovery. 7433 references
identified. 208 full text articles were reviewed. 57 were eligible. 22 studies included
the relevant data. CRP at ICU discharge was elevated (>10mg/L) in most cases (70%
of mixed medical / surgical patients and 100% of severe sepsis survivors). Lower
CRP observed in trauma patients (23mg/L), VAP (46mg/L), > 6 days in ICU
(45mg/L), and medical ICU patients (36mg/L). CRP was higher in sepsis (107mg/L)
and surgical ICU patients (99mg/L). IL-6, TNF-a, and PCT were elevated in most
patients at ICU discharge. Ninety percent of acute COPD exacerbations admitted to
ICU had elevated CRP at hospital discharge and 43% general adult ICU patients
fulfilled SIRS criteria 3 days after ICU discharge. Anaemic ICU survivors had
elevated CRP and IL-6 at 6 months. There were no studies that measured both
inflammation and physical function after ICU discharge.
Association of inflammation with functional outcome after critical illness
Aims: Prevalence of inflammation in heterogeneous ICU cohort, association of CRP
with Rivermead Mobility Index (RMI) and other outcome measures at 3 months. At
ICU discharge, 173 patients (94%) had elevated serum CRP with a median
concentration of 27 (11-60) mg/L. At hospital discharge 169 patients (90%) had
elevated CRP with a median concentration of 21 (8-42) mg/L, At 3 months 72
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patients (59%) had elevated CRP with a median concentration of 4 (1-12) mg/L.
CRP was associated with RMI (p<0.01), and percentage of predicted handgrip
strength (HGS) (p=0.03) at 3 months.
CMV infection, systemic inflammation and the post ICU syndrome Aims:
Prevalence of active and latent CMV at ICU discharge; association between CMV,
inflammation, and recovery. 115 patients (62.8%) had latent CMV. 13 (11.4%) had
active CMV (11.4% of those with prior CMV and 7.2% of ICU survivors). Active
CMV associated with longer hospital length of stay (57 days v 28 days p=0.016),
poorer baseline physical function (HGS 12 v 16 p=0.032; RMI 1 v 2 p=0.018). At 3
months, patients with latent CMV infection had higher CRP (5.4 v 2.8mg/L p=0.06),
higher HNE (118 v 91.3 pg/mL p<0.00), lower TGF |3 (9.2 v 11.4 ng/mL p=0.01), and
were slower on 2 min timed up and go test (p=0.03). Active CMV infection at ICU
discharge was not associated with inflammation or physical function at 3 months.
Prediction of physical disability after ICU discharge Aims: To identify risk
factors for poor physical function; to derive a prognostic index to identify for poor
functional outcome. Age, Functional Comorbidity Index, Scottish Index of Multiple
Deprivation quintile, CMV IgG status, ventilator days, baseline RMI, physical
component of SGA, CRP, and SLPI met statistical criteria for consideration in the
multivariable models. 2 linear multivariable models with reasonable fit (R2=0.175;
0.193) were constructed. AUCs were 0.759 for the clinical model and 0.725 for the
model incorporating biochemical markers. The models did not perform any better
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Chapter 1 - Introduction
1.1 Critical Care
1.1.1 History and definitions
The origins of the modern specialty of Critical Care are debated but most
accounts celebrate the contributions of a handful of individuals who recognised the
importance of concentrating resources within specialised units to deliver high
quality care (Vincent, 2013) (Ristagno & Weil, 2009). During the Crimean War,
Florence Nightingale highlighted the importance of good postoperative care, and
the development of special wards for managing these patients.
The development of the first intensive care unit (ICU) is credited to the
Danish anaesthetist Bjorn Ibsen, who in 1953 at the height of an epidemic provided
positive pressure ventilation to patients suffering from paralysis caused by polio. A
shortage of negative pressure ventilation chambers (iron lungs) led to the
establishment of units where positive pressure ventilation could be delivered -
initially by anaesthetists.
Since then, units providing advanced respiratory and multiple organ
support (ICU), and other units providing increased levels of monitoring and
therapy (High Dependency Units (HDU)), have developed sporadically -
responding to the demands of evolving patterns of human disease, and to surgical
advancement.
The units within which advanced monitoring and organ support could be
provided therefore defined critical illness. These units differed widely in terms of
provision of organ support, expertise, and specialisation.
In the year 2000, in a document entitled "Comprehensive Critical Care - A
Review of Adult Critical Services", the UK government developed a strategy for
improvement of critical care services in England and Wales (Day, 2009). A key part
of this strategy was to move away from defining critical care by the location of the
patient - i.e. within an ICU, or HDU, but on the requirements of the patient as
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determined by the severity of their illness. Within this document, definitions of
critical care were established and are summarized below (Table 1-1).
Level of Care Description
0 Patients whose needs can be met through normal ward care in
an acute hospital.
1 Patients at risk of their condition deteriorating, or those recently
relocated from higher levels of care, whose needs can be met
on an acute ward with additional advice and support from the
critical care team
2 Patients requiring more detailed observation or intervention
including support for a single failing organ system or post¬
operative care and those 'stepping down' from higher levels of
care
3 Patients requiring advanced respiratory support alone or basic
respiratory support together with support of at least two organ
systems. This level includes all complex patients requiring
support for multi-organ failure.
Table 1-1 Levels of Care
In Scotland, critical care is delivered in 3 main types of unit - HDUs
(providing level 1-2 care), ICUs (providing level 3 care) and combined units
containing a mixture.
1.1.2 Epidemiology
In Scotland, a well established national audit programme administered by
the Scottish Intensive Care Society Audit Group (SICSAG) provides high quality
data relating to the provision of critical care across the whole country
(http://www.sicsag.scot.nhs.uk). In 2010, 9802 patients were admitted to the
combined ICU/HDUs and ICUs and 25000 patients were admitted to HDUs. The
majority of patients were post-operative, with the remainder admitted from
accident and emergency departments and hospital wards.
Of those admitted to ICUs or combined units, the average length of stay was
5 days and 70% of the patients required mechanical ventilation. Twelve per cent of
these patients required renal support and 80% of patients admitted were level 3.
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ICU mortality was 18% whilst hospital mortality for ICU treated patients
30% (Cole, 2010).
1.2 Long-term complications of critical illness
As more patients survive critical illness, the problems facing survivors
become ever more evident. Most patients suffer a combination of physical,
psychological, and social problems that impact significantly on their physical and
mental wellbeing (Desai, Law, & Needham, 2011).
Increasingly these issues are recognised not just as a major burden on
individual survivors. As the number of patients surviving critical illness grows, so
too does the socioeconomic effects of their disabilities and comorbidities.
1.2.1 Pulmonary complications
Most of the data relating to pulmonary function after critical care relates to
ARDS patients. Patients suffer a variety of abnormalities including restrictive and
obstructive deficits, diffusion limitation, and dyspnoea. They are generally mild or
moderate, and improve significantly over the first 6 months, with improvement
continuing at a reduced rate up to a year after ICU discharge. Defects are still seen
after 5 years of follow up (Herridge et al., 2003; Herridge et al., 2011; Heyland, Groll,
& Caeser, 2005; Neff, Stocker, Frey, Stein, & Russi, 2003; Orme et al., 2003; Schelling
et al., 2000).
1.2.2 Neuromuscular dysfunction
The most prevalent symptoms for ICU survivors are fatigue and muscle
weakness. Muscle weakness is severe in about a quarter of patients who require
prolonged mechanical ventilation (De Jonghe et al., 2002). Muscle biopsy studies
reveal skeletal muscle abnormalities in virtually all patients recovering from critical
illness (Coakley, Nagendran, Honavar, & Hinds, 1993) and include axonal
neuropathy, denervation, fibre atrophy, non-specific neuropathy and necrotising
myopathy.
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Acute respiratory distress syndrome (ARDS) survivors experience clinically
important functional impairment after ICU discharge that is significantly associated
with muscle wasting, weakness, and fatigue (Herridge et al., 2003). Most of the
physical recovery observed in these patients happens close to ICU discharge, after
which it flattens out and often does not return to pre-illness levels (Herridge et al.,
2011). Interestingly, these patients have normal pulmonary function tests (Herridge,
2009).
Although functional limitation seems to be worst in ARDS survivors (T. A.
Davidson, Caldwell, Curtis, Hudson, & Steinberg, 1999), other groups are affected.
Trauma patients have poorer physical function than other ICU patients (Hilde
Myhren, Ekeberg, & Stokland, 2010).
ICU-acquired weakness (ICU-AW), the term currently used to describe the
spectrum of neuromuscular lesions acquired during a critical care admission occurs
in 25% to 58% of ventilated patients and up to 100% of severely septic patients (R. D.
Griffiths & Hall, 2010). Its pathophysiology is debated but the risk factors of
corticosteroid treatment, severe illness, poor glycaemic control, and immobility are
generally accepted (R. D. Griffiths & Hall, 2010).
Recovery from ICU-AW is not guaranteed. Many patients have on-going
electrophysiological or clinical neuromuscular dysfunction at 12 months following
ICU discharge (Guarneri, Bertolini, & Latronico, 2008).
1.2.3 Depression and anxiety
Symptoms of depressive illness are often evident at hospital discharge.
These findings are associated with depression in the months following hospital
discharge. The prevalence of depression ranges from 17-43% and varies according
to study cohort and sampling time point (Davydow, Desai, Needham, & Bienvenu,
2008). Prevalence decreases in the 12 months following discharge. Age, gender and
severity of illness do not seem to be associated with an increased incidence of
depression. Presence of cognitive impairment, and poor health-related quality of
life (HRQOL) may be associated - relationships that are probably confounded by
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other factors (Davydow, Gifford, Desai, Bienvenu, & Needham, 2009) (Davydow,
Desai, et al., 2008).
Anxiety is also frequently observed in ICU survivors. Prevalence depends
on the assessment tool used and the chosen cut-offs, however rates are probably
around 10% at 1 year and decline over time. Female gender, younger age, and pre¬
existing anxiety are predictors of post-ICU anxiety disorders (Eddleston, White, &
Guthrie, 2000; Rattray & Hull, 2008; Rattray, Johnston, & Wildsmith, 2005).
1.2.4 Post-traumatic stress disorder
Post-traumatic stress disorder (PTSD) affects between 10 and 39% of ICU
survivors of ICU survivors. Risk factors appear to be prior psychiatric illness, the
use of benzodiazepine drugs for sedation, and recollection of frightening or
alarming physical experiences during the ICU stay (Davydow, Gifford, Desai,
Needham, & Bienvenu, 2008).
1.2.5 Neurocognitive impairment
Long term neurocognitive dysfunction is extremely common in ICU
survivors and is present in up to 91% of general ICU survivors and 78% of ARDS
survivors at ICU discharge (Hopkins & Jackson, 2006). It is related to duration of
acute brain dysfunction (delirium) during critical illness (Girard et al., 2010;
Pandharipande et al., 2013). Improvement after ICU discharge is gradual at best
and problems are still seen up to 6 years after ICU discharge. Memory is the most
common domain effected, followed by executive function, and attention deficits. In
a highly selective cohort that excluded patients with pre-existing cognitive
impairment, 80% of general ICU patients ventilated for more than 12 hours had
cognitive impairment at ICU discharge (60% had severe impairment). Seventy
percent had persistent cognitive impairment at 1 year (36% had severe impairment).
Acquired cognitive impairment is thus common and long lasting (Girard et al.,
2010).
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1.2.6 Health-related Quality of life
Quality of life has been defined by WHO as "the individuals -perception of their
position in life in the context of culture and value systems in which they live and in relation
to their goals, expectations, standards and concerns "(WHO, 1998). Health-related
quality of life focuses on those aspects of quality of life that impact negatively on
health (CDC, 2012). A number of assessment tools have been developed, and are
used to measure HRQOL in survivors of critical illness of which the medical
outcomes study forms (SF-12 and SF-36) are the most common.
ARDS is the most frequently studied cohort of critical care survivors.
Perhaps the first cohort studied was by Hughes and colleagues who examined
performance on the Sickness Impact Profile Score (SIP) and found decreased
physical function in ICU survivors that dramatically improved over the first 3-6
months but remained low at 1 year. In other studies, scores on the SF-36 are well
below age and gender-matched controls at ICU discharge, and persist for up to 5
years with the most dramatic improvement seen over the first 12 months. There
seems to be a lesser impact on the mental component scores and these seem to
change less with time (A. M. Cheung et al., 2006; Herridge et al., 2003; Herridge et
al., 2011; Orme et al., 2003; Schelling et al., 2000).
1.2.7 Importance of a conceptual model for patient outcomes
HRQOL is commonly used as an outcome measure in interventional studies
due to the demonstrable validity and ease-of-use of the newer scoring systems.
Furthermore, the available HRQOL scoring systems are amenable to clinical
intervention with drug and physical therapies. The challenge faced by clinical
researchers is relating clinical variables to health-related quality of life measures. Of
paramount importance to this process is that derivation of conceptual models to
help explain how clinical variables interact with social and environmental
influences to affect patients' quality of life.
One such conceptual model is reproduced in diagram-form below (Figure 1-
1). This model illustrates five increasing levels of complexity ranging from
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biological and physical factors through to perceived quality of life. The model helps
explain the contributions of environmental and patient factors that add this
complexity.
Better understanding of this complexity helps place in context the findings of
outcomes research. It is necessary to inform researchers the potential pitfalls of
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Figure 1-1 Conceptual Model of Patient Outcome adapted from Wilson et al (Wilson
& Cleary, 1995).
1.2.8 Economic implications of critical illness survivorship
The economic implications of critical illness should not be overlooked. A
large proportion of patients don't return to work for many years after critical illness,
and consume a huge quantity of health care resource in the years following ICU
discharge (J. Griffiths et al., 2013; Herridge et al., 2003; Lone et al., 2013). Although







readmissions, outpatient appointments, primary care, mental health services, and
rehabilitation services are likely to run to many tens of thousands of US dollars per
year. In some contexts these costs may run to hundreds of thousands of dollars
(Lone et al., 2013).
1.2.9 Post-ICU disability - a major public health concern
Whilst persistent ICU acquired disability is now recognised, it is still not
clear how to prevent or treat it (Herridge, 2009). Rehabilitation for critically ill
patients who have illnesses that fall out with the remit of established disease specific
rehabilitation pathways (stroke, myocardial infarction, head injury) is not routinely
provided.
Reflecting the importance of this issue, a National Institute of Clinical
Evidence (NICE) group was recently charged with creating a short guideline to
inform rehabilitation practice in patients whose illness necessitated a critical care
admission ("NICE Guideline 83 - Rehabilitation after critical illness," 2009) (T. Tan,
Brett, Stokes, & Guideline Development, 2009). The striking finding of the review
board was the lack of evidence pertaining to timing, composition, and effectiveness
of rehabilitation interventions in this group of patients.
It is also clear that there is sparse data linking the critical illness event, to the
pathologies demonstrated in the post-ICU syndrome. In order to develop effective
treatments, this area needs more rigorous investigation.
1.3 Post-ICU Inflammation
1.3.1 Definition of inflammation
Inflammation is the term used to describe activation of the innate immune
system of the human organism in response to tissue injury. Tissue injury may be
the result of infection, mechanical trauma, extremes of temperature, or radiation. It
is characterized by increased blood supply, increased capillary permeability, and
influx of immune cells to the site of injury. The aim of inflammation is the
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elimination of pathogen, removal of dead tissue and waste products of the
inflammatory process, and return to normal function.
In the most severe cases, the localized response spills out into the systemic
circulation and causes more global activation of the immune system and manifests
clinically as the systemic inflammatory response syndrome (SIRS). SIRS is seen in
virtually all critically ill patients and when it is overwhelming it is associated with
failure of organ systems producing acute kidney injury, lung injury, and
cardiovascular failure, amongst others.
1.3.2 The key events of inflammatory initiation and resolution
Inflammation is characterised by the infiltration of the inflammatory site by
granulocytes (e.g. neutrophils, eosinophils and basophils). This process begins with
pattern recognition of pathogen associated molecular patterns (PAMPS) and the
endogenous equivalent damage associated molecular patterns (DAMPS) by pattern
recognising receptors (PRRs) on tissue resident macrophages and mast cells (Barton,
2008) (Medzhitov, 2008a). PRR ligation results in the release of a myriad of
inflammatory mediators (chemokines, cytokines, vasoactive amines, and
eicosanoids). These mediators work in synergy to produce a localised inflammatory
exudate consisting of plasma proteins and granulocytes (Medzhitov, 2008b).
Following their recruitment into the inflammatory environment,
granulocytes and particularly neutrophils become activated, a process that is caused
directly by pathogens and indirectly via stimulation by inflammatory cytokines
Activated neutrophils undergo degranulation - releasing proteases, reactive oxygen
species (ROS), reactive nitrogen species, human neutrophil elastase (HNE) and
cathepsin G that act to destroy the invading pathogen (Medzhitov, 2008b). The
products of neutrophil degranulation are useful for pathogen killing, however their
effects are non-specific and therefore cause collateral damage to host tissues (Segel,
Halterman, & Lichtman, 2011).
The success of the inflammatory response therefore requires a programme of
resolution and repair that can only be achieved by the successful and safe removal
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of inflammatory cells from the site of inflammation (Segel et al., 2011). The first and
most important part of this programme, is the removal of the inflammatory
stimulus - the pathogen or damaged tissue (Serhan et al., 2007). By eliminating this
inflammatory trigger, the production of pro-inflammatory mediators is halted, and
further neutrophil recruitment and oedema formation is prevented (Serhan et al.,
2007).
The next stage of inflammatory resolution is inflammatory cell clearance.
Granulocytes that undergo apoptosis (programmed cell death) maintain their cell
membranes and die without spilling their damaging contents. This contrasts with
necrosis, which results in perpetuation of the immune response. Apoptosis is
therefore the preferred mode of cell death. Apoptotic cells also express cell surface
proteins that are recognized by macrophages and promote phagocytosis. Failure of
phagocytosis results in apoptotic neutrophils that eventually undergo necrosis,
known as 'secondary' necrosis, with the same consequences as 'primary' necrosis in
terms of pro-inflammatory consequences. Finally, macrophages must be removed
from the site of injury and some of these undergo apoptosis, whilst the rest are
removed via the lymphatic system (Serhan et al., 2007).
Whilst many of the regulatory steps involved in the activation of acute
inflammation are well established, those involved in inflammatory resolution are in
the early stages of investigation. It is becoming clear, however, that the steps
involved are complex, and depend on events that occur early during inflammatory
activation (Serhan & Savill, 2005).
Chemokines are small proteins that attract cells and control cell migration
during inflammation. A shift in chemokine expression is thought to be one of the
earliest events in inflammatory resolution and results in the preferential attraction
of monocytes into the inflamed region (Lawrence & Gilroy, 2007).
Early in the inflammatory process, arachidonic acid is oxygenated into
inflammatory prostaglandins and leukotrienes. Later on, synthesis is diverted to
producing lipoxins that suppress chemotaxis, vascular dilation, permeability,
fibrosis and pain and promote ingestion of apoptotic neutrophils. Pro-resolution
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lipids - resolvins, protectins and maresins are also produced during the resolution
phase whilst their production is dependent on the pro-inflammatory activation of
prostaglandin E2 (PGE2) and prostaglandin D2 (PGD2) early in the inflammatory
reaction (Schwab & Serhan, 2006).
1.3.3 Potential causes of post-ICU inflammation
Persistence of inflammation beyond critical illness may be the result of a
number of pathophysiological possibilities.
It is possible that there is a failure of some aspect of the inflammatory
resolution pathway discussed above. This may be due to ineffective neutralisation
of the inciting pathogen, or a failure to adequately clear inflammatory cells.
It is also possible that inflammation detected in the post-ICU period is not a
failure to resolve acute inflammation, but a return to a chronic inflammatory
baseline. Given the age, frailty, and pre-existing comorbidity of many ICU patients,
it may be that many patients will have chronic low-grade activation of their immune
system prior to their episode of critical illness. Chronic inflammation resulting from
diseases such rheumatoid arthritis, Type 2 diabetes (Donath & Shoelson, 2011),
COPD (Walter et al., 2008), advanced age (Bruunsgaard & Pedersen, 2003), are often
present and may co-exist in the same patient.
Another possibility is activation of the innate immune system caused by the
reactivation of latent viruses (see 1.3.7).
There are likely to be other potential explanations for chronic inflammation
after critical illness. Most obviously perhaps, is the possibility that survivors of
critical illness are more likely to be affected by recurrent infections in the post ICU
period. This certainly seems to be the case with sepsis survivors (T. Wang et al.,
2012).
1.3.4 Effects of inflammation on muscle mass and function
Chemical products of the inflammatory response have an established role in
regulating muscle mass. Tumour necrosis factor alpha (TNF-a), interleukin 1 (IL-1),
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interleukin 6 (IL-6), and endotoxin infusions cause muscle wasting syndromes
(Fong et al., 1989; Hoshino et al., 1991) due to increased protein catabolism (Baracos,
Rodemann, Dinarello, & Goldberg, 1983; Flores et al., 1989; Goodman, 1991, 1994;
Llovera, Lopez-Soriano, & Argiles, 1993), inhibition of protein synthesis (Charters &
Grimble, 1989), inhibition of muscle cell differentiation (Miller, Ito, Blau, & Torti,
1988) and reduced amino acid uptake (Zamir, Hasselgren, James, Higashiguchi, &
Fischer, 1993).
Numerous mechanisms have been proposed. Ubiquitin and nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-kappa B) mechanisms have
been most extensively studied. Muscle cells increase their transcription of ubiquitin
messenger ribonucleic acid (mRNA) in response to TNF-a, leading to muscle
protein catabolism via the ubiquitin protease pathway (Garcia-Martinez, Agell,
Llovera, Lopez-Soriano, & Argiles, 1993; Garcia-Martinez, Llovera, Agell, Lopez-
Soriano, & Argiles, 1994, 1995; Raj et al., 2003). NF-kappa B activation by TNF-a
leads to disturbance of the muscle regulating factor myogenic differeration 1
(MyoD). MyoD regulates muscle specific transcription and inhibition results in
reduced myogenesis (Costelli et al., 2005; Dejong et al., 2005; Langen, Schols,
Kelders, Wouters, & Janssen-Heininger, 2001; Y. P. Li & Reid, 2000).
Chronic diseases such as cancer, chronic obstructive pulmonary disease
(COPD), heart failure and end stage renal disease as well as normal aging are
associated with loss of muscle mass and function. Numerous studies have observed
associations between markers of inflammation and muscle function in these groups
(Barbieri et al., 2003; Dejong et al., 2005; Eid et al., 2001; Raj et al., 2003; Roubenoff et
al., 2003; Schaap et al., 2009; Schaap, Pluijm, Deeg, & Visser, 2006; Toth, Ades,
Tischler, Tracy, & LeWinter, 2006; Visser et al., 2002; Yende et al., 2006).
1.3.5 Inflammation and the central nervous system
Systemic inflammation is also implicated in diseases of the central nervous
system (Warnberg, Gomez-Martinez, Romeo, Diaz, & Marcos, 2009). A relevant
example is the role of inflammation in the pathophysiology of dementia and in
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particular Alzheimer's disease (Wyss-Coray, 2006). In 779 patients enrolled in the
MacArthur study of successful aging, those patients with highest levels of
interleukin-6 had the greatest risk of cognitive decline 7 years later (Weaver et al.,
2002). In 691 cognitively intact elderly patients in the Framingham Heart Study,
higher levels of IL-1 and TNF alpha production were associated with subsequent
onset of dementia at a mean follow up time of 7 years (Z. S. Tan et al., 2007).
It is also plausible that inflammation plays a role in the pathophysiology of
depressive disorders. The observation that components sickness behavior such
nausea, anorexia, lack of interest, sleep disturbance, depression, irritability, and
cognitive disturbance broadly resemble some of the features of clinical depression,
has led some investigators to believe that inflammation has a causative role. In
support of this, many diseases characterised by chronic inflammation (COPD, type
2 diabetes, rheumatoid arthritis) are associated with a greater incidence of
depression. In addition, infusion of recombinant cytokines for the treatment of
cancer has been associated with onset of major depressive disorders (Dantzer,
O'Connor, Freund, Johnson, & Kelley, 2008).
PTSD is also commonly associated with elevated markers of inflammation
(Gill, Saligan, Woods, & Page, 2009) and levels of cytokines in the period following
myocardial infarction are associated with subsequent development of PTSD (von
Kanel et al., 2010).
Hence it is plausible that persistent inflammation in ICU survivors could
play a causative role in the onset of cognitive dysfunction, depressive symptoms,
and PTSD or indeed prevent recovery from the depressive symptoms of sickness
behaviour or acute illness related cognitive dysfunction.
1.3.6 Persistent inflammation after intensive care
Whilst the early initial inflammatory response has been well investigated in
relation to both short and long term outcomes, inflammation that persists into the
recovery phase has been relatively neglected. This may be due in part to the
logistical difficulties in collecting and processing community samples, but may also
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reflect the lack of understanding of the pathological processes at play during this
phase of critical illness.
Several investigators have recognised that inflammation at the time of ICU
discharge may be significant (Al-Subaie et al., 2010; Grander et al., 2010; Grander &
Dunser, 2010; K. M. Ho, G. J. Dobb, K. Y. Lee, S. C. Towler, & S. A. R. Webb, 2006;
Ho, Lee, Dobb, & Webb, 2008; Axel Kaben et al., 2008; Litton, Ho, Chamberlain,
Dobb, & Webb, 2007; Memis et al., 2007). Local practice and clinician preference
ultimately determines when patients are discharged from the intensive care unit.
Despite this variation, many patients have evidence of inflammation at this time.
Serum CRP levels at ICU discharge are elevated (Grander et al., 2010; Kwok M. Ho
et al., 2006; Ho et al., 2008; Axel Kaben et al., 2008; Litton et al., 2007) and are
associated with increased mortality (Grander et al., 2010; Ho et al., 2008; Litton et al.,
2007; Memis et al., 2007), and ICU readmission rates (Kwok M. Ho et al., 2006; Axel
Kaben et al., 2008).
1.3.7 Cytomegalovirus and inflammation in ICU survivors
Cytomegalovirus (CMV) is one of 9 viruses of the Herpesviridae family that
cause disease in humans (Pellett & Roizman, 2007). Owing to common biological
characteristics such as a restricted number of hosts, long reproductive cycle, slow
culture times, site of latency, and its tendency to cause cytomegaly, CMV is
classified in the betaherpesvirinae subfamily . CMV is transmitted vertically from
mother to foetus, or by contact with the body fluids of an infected individual. CMV
infection is highly prevalent. In the developed world, more than a third of primary
school age children have serological evidence of prior CMV exposure and more
than 80% of people are infected by 60 years (Staras et al., 2006).
Acute CMV infection is usually subclinical in the immunocompetent host.
Occasionally, patients suffer an episode of mononucleosis and in very rare cases,
patients suffer a severe multi-system disease. In cases of immunodeficiency,
reactivation of latency CMV infection or primary CMV infection can result in
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pneumonitis, hepatitis, retinitis, colitis, and encephalitis. CMV pneumonitis
following bone marrow transplantation has a mortality of up to 80%.
Traditionally, CMV infection is associated with several well described
contexts: following bone marrow transplantation, following solid organ
transplantation, and in patients with HIV infection when CD4 count falls below
50,000. Increasingly, critical illness is recognised as a context in which up to 40% of
previously exposed adults will experience infection or reactivation (Chiche et al.,
2009; Cook, Yenchar, Kraner, Davies, & Ferguson, 1998; Heininger et al., 2011;
Heininger et al., 2001; Kutza, Muhl, Hackstein, Kirchner, & Bein, 1998; Limaye et al.,
2008; Stephan et al., 1996). In addition, CMV reactivation is associated with
increased mortality, longer duration of mechanical ventilation, longer duration of
ICU and hospital length of stay, and a greater number of nosocomial infections.
CMV reactivation is therefore common and is not benign in critically ill patients.
CMV infection is also known to have effects on the immune system. Acute
infection is associated with elevated levels of inflammatory cytokines that persist
after the immune system has effectively controlled viral replication (van de Berg et
al., 2010). As a frequent occurrence in critically ill patients, and a potential mediator
of systemic inflammation, it is therefore hypothesised that CMV reactivation might
be a risk factor for persisting inflammation and prolonged recovery after critical
illness.
1.3.8 Inflammation and functional outcome
Through whatever pathophysiological process, it seems likely that
inflammation in survivors of critical illness persists beyond the period of ICU
discharge and into the recovery phase. In addition, there is sufficient experimental
and observational data to suggest that the presence of circulating inflammatory
mediators during this period might be sufficient to retard physical recovery, and
contribute in a negative manner to psychological outcomes. Further study is
required to understand whether these relationships are indeed causal.
Inflammation may therefore be of crucial importance in the pathophysiology of the
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post-ICU syndrome. Given the recent intense interest in unravelling the complex
events of inflammatory resolution, and the pursuit of new drug treatments in this
field, a better understanding of its contribution to post-illness recovery is long
overdue.
1.4 Main hypotheses and outline of thesis
The over-riding hypothesis of this thesis is that acute inflammation does not
resolve adequately in some individuals after critical illness and that this hampers
physical recovery. A further hypothesis is that potentially modifiable factors such
as critical illness-induced CMV reactivation may contribute to a sustained innate
immune response and might therefore be implicated in poor functional recovery.
Finally, the identification of early evidence of dysfunctional inflammatory
resolution may assist in the identification of those who are likely to have a poor
functional outcome after critical illness and therefore might gain greatest benefit
from rehabilitation outcomes.
Chapter 2 describes a systematic review that was conducted in order to
identify any previous studies of the inflammatory response after discharge from
critical care. The aim of this work was to present all the available evidence of the
prevalence of systematic inflammation at 3 distinct time points. These were ICU
discharge, between ICU discharge and hospital discharge, and after hospital
discharge. Furthermore, the review was designed to identify studies that in
addition to measuring the inflammatory response had also measured some
characteristic of physical recovery.
Chapter 3 reports an observational study of 197 survivors of critical illness.
These patients made up a representative sample of the 240 patients that participated
in the RECOVER study (a randomised controlled trial of a complex in-hospital
rehabilitation package) (T. S. Walsh et al., 2012). These patients donated weekly
blood samples starting at the point of ICU discharge until they were discharged
from hospital. A further sample was donated at a follow up appointment, usually
in the patient's home. Analysis was carried out on the blood samples to determine
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circulating concentrations of inflammatory mediators in the recovery phase of
critical illness. These results were correlated with measures of recovery (primary
and secondary outcome measures from the RECOVER study) in order to explore the
associations between inflammation and physical recovery.
Chapter 4 builds on the work described in Chapter 3 to provide a rationale
for the role of CMV latency and reactivation as a possible mechanism for persistent
inflammation after ICU discharge and hence a possible contributor to poor
functional outcome after critical illness. CMV immunoglobulin G (IgG) was
measured in the plasma of ICU survivors at ICU discharge to identify those with
prior CMV infection. Quantitative CMV assays were carried out on IgG positive
samples to identify those with evidence of active CMV infection. The characteristics
of CMV infected patients, their inflammatory profiles, and their physical outcomes
were explored.
Chapter 5 describes derivation of a prognostic model to distinguish at an
early stage patients that are likely to struggle to recover (those likely to benefit from
intensive rehabilitation) from those who will do well, regardless of input. Statistical
modelling was carried out using a linear regression technique. A selection of
models is presented accompanied by a critique of their relative merits, and
limitations. These models were differentiated by their inclusion, or exclusion of
biomarkers of inflammation, and also their adherence to the assumptions of linear
regression modelling.
Chapter 6 summarises the major findings of the thesis drawing from all 4
elements of the research programme in the context of the literature to address each
of the aims of the thesis in turn. Conclusions are stated and areas for future study
are proposed.
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Chapter 2 - Prevalence of Systemic Inflammation in
Survivors of Critical Illness and Relationship with
Physical Recovery: A Systematic Review of the
Literature
2.1 Introduction
Systemic inflammation in critical illness has been extensively studied in the
acute phase of critical illness (usually defined as during ICU admission), but it is
unclear how many patients have evidence of on-going inflammation in the recovery
phase (defined as the period starting at the point of ICU discharge). During this
phase of illness, organ failures have for the most part resolved and patients are
starting a long battle to return their bodies to pre-illness levels of function. It is a
hypothesis of this thesis that inflammation and recovery of muscle function are
inter-related during this period but the extent to which this hypothesis has been
previously investigated has not been explored.
In order to investigate the effects of inflammation in this target population, it
is necessary to clarify what is meant by the term "inflammation". Inflammation is
the normal response of the human body to external invasion or injury. Initiation of
inflammation is an active process triggered by host recognition of pathogens or
damaged tissue. Traditionally resolution of inflammation was considered a passive
process. The theory was that inflammation subsides spontaneously when pro¬
inflammatory signals cease. It is now considered an active process, orchestrated by
circulating mediators created during the early inflammatory response and their
effects on the apoptotic and phagocytic pathways of immune cells.
Inflammation is a physiological response. It is not a diagnosis. The classic
signs of heat, pain, swelling, and loss of function are the local manifestations of a
systemic process. The cytokine release, signalling, and cell recruitment occurring on
a systemic level often occurs in the absence of overt clinical signs. When the
response is greater in magnitude, certain systemic features of inflammation emerge.
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Thermoregulatory changes resulting in fever or hypothermia, sympathetic
stimulation results in increased heart rate and inotropy, and changes in endothelial
function result in vasodilation and lowered blood pressure. Some of these features
form the basis of a consensus definition of a "systemic inflammatory response
syndrome" or SIRS (Bone et alv 1992).
Clinical signs are therefore useful in the localisation of an inflammatory
trigger, and the identification of patients with particularly severe illness, but they
lack sensitivity in diagnosing the presence or absence of an inflammatory response.
To detect subclinical inflammation, it becomes necessary to measure characteristics
of the inflammatory process that are present at the start of the process and persist as
long as the inflammatory process continues.
An early event in inflammation is the release of pro-inflammatory molecules
such as IL-1, IL-6 and TNF-a in response to binding of damage-associated molecular
patterns (DAMPs) to pathogen recognition receptors (PRRs) such as the Toll-like
receptors (TLRs). These events trigger a wide variety of responses including the
expression of adhesion molecules on vascular endothelium, the release of acute
phase proteins, and the induction of a number of plasma enzyme systems.
Relevantly, these events are accompanied by changes in the expression and activity
of a plethora of inflammatory mediators often accompanied by release of substances
into the blood that normally undetectable or are detectable only at a very low
concentration.
Nearly 180 of these substances have been studied as potential biomarkers of
sepsis (Marshall & Reinhart, 2009; Pierrakos & Vincent, 2010). Whilst many of them
are sensitive markers of systemic inflammation, their use in the diagnosis of sepsis
is limited due to their lack of specificity. When the focus of interest is on the
consequences of the inflammatory process and the aetiology is not of key
importance, the sensitivity of these biomarkers is valuable. Detection of increased
concentrations of these molecules above the normal range will signify activation of
inflammatory pathways even when there are no clinical signs of inflammation.
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This systematic review was designed to identify studies that included
measurements of the clinical or molecular manifestations of the innate immune
response specifically focussing on the period after ICU discharge. The aims were to
describe the proportion of patients that have clinical manifestations of inflammation,
or that have elevations in systemic biomarkers of inflammation and to explore the
relationship between inflammation and measures of physical recovery in these
studies. This part of the thesis was designed to use rigorous systematic review
methodology to unearth and appraise all available data relating to these aims in
previously published studies.
2.2 Hypothesis
Acute inflammation persists after ICU discharge and this is associated with
physical recovery after critical illness.
2.3 Aims and research questions
To perform a systematic search of previous literatures and collate and
interpret the available data pertaining to the following 2 questions:
• What is the evidence that systemic inflammation persists into the recovery
phase of critical illness?
• Is there any association between markers of systemic inflammation and
physical function after ICU discharge?
2.4 Methods
2.4.1 Sources of articles
Electronic databases EMBASE and MEDLINE databases were systematically
searched using the OVID user interface. CINAHL was searched using the EBSCO
host interface. In addition grey literature sources were searched for conference




Participants are human Studies of patients in Cardiothoracic
AND intensive care units, coronary care units,
Adults >16 years old or neurosurgical intensive care units.
AND Studies including participants <16 years
ICU patients or survivors
old.
AND
Included measurements of the clinical or
molecular manifestations of the systemic
inflammation at ICU discharge or any
time point after ICU discharge
Table 2-1 Inclusion and exclusion criteria
Inclusion and exclusion criteria are summarised in Table 2-1. A search was
carried out to identify reports of studies of adult ICU patients published between
January 1981 and December 2011 in whom clinical or biochemical markers of
systemic inflammation were measured. Studies carried out in medical, surgical, or
mixed intensive care units were considered. To maximise generalisability to a
general intensive care population, studies including children, neonates,
neurosurgical, or post-operative cardiothoracic patients were not considered. The
search strategy used for the MEDLINE and EMBASE searches is shown in Table 2-2.
Search strategies for CINAHL, CPCISSH and CPCIC can be found in Appendix A.
1 interleukin*.ti,ab.
2 (CRP or TNF* or "C-reactive").ti,ab.
3 inflammation/
4 acute phase reaction/







11 tumor necrosis factor/
12 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11
13 (critical adj3 care).ti,ab.
14 (intensive adj3 care).ti,ab.
15 (intensive adj3 therapy).ti,ab.
16 (ICU or ITU).ti,ab.




21 intensive care units/
22 respiratory care units/
23 intensive care unit/
24 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25 humans/ not animals/
26 12 and 24 and 225
27 limit 28 to yr="1982 -Current"
28 remove duplicates from 29
Table 2-2 Search strategy for MEDLINE and EMBASE database using the OVID
interface
A measurement of the clinical manifestations of systemic inflammation was
defined by the presence one of the following:
1. Measurement of all of the elements making up the systemic inflammatory
response syndrome (SIRS) as defined by the Bone et al (Body temperature,
heart rate, respiratory rate (or PaCCh), and leukocyte count) to allow
calculation of a SIRS score (Bone et al., 1992) (see also table 2-3).
2. A diagnosis of SIRS according to the definition by Bone et al (Bone et al.,
1992).
Criteria Limit
Body temperature >38C or <36C
Heart rate >90 bpm
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Respiratory rate >20/min or PaC02 <32mmHg
White blood cell count >12,000/mL
Table 2-3 American College of Chest Physicians / Society of Critical Care Medicine
consensus conference definition of SIRS.
A measurement of the molecular manifestations of systemic inflammation
was defined as the measurement of a molecule in the serum or plasma considered
by the authors to be a component of the inflammatory response such that an
elevated concentration of that molecule would be likely to indicate activation of the
innate immune system.
For a study to be considered, the marker of systemic inflammation had to be
measured at one of 3 pre-specified time points: within 24 hours of ICU discharge,
between ICU discharge and hospital discharge, and after hospital discharge.
In many studies, markers were measured whilst the patient was in ICU for
periods of follow up which were not clearly linked with these 3 time points. For
this reason the review adhered to the following principles: if a study reported a
measurement of systemic inflammation whilst the patient was in ICU it was
included if sampling continued until ICU discharge. If there was no reference to
ICU discharge, the study was only considered if the last sample taken was at a time
point greater than 14 days after ICU admission on the basis that there was
reasonable probability that the majority of patients being sampled at this time point
would have been discharged from ICU (Rosenberg, Zimmerman, Alzola, Draper, &
Knaus, 2000). For these studies, the authors were contacted for further information.
No language restrictions were placed on the search. Where an English
abstract was available, the study remained in the review provided there was
sufficient information in the abstract. Where no English abstract was available,
foreign language publications were excluded.
2.4.3 Selection of studies
Following retrieval of the search results and removal of duplicates, the title
list was searched to remove clearly irrelevant studies (e.g. studies of paediatric,
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neonatal, cardiothoracic, or neurosurgical patients, review articles, editorials, case
reports and commentaries). Two authors independently screened the abstracts of
the remaining studies and excluded studies that did not meet inclusion criteria.
Disagreements about eligibility were resolved by discussion between the 2
screening authors. An inclusive approach was adopted. Where there was
insufficient information in the abstract to allow outright rejection, the article
remained in the review list.
Full text versions of the remaining articles were obtained whenever possible
using the resources of the NHS, University of Edinburgh, and the British Library.
Where an article could not be retrieved in full text and there was insufficient
information in the abstract to determine eligibility, it was excluded from the review.
Two authors reviewed the full-text articles independently. This resulted in a
final short list for further evaluation and data extraction.
2.4.4 Data extraction
A single author extracted data into a data table (see appendix C).
Parameters extracted were: author, publication title, publication journal,
publication year, country, number of patients, number of patients lost to follow up,
inflammation mediator, time point, prevalence estimate, and precision of estimate
(95% confidence interval). Where a prevalence estimate was not available, a
summary measure was extracted (mean +/- standard deviation or median +/-
interquartile range or range). Where a relationship between a measure of
inflammation and physical outcome was documented, a relevant summary statistic
for the relationship was extracted along with a 95% confidence interval where
applicable.
2.4.5 Contact with study authors
When relevant data was not provided in the text, attempts were made to
contact authors for raw data to allow calculation of prevalence estimates.
Acknowledging that raw data may not be available in older studies, authors were
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asked if they could provide summary measures with distributions as a minimum.
Authors were contacted by email and post on 2 occasions 1 month apart allowing 2
months in total to respond after the initial contact. An example data request letter
and form can be found in Appendix B.
2.4.6 Data synthesis
It was anticipated that a variety of different inflammatory markers would
have been measured depending on the primary objective of each included study. In
order to calculate the proportion of patients considered to have molecular evidence
of systemic inflammation, cut-off values for each of the markers had to be
determined. In order to do this, each included biomarker was noted, and literature
searches were carried out to identify the range of values that could be expected in a
normal healthy population. It was intended that a cut-off of the 97.5th centile would
be identified as the upper limit of normal for each chosen biomarker. Subjects with
biomarker concentrations greater than this cut-off were considered inflamed. In
order to allow comparability between cut offs, summary estimates (mean (SD), or
median (IQR)) were quoted.
A narrative account of the prevalence and summary data extracted from
each study is provided in addition to a summary account in the main data table. No
attempt was made to combine estimates in a meta-analysis due to the heterogeneity
of the included studies in terms of study population, stage of illness, inflammatory
mediators measured, and the methods used to measure them.
An assessment of study validity was carried out (details of the process of
validity assessment can be found in section 2.4.7). The results of each study were
discussed with reference to their internal and external validity.
2.4.7 Validity assessment
Although 2 questions were asked in the current review, the first relating to
prevalence of inflammation, and the second relating to inflammation as a risk factor
for poor recovery, the literature search only identified studies including data that
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could answer the first. Therefore, the following discussion is limited to validity
assessment of prevalence estimates in this review.
2.4.7.1 Definition of validity assessment
Validity assessment (often termed quality assessment) is an essential
component of a systematic review. It is an assessment of the degree to which each
reported finding accurately reflects what is happening in the real world (internal
validity), and the extent to which that finding can be generalised to the population
of interest (external validity). For a study to have internal validity, it must answer
the specific question being asked by the researcher, and the populations and
methods employed must be capable of answering this question. For a study to have
external validity, the sample population must be true reflection of the population of
interest. This is often a major challenge to study design.
Bias, the 'systematic error introduced into sampling or testing by selecting or
encouraging one outcome or answer over others' (Pannucci & Wilkins, 2010) is the
biggest threat to study validity and can creep into the research process at any stage
from conception and design, right through to analysis and publication (Bhopal,
2008). Presentation of information about the risk of bias of included studies allows
readers to decide how much confidence to place in any data presented. This is
particularly important for systematic reviews of health care interventions where
clinical decision-making might be influenced. Since it is virtually impossible to
eliminate the influence of bias on the results of a clinical study, even in the most
rigorous randomised controlled trials, validity assessment can be considered an
assessment of the risk of bias - an approach supported by the Cochrane
collaboration.
Assessment of validity is not the same as assessment of methodological
quality. The traditional approach to validity assessment has been to assume a lower
risk of bias if certain characteristics of methodological rigor are satisfied (such as by
giving evidence of a power calculation). The issue with this approach is that some
of the factors considered to represent methodological excellence, do not actually
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negatively impact on bias. Additionally, lack of evidence of certain methodological
features in a study report, may represent poor reporting rather than poor design or
conduct.
2.4.7.2 Sources of bias in prevalence studies
Bias can affect clinical studies at any stage from the framing of the research
question, right through to the analysis and publication of results (Bhopal, 2008).
Most prevalence studies are epidemiological studies of diseases, and within them a
number of study design features have been identified as sources of bias (Loney,
Chambers, Bennett, Roberts, & Stratford, 1998). Prevalence is defined as 'the total
number of individuals who have an attribute or disease at a particular time divided
by the population at risk' (Porta, 2008). With this in mind, for a prevalence estimate
to be valid, 3 general requirements need to be met:
1. The method used to identify or diagnose the disease or attribute is a valid
and reliable method of doing.
2. The design and conduct of the study results in a sample that is
representative of the target population
3. The target population of the study reflects the population of interest.
Where 1 and 2 reflect internal validity and 3 reflects external validity.
2.4.7.3 Validity assessment instruments
A vast number of tools have been designed to assist authors of systematic
reviews in the process of validity assessment. Sanderson and colleagues (Sanderson,
Tatt, & Higgins, 2007) identified 86 tools for assessing the quality and susceptibility
to bias in observational studies and Shamliyan and colleagues identified 97 tools
that could be used to evaluate studies of prevalence or risk factors of disease (T.
Shamliyan, Kane, & Dickinson, 2010). Despite this choice of instruments, most
systematic reviews of epidemiological outcomes fail to make adequate assessments
of validity. This is partly due to a lack of consensus about how this should be
optimally carried out (T. Shamliyan, Kane, & Jansen, 2012). Choosing an optimal
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tool to assess validity in observational studies is therefore challenging. Selection of
an appropriate method warrants careful consideration of a number of key issues. A
summary of these is provided at the end of this section (Table 2-4).
Most validity assessment tools are scales or checklists. Scales prompt
authors to score several aspects of study design or conduct that are then combined
to create a summary score. Checklists prompt authors to look for the presence or
absence of various features deemed important for study quality. These tools can
often be administered rapidly and are reliable (agreement between individual
assessors can be high). However their validity is questionable (Sanderson et al.,
2007).
The use of summary scores to quantify overall risk of bias is considered to be
misleading because it makes unfounded assumptions about the relative importance
each assessed validity criterion. Indeed the use of validity assessment scales is
'explicitly discouraged' by the Cochrane collaboration (Higgins & Green, 2011). In
their critique of quality scales, the Cochrane draw attention to one such scale
developed by Jadad and colleagues. This scale has been widely used to assess the
'quality' of randomised controlled trials. In addition to the problems associated
with weighting, this score is also criticised for its focus on reporting of trials rather
than steps taken to reduce risk of bias.
Instead a 'domain-based' approach is recommended, allowing a subjective
assessment of risk of bias (high, unclear or low) in specific domains. This approach
makes allowances for the subjective nature of validity assessment, and gives the
reader the information they need to interpret the findings presented to their own
satisfaction.
The development process for a validity assessment tool is extremely
important. This should include a rigorous method of criteria selection that is based
on the best evidence or the opinion of research methodology experts. Reliability is
the degree to which different independent assessors obtain the same result using the
same measurement instrument and is discussed further in section 3.10.1. The
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reliability of any new tool should be assessed to ensure that the assessments carried
out by different researchers using the same tool give the same answer.
For the majority of scales and checklists, the development process is not
described or there are issues relating to the inclusion of features not relevant to
study validity. Similarly, very few authors are able to demonstrate reliability data
(Higgins & Green, 2011; Sanderson et al., 2007).
A pre-requisite to reliability is ease of use. Instruments that are detailed and
lengthy may allow a very precise analysis of all relevant sources of bias but the
added complexity may make them cumbersome to administer. This may jeopardise
reliability, especially when assessing a large number of studies.
Systematic reviews of healthcare interventions are likely to source data from
interventional studies. Validity tools therefore focus on sources of bias in
interventional studies (such as the Cochrane domain based evaluation tool)
(Higgins & Green, 2011). For epidemiological outcomes, (e.g. incidence, prevalence,
or association), depending on how inclusive the authors wish to be; data may
potentially be drawn from a variety of study designs (e.g. cohort studies, cross-
sectional studies, or interventional studies). Thus the ability to apply a particular
tool to a variety of study designs is a relevant consideration.
Most validity tools focus on the features of single study designs. This limits
their applicability to reviews that consult multiple designs. One approach might be
to use several different tools to allow the assessment of data in each study design
included. However, this precludes the comparison of validity between studies. The
ideal solution would be to use tools that assess elements of bias relevant to the
research question regardless of study design.
Feature Considerations
Addresses sources of bias
relevant to research question
Effect of an intervention






Validity Rigorous development process
Expert consensus
Evidence based criteria
Reliability Evidence of reliability testing
Complexity Balances comprehensiveness with ease of use
Applicability Can be applied to single study only
Can be applied to multiple study designs
Table 2-4 Considerations when choosing a validity assessment tool
2.4.7.4 Criteria for validity assessment tools for this review
• Based on the considerations described in Table 2-4, a number of criteria were
defined to allow selection of potentially useful validity assessment tools.
These were:
• Research question: The tool can be used to assess important biases in
prevalence estimation.
• Underlying design: Scales should be avoided. Domain based approaches
should be favoured over checklists.
• Validity: The tool has undergone a rigorous development process based on
the available evidence base or expert opinion
• Reliability: The tool has been demonstrated to be reliable.
• Complexity: The tool is simple to use but includes criteria for assessing all
relevant bias
• Applicability: The tool can assess risk of bias relating to prevalence
estimates in multiple study designs.
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2.4.7.5 Available tools for prevalence estimates
A recent systematic review identified and assessed validity assessment tools
suitable for evaluating studies of prevalence estimates (T. Shamliyan et al., 2010).
Of the 97 instruments identified by the authors, 22 were considered potentially
suitable for assessing the validity of prevalence estimates. Based on their
assessment:
Underlying design: Fourteen (64%) were scales and 8 (36%) were checklists.
None of the identified instruments employed a domain-based approach to validity
assessment.
Validity: In the case of eleven (50%) instruments, the authors described the
development process. Nine of these described adaptations or modifications to
previously described tools originally designed for another purpose.
Reliability: Thirteen (59%) quoted reliability data. In those assessed,
agreement was considered to be good to excellent with agreement between
assessors ranging from 70% to 95%.
Applicability: Six of the instruments were considered to be applicable across
the full range of observational study designs. Eight of the studies were only
applicable to single study designs. The remaining six were applicable to a limited
number of study designs.
Considering each criterion in turn, of the 22 instruments identified, 14 were
excluded because they were scales. Of the 8 checklists, only 3 described any form of
development process and of these, 1 was a modification of another tool. Both of the
remaining checklists were designed for risk factor estimates and of limited use for
prevalence estimates.
In keeping with the findings of the authors, none of the tools identified in
the review could be considered evidenced based, reliable, instruments for assessing
the bias in prevalence studies. In addition, none of the tools could be considered to
be domain-based evaluations of risk of bias in prevalence estimates.
Since the publication of this review, researchers have continued to pursue
improved instruments for assessing risk of bias in prevalence studies by the
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pragmatic adaptation of previous instruments (Hoy et al., 2012), and by literature
review and expert consultation (T. A. Shamliyan et al., 2011). An example of the
later approach, published by Shamliyan and colleagues in the Journal of Clinical
Epidemiology, demonstrates the rigorous development process of a checklist
specifically developed to help appraise the quality of prevalence studies and
represents the current most credible instrument for this purpose. The elements in






Design / target population
External Validity Sampling source / method
Assessment of sampling bias
Response rate
Exclusion rate from analysis
Addressing sampling bias in analysis
Study flow / recruitment rates
Internal Validity Source of measure
Reference period
Disease definitions e.g. frequency / severity of
symptoms
Validation of measurement technique
Reliability of measurement technique
Reporting of estimates e.g. precision,
subgroups of interest
Table 2-5 Validity assessment criteria by Shamliyan et al. Criteria highlighted in
bold font were considered unlikely sources of bias in the current review.
Whilst this tool is likely to be the best available approach for assessing
validity in prevalence studies, it has limitations in the current review.
First, the presence or absence of ethical approval might be an indicator of
methodological quality but it does not assist in detection of bias.
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Second, some of the criteria in the checklist make the assumption that the
study authors set out to measure prevalence and that this was a predefined part of
the analysis if not the primary analysis. In the current review, measurements of
inflammation were performed as a supplementary analysis and not the primary
analysis. Indeed the derivation of prevalence estimates was carried out by the
author of this review based on raw data provided by the study authors.
As a result, external sources such as funders and their involvement in the
study analysis would be unlikely sources of bias. Similarly, it seems unlikely that
declared conflicts of interest of authors would be relevant if raw data is being used
to perform the analysis. In addition, reporting of prevalence estimates cannot be
considered an assessment of bias of the primary study and is therefore a redundant
component of the checklist.
2.4.7.6 A review-specific validity assessment tool
Modifying an existing domain-based risk of bias instrument produced by
Roy and colleagues which is itself a modification of preceding quality assessment
scales, the sources of bias described in 2.4.7.2 and the relevant criteria identified by






Risk of Bias Item Criteria (circle) Notes
External Validity





Yes (LOW RISK): The study's target
population was a close representation of
adult ICU survivors.
No (HIGH RISK: the study's target
population was clearly NOT
representative of adult ICU survivors (e.g.
described a single disease or patients
managed in a trauma ICU)
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Not reported
2. Was the sampling
frame (setting from
which the sample




Yes (LOW RISK): The sampling frame
was a true or close representation of the
target population
No (HIGH RISK): The sampling frame
was NOT a true or close representation of
the target population
Not reported
3. Was some form of
random selection
used to select the
sample?
Yes (LOW RISK): A random selection
method was used.
No (HIGH RISK): A random selection
method was NOT used.
Not reported
4. Was the likelihood
of non-response bias
low?
Yes (LOW RISK): Response rate >75% or
<75% and analysis demonstrated no
significant differences in non-responders.
(Were the number of
subjects originally
sampled that did not
have a measure of
systemic
inflammation







rest of the sample?)
No (HIGH RISK): Response rate <75%
and analysis demonstrated significant
















Yes (LOW RISK): An appropriate case
definition was used.
No (HIGH RISK): An alternative definition
was used or no definition was provided.
Not applicable:(investigators did not impose
a definition as aim of study was different from
aims of review)
Not recorded: A definition was clearly used























Yes (LOW RISK): The study instrument has
been shown to have reliability and validity.
No (HIGH RISK): The instrument had NOT











Yes (LOW RISK): The same mode of data
collection was used for a II subjects
No (HIGH RISK): The same mode of data
collection was NOT used for all subjects
Not reported
Table 2-6 Review-specific risk of bias instrument
2.4.8 Reporting
The review was reported according to the relevant sections of the MOOSE
guidelines for Meta-Analyses and Sytematic Reviews of Observational Studies
(Stroup et alv 2000).
2.5 Results
The main results are summarised in the data table that can be found at the
end of the chapter (Table 2-12).
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2.5.1 Study Selection
After electronic database searching and de-duplication, 7433 unique
references were retrieved. In total, 3327 abstracts were screened and from these 208
articles fulfilling or potentially fulfilling eligibility criteria were retrieved for full
text review. 57 papers (Akbas, Karakurt, Unluguzel, Celikel, & Akalin, 2010; Al-
Subaie et al., 2010; Altrichter et al., 2011; Azevedo et al., 2011; Balci, Sivaci, Akbulut,
& Karabekir, 2009; Barth et ah, 2002; Bateman, McArdle, & Walsh, 2009; Book et ah,
2007; Chen, He, & Li, 2009; Cho et ah, 2005; Clark, Hentzen, Plank, & Hill, 1996;
Damas et ah, 2006; de Pablo et ah, 2011; Dorizzi et ah, 2006; Farah & Makhoul, 2011;
Friedland et ah, 1996; Grander et ah, 2010; Hansen, Thiel, Wouters, Christiansen, &
Van den Berghe, 2003; Heizmann, Koeller, Muhr, Oertli, & Schinkel, 2008;
Hekimoglu Sahin, Memis, & Sut, 2009; K. M. Ho, G. J. Dobb, K. Y. Lee, S. C. Towler,
& S. A. Webb, 2006; Ho et ah, 2008; Iapichino, Marzorati, et ah, 2010; Iapichino,
Umbrello, et ah, 2010; Jensen et ah, 2006; A. Kaben et ah, 2008; Kauss et ah, 2010;
Litton et ah, 2007; Luzzani et ah, 2003; Makris, Dulhunty, Paratz, Bandeshe, &
Gowardman, 2010; Martensson et ah, 2010; Memis et ah, 2007; Oda et ah, 2005;
Parnaby, Eaton, Shafi, & Bell, 1994; Povoa et ah, 2006; Povoa, Teixeira-Pinto, &
Carneiro, 2011; Rauchschwalbe et ah, 2004; Reny et ah, 2002; Rixen & Siegel, 2000;
Schneider et ah, 2011; Sihler, Raghavendran, Westerman, Ye, & Napolitano, 2010;
Silvestre, Coelho, & Povoa, 2010; Stegenga et ah, 2010; Tsangaris et ah, 2009; Tsuruta
et ah, 2010; Umbrello et ah, 2010; Watanabe, Hirasawa, Oda, Shiga, et ah, 2005;
Weimann et ah, 1998; Whang et ah, 1998; Woehrle et ah, 2008; Yousef, Amr, &
Suliman, 2010; Yucel, Memis, Karamanlioglu, Sut, & Yuksel, 2008; Zeckey et ah,
2011; Zenahlikova et ah, 2010; Zugel, Kox, Lichtwark-Aschoff, Gippner-Steppert, &
Jochum, 2011) fulfilled eligibility criteria (or did not contain enough information to
exclude) from the review. A flow diagram is presented detailing exclusions at
various stages of the review (Figure 2-1).
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2.5.2 Data completeness
Of the 57 papers considered to be eligible after full text review, none had
prevalence estimates for systemic inflammation. Therefore the authors of all these
studies were contacted to provide further data. The authors for 34 (65%) of the
articles responded (Akbas et al., 2010; Al-Subaie et al., 2010; Azevedo et al., 2011;
Balci et al., 2009; Bateman et al., 2009; Cho et al., 2005; Damas et al., 2006; de Pablo et
al., 2011; Grander & Dunser, 2010; Hansen et al., 2003; K. M. Ho et al., 2006; Ho et al.,
2008; Iapichino, Marzorati, et al., 2010; Iapichino, Umbrello, et al., 2010; Jensen et al.,
2006; Kauss et al., 2010; Litton et al., 2007; Makris et al., 2010; Martensson et al., 2010;
Memis et al., 2007; Oda et al., 2005; Povoa et al., 2006; Povoa et al., 2011; Reny et al.,
2002; Tsangaris et al., 2009; Tsuruta et al., 2010; Umbrello et al., 2010; Watanabe,
Hirasawa, Oda, Shiga, et al., 2005; Weimann et al., 1998; Yousef et al., 2010; Yucel et
al., 2008; Zugel et al., 2011). Nine studies were excluded at this stage. Seven of
these did not measure inflammation at an appropriate time point (Cho et al., 2005;
Oda et al., 2005; Povoa et al., 2011; Reny et al., 2002; Tsangaris et al., 2009;
Zenahlikova et al., 2010; Zugel et al., 2011). Two studies (Umbrello et al., 2010;
Yucel et al., 2008) used the same data as other included studies (Iapichino, Umbrello,
et al., 2010; Memis et al., 2007) and were excluded. Raw data to allow calculation of
prevalence estimates was provided for 13 studies (23%) (Akbas et al., 2010; Al-
Subaie et al., 2010; Azevedo et al., 2011; Damas et al., 2006; Grander et al., 2010;
Heizmann et al., 2008; K. M. Ho et al., 2006; Iapichino, Marzorati, et al., 2010;
Iapichino, Umbrello, et al., 2010; Litton et al., 2007; Makris et al., 2010; Martensson et
al., 2010; Watanabe, Hirasawa, Oda, Shiga, et al., 2005). These studies were
included in the analysis. Where prevalence data was not provided, summary
estimates of biomarker concentrations were available for 8 studies and these were
also included in the analysis (Balci et al., 2009; Bateman et al., 2009; Hansen et al.,
2003; Hekimoglu Sahin et al., 2009; Ho et al., 2008; Jensen et al., 2006; A. Kaben et al.,
2008; Silvestre et al., 2010). None of the studies measured physical function after
ICU discharge. One investigator measured health-related quality of life but was
unable to provide data to data to allow calculation of association with inflammatory
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markers (Bateman et al., 2009). Finally, 1 author volunteered data from another
study (Van den Berghe et al., 2006) and the summary data from this study was
included.
Figure 2-1 Systematic Review Flow Diagram
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2.5.3 Design
Of the 22 analysed studies, 19 (86%) were observational and 3 (14%) were
interventional. Of the observational studies, 3 (16%) were case-control studies, 1
(5%) was a cross-sectional study, and 15 (79%) were cohort studies.
2.5.4 Measures of inflammation and cut offs
The most common measure of inflammation was C-reactive protein (CRP),
measured in 20 (91%) of studies. Pro-calcitonin (PCT) was measured in 3 (14%)
studies. IL-6 was measured in 3 (14%) studies. TNF a was measured in 1 (5%)
study. SIRS criteria were measured in 1 (5%) study. Myeloperoxidase (MPO) was
measured in 1 study (5%). For a fuller discussion of inflammatory biomarkers see
section 3.9).
For TNF a and IL-6, reference ranges from a population-based sample of
community dwelling adults were used to determine a definition of 'evidence of
inflammation' (Marques-Vidal et al., 2011). The authors report quartiles for those
patients with detectable levels of these molecules in serum. In the absence of
reported higher centiles, patients with TNF a and IL-6 levels above the 75th centile
quoted in this study were deemed to have molecular evidence of systemic
inflammation (4.5pg/mL for TNF a and 3.5pg/mL for IL-6).
The cut off for CRP was based on the distribution of CRP concentration
observed in a healthy population. In healthy young adults, median CRP
concentration is 0.8mg/L (90th centile 3mg/L, 99th centile lOmg/L) (Shine, de Beer, &
Pepys, 1981). CRP rises slightly with age. Despite this, CRP concentration in
healthy adults seldom rises above 3mg/L (Ballou et al., 1996; Delongui et al., 2013).
A CRP cut off of lOmg/L was chosen to identify those patients with evidence of
significant on going inflammation.
For PCT, the cut off was derived from a study of population of 451 healthy
controls (Morgenthaler et al., 2002). In this population, the 97.5th percentile was
46.7ng/L (0.05ng/mL). The PCT cut off to detect systemic inflammation was
therefore set at 0.05ng/mL.
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The cut off for myeloperoxidase (MPO) concentration was set as the 75th
centile of the control group for a nested case-control study of cardiovascular risk
(Meuwese et al., 2007). This cohort consisted of 2,237 patients with a median
concentration of 638 pg/mL (IQR 454-954pg/mL). The cut offs for each biomarker
are summarised below (Table 2-7).
Biomarker Cut off
IL-6 3.5 pg/mL
TNF a 4.5 pg/mL
CRP 10 mg/L
PCT 0.05 pg/mL
MPO 951 pg/mL (0.951 ng/mL)
Table 2-7 Cut offs for systemic inflammation for the different biomarkers used in the
review
2.5.5 Validity
Whilst adequate information was provided in the texts of most of the articles
to make an assessment, inadequate reporting precluded full assessment in some
cases. It should be noted that a lack of reporting was not interpreted as high risk of
bias and is not a judgment on the quality of the work either. Prevalence of
inflammation was not the primary research question of any study and therefore
reporting of validity data relevant to this review may not have been relevant for the
main research question of the article.
2.5.5.1 External validity
As anticipated at the planning stage, there was significant heterogeneity in
the target populations chosen by the authors to meet the specific needs of their
research question. As a result, the external validity of some of the included studies
to all ICU patients was limited. Eight of the included studies (36%) aimed to study
a target population that could be considered representative of general adult ICU
survivors. The remaining 14 studies were more specialised in their target
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populations. However, the subgroups have well defined in these studies and
provide some information about inflammation in specific sub-groups. The target
population for each study is shown in Table 2-8.
Target population Study
Mixed medical / surgical ICU Al Subai, Ho, Silvestre, Watanabe, ,
Povoa (Al-Subaie et al., 2010; Ho et al.,
2008; lapichino, Umbrello, et al., 2010;
Povoa et al., 2011; Silvestre et al., 2010;
Watanabe, Hirasawa, Oda, Shiga, et al.,
2005)
Chronic Obstructive Pulmonary Disease
with respiratory failure
Akbas (Akbas et al., 2010)
Trauma Balci (Balci et al., 2009)
Anaemia at ICU discharge Bateman (Bateman et al., 2009)
Medical ICU Grander, Van den Berghe (Grander et
al., 2010; Van den Berghe et al., 2006)
Surgical ICU Hansen, Kaben (Hansen et al., 2003; A.
Kaben et al., 2008)
Severe Sepsis Hekimoglu Sahin, Martensson, Memis
(Hekimoglu Sahin et al., 2009;
Martensson et al., 2010; Memis et al.,
2007)
Unplanned ICU admissions Ho, Makris (K. M. Ho et al., 2006; Makris
et al., 2010)
Long term ICU patients lapichino (lapichino, Marzorati, et al.,
2010), Azevedo (Azevedo et al., 2011)
Unexpected in ward after ICU Litton (Litton et al., 2007)
Ventilator associated pneumonia Damas (Damas et al., 2006)
Matched control groups from case- Ho, Makris, Litton (K. M. Ho et al., 2006;
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control studies Litton et al., 2007; Makris et al., 2010)
Table 2-8 Target population of selected studies
Unlike large epidemiological studies, the available sampling frames for a
study of inflammatory biomarker concentrations is limited. The unobtainable ideal
would be to take a random sample of all ICU adult ICU survivors, everywhere in
the world at exactly the same point in time after ICU discharge..
As a pragmatic compromise, it was considered that if the inclusion and
exclusion criteria for a study did not exclude important subgroups of patients, the
sampling frame would be considered adequate and therefore unlikely to be a source
of bias. On this basis, fourteen studies (64%) were considered to be at low risk of
bias and 6 studies (27%) were considered to be at high risk of bias.
Unlike epidemiological studies, in clinical studies, sampling does not occur
at random. Instead, eligible patients are identified consecutively and then
approached for consent. Therefore none of the studies fulfilled the criteria for
random selection, therefore introducing a potential source of selection bias in all
cases.
Follow up rates in the study were generally good. Therefore most of the
patients enrolled in the studies had a measurement of inflammation carried out. On
this basis, 15 studies (68%) were considered at low risk of non-response bias. Seven
(32%) were considered at high risk of non-response bias..
Overall, external validity was poor. Excluding the 5 studies in which a full
assessment was precluded by lack of data (Azevedo et al., 2011; Balci et al., 2009; A.
Kaben et al., 2008; Memis et al., 2007; Van den Berghe et al., 2006) all the studies had
1 or more flaws in external validity, 11 (68%) had 2 or more flaws, and 4 (25%) had 3
flaws.
When target population was discounted (to allow for validity assessment in
specific sub-groups), only 1 study lacked any flaws in external validity (Grander et
al., 2010). 15 (93%) studies had 1 or more flaws, and 7 (44%) had 2 flaws.
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2.5.5.2 Internal validity
Fifteen of the studies (68%) described their methods for ascertainment of the
measure of inflammation. In one study, SIRS criteria were measured. Of the
remaining studies, biomarkers were measured. In most cases, hospital biochemistry
analysers capable of measuring a wide range of molecules were used. In a minority
of cases, ELISAs and other laboratory-based techniques were used. All the
described methods were considered reliable and valid methods for measuring the
relevant biomarkers (see Table 2-9).
In fifteen of the studies (68%), the same instrument or method was used for
all the measurements. The remainder did not report a method and made no
comment about the consistency of the approach.
In summary, internal validity was considered to be good.





Akbas, Ho 2006, Ho
2008, Litton 2007.
Grander
Hitachi Modular P Auto-analyser Hansen
CRP
Roche Tina Quant (for use
on Hitachi auto-analysers)
Auto-analyser Silvestre
Beckman Coulter LX-20 Auto-analyser Al-Subai
Beckman Coulter CX-9 Auto-analyser Hekimoglu Sahin,
Memis
Boehringer-Mannheim Nephelometric Balci
PCT Brahms AG Lumitest Luminometric Balci, lapichino 2010





Table 2-9 Biomarker measurement methods
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2.5.6 Evidence of inflammation at ICU discharge
2.5.6.1 CRP
Figure 2-2 illustrates the proportion of patients in each study with evidence
of systemic inflammation at ICU discharge according to the definition derived in
2.5.4. Median CRP concentration at ICU discharge is then presented both according
to study, then according to disease-specific subgroups to explore the ICU cohort on
systemic inflammation at this time point.
Of the 22 included studies, 18 (82%) measured CRP at the point of ICU
discharge. CRP concentration was elevated (>10mg/L) in the majority of patients
ranging from 70% in a large study of mixed medical and surgical ICU patients
(Grander et al., 2010) to 100% in patients with severe sepsis (Martensson et al., 2010)
and a cohort of patients who subsequently were readmitted to ICU (K. M. Ho et al.,
2006). The percentages observed in each sample are illustrated in bar chart format
(Figure 2-2). For case-control studies, the cases and controls have been reported
separately. In one of the cohort studies, data was only available for the subgroups
and not for the cohort as a whole. In this case, data for the subgroups is shown.
The CRP concentration varied according to the population studied. The
median (IQR) CRP concentration at ICU discharge for each study cohort is
presented in Figures 2-3 to 2-8. The mean of the median concentrations of CRP at
ICU discharge in the mixed medical / surgical cohorts was 60mg/L. Lower mean
CRP concentration was observed in trauma ICU patients (23mg/L), patients with
VAP (46mg/L), prolonged length of stay (45mg/L), and medical ICU patients
(36mg/L). Higher mean CRP concentrations were noted in sepsis survivors
(107mg/L) and surgical ICU patients (99mg/L). Unsurprisingly, the patients
selected as cases for the observational studies of ICU readmission (K. M. Ho et al.,
2006; A. Kaben et al., 2008) and unexpected death after ICU discharge (Litton et al.,
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Azevedo lapichino (Long stay general ICU)
Figure 2-8 CRP concentration at ICU discharge in long stay ICU survivors
61
2.5.6.2 IL-6
Three studies (14%) measured IL-6 at ICU discharge (Iapichino, Marzorati, et al.,
2010; Iapichino, Umbrello, et al., 2010; Watanabe, Hirasawa, Oda, Shiga, et al., 2005).
These included one study of mixed medical and surgical ICU survivors (Watanabe,
Hirasawa, Oda, Shiga, et al., 2005), one study of ICU patients with a length of stay
longer than 6 days (Iapichino, Marzorati, et al., 2010), and one study of ICU patients
with sepsis (Iapichino, Umbrello, et al., 2010). The percentage of patients in each of
these samples with IL-6 concentration above 3.5 pg/mL was 99%, 63% and 100%
respectively. Median (IQR) IL-6 concentration at ICU discharge in these samples
were 80 (42-183) pg/mL, 76 (2-100) pg/mL, and 20 (15-39) pg/mL. There is therefore
evidence of significant elevations in IL-6 concentration in the 3 studies at ICU
discharge.
2.5.6.3 PCT
Study / cohort Median (IQR) PCT concentration at
ICU discharge (ng/mL)
Balci (Trauma ICU) 1.18 (0.99-1.44)
lapichino (ICU stay >6 days) 0.17 (0.09-0.33)
Martensson (SIRS no AKI) 0.18 (0.15-0.54)
Martensson (Severe Sepsis no AKI) 0.53 (0.39-1.20)
Martensson (Septic shock no AKI) 0.58 (0.43-0.77)
Martensson (Septic shock AKI) 1.05 (0.48-2.89)
Table 2-10 PCT concentration at ICU discharge
Three studies (14%) measured PCT at ICU discharge (Balci et al., 2009;
Iapichino, Marzorati, et al., 2010; Martensson et al., 2010). Only 2 of the authors of
these studies provided data to allow a prevalence calculation (Iapichino, Marzorati,
et al., 2010; Martensson et al., 2010). All the patients in the Iapichino study of ICU
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patients with a stay of greater than 6 days had a PCT concentration greater than
0.05ng/mL (Iapichino, Umbrello, et al., 2010). All subgroups of sepsis survivors in
Martensson's study had elevated PCT concentrations according to this definition.
In the subgroup of patients that had SIRS, 89% of patients had elevated PCT.
The median (IQR) concentrations of PCT in the various study groups is
given in Table 2-10.
2.5.6.4 TNF-a
One study measured TNF-a at ICU discharge (Iapichino, Umbrello, et al.,
2010). In this study of septic ICU patients the median (IQR) TNF a concentration
was 20 (15-39) pg/mL. The percentage of patients with a TNF a concentration above
4.5 pg/mL was 100%.
2.5.6.5 MPO
MPO was measured at ICU discharge in 1 study of patients with SIRS and
sepsis (Martensson et al., 2010). MPO was elevated at ICU discharge in 0%, 11%,
56% and 0% of ICU survivors with SIRS, severe sepsis without AKI, septic shock
without AKI, and septic shock with AKI respectively. Median MPO concentrations
for each sample are presented in Table 2-11. Notably, the concentrations measured
are much lower than the expected reference ranges given in the control cohort from
which the cut off was derived (951ng/mL).
Study / Cohort Median (IQR) MPO concentration (pg/L).
Martensson (SIRS no AKI) 103 (77-112)
Martensson (Severe Sepsis no AKI) 72 (109-215)
Martensson (Septic shock no AKI) 70 (60-90)
Martensson (Septic shock AKI) 78 (106-145)
Table 2-11 MPO concentration at ICU discharge according to study population
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2.5.6.6 SIRS Criteria
One study measured SIRS criteria at ICU discharge (Makris et al., 2010).
Ninety-five percent of ICU survivors who were subsequently readmitted to ICU
during the same hospital admission met criteria for SIRS. A comparable percentage
(92%) of patients who were not subsequently re-admitted to ICU had SIRS.
2.5.7 Evidence of inflammation after ICU discharge
Three of the included studies measured inflammation after ICU discharge
(Akbas et al., 2010; Bateman et al., 2009; Makris et al., 2010).
Makris and colleagues measured SIRS criteria 72 hours after ICU discharge
in a case-control study comparing 244 patients who were subsequently re-admitted
to ICU (cases), and 244 controls that were not readmitted (controls) (Makris et al.,
2010). In the cases, 69% of the patients fulfilled criteria for SIRS whilst in the
controls only 42% of the patients fulfilled criteria for SIRS.
Sequential measurement of inflammatory biomarkers after ICU
Weeks after ICU discharge
Figure 2-9 Sequential measurement of inflammatory biomarkers in ICU
survivors with anaemia at ICU discharge
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Akbas and colleagues measured CRP concentration in 10 ICU survivors at
hospital discharge and found that 9 of them (90%) had a CRP concentration of
greater than lOmg/L (Akbas et al., 2010). The median (IQR) of CRP concentration
was 23 (16-93) in this sample.
Bateman and colleagues studied 24 ICU survivors that had evidence of
anaemia at ICU discharge (Haemoglobin concentration <100g/dL) (Bateman et al.,
2009). CRP and IL-6 were measured at weeks 1, 3, 6, 9, 13, and 26 after ICU
discharge. Following a steep decline in both biomarkers, CRP concentration fell
below lOmg/L at 13 weeks. IL-6 remained elevated even after 26 weeks (Figure 2-9).
2.5.8 Association of inflammation with physical recovery
None of the studies measured physical outcome measures as well as markers
of inflammation after ICU discharge. There is therefore no known work that links
inflammation after ICU discharge with physical recovery after ICU discharge. One
study (Bateman et al., 2009) measured health-related quality of life after ICU
discharge but were unable to provide data to test the association with systemic
inflammation.
2.6 Discussion
This systematic review is a key part of the background work for the
following chapters. It aimed to identify all previous studies that have measured
systemic inflammation in survivors of critical illness, and all previous studies that
have measured physical recovery in addition to systemic inflammation. From a
basic scoping search carried out during the planning stage of the review, it was
evident that very few investigators were likely to have posed either of these 2
research questions. It was considered of great importance to be inclusive as possible
so that all potentially relevant studies would be identified even if they were
subsequently excluded.
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The review unearthed the data from 22 studies of ICU patients that had
measured systemic inflammation at or after ICU discharge and found that in almost
all ICU survivor populations, systemic inflammation is present at ICU discharge.
Data pertaining to later time points is scarce and no previous studies had
specifically explored the relationship between systemic inflammation and recovery
of function after critical illness.
One major difficulty with the review was the setting of definitions. A large
number of molecules are associated with inflammation and many of them are
undetectable in the blood when the innate immune system is inactive. Conversely
some investigators suggest that elevation of cytokines is a normal part of aging and
that in some populations, cytokine induction might be the norm rather than the
exception (Candore, Caruso, Jirillo, Magrone, & Vasto, 2010).
Using a threshold level of inflammatory mediators to define inflammation is
therefore potentially misleading. Just like a diagnostic test, if the threshold is set too
high, the test will become more specific but much less sensitive. This will result in a
large number of patients with an activated immune system who are not identified
by the biomarker measurement - the false negatives. Set too low, and the test
becomes very sensitive but not specific. This results in a higher number of patients
identified as being systemically inflamed but who are not - the false positives.
Because there is no biochemical definition of systemic inflammation, and no 'gold
standard' test to which investigators can refer, the author of this review had to rely
on the best available healthy control population data.
Whilst the author accepts this limitation, especially for the biomarkers used
less commonly in clinical practice, the steps taken to mitigate the risk posed by this
limitation are emphasised. Firstly, in the case of CRP, a high cut off (>10mg/L) was
chosen. This level is grossly abnormal even in very elderly patients and the author
therefore has a degree of confidence that patients with CRP concentrations above
this threshold have a significant degree of innate immune activation. Second, the
quoting of a summary estimate (e.g. median (IQR)) next to the proportion in the
data table gives the reader an indication central tendency of the measurement and
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can compare this to the normal ranges quoted in the table of reference ranges (Table
2-7).
It is worth noting that the decision not to undertake a meta-analysis to
combine and summarise the results was made in advance of carrying out the
analysis. This decision was made on the basis that the study cohorts were likely to
be heterogenous, and therefore would not improve the clarity of the results.
Furthermore, the overall aim on the review was to identify what research others had
carried out in this area in order to plan future work and this aim would not be
addressed by a meta-analysis or meta-regression analysis.
One of the strengths of the review was the process of the literature search
undertaken. The syntax for the search can be reviewed in the appendix. This was
comprehensive, and was adapted for each relevant database search. It covered the
breadth of the medical and clinical science literature and included searches
databases of databases that listed sources of grey literature including conference
proceedings and abstracts. The risk of missing studies was therefore extremely low.
Article selection was a long and detailed process. Over 7,000 articles were
identified by the search, and many of these could be excluded immediately by
reference screening on the basis that they did not describe clinical studies of general
adult ICU patients. Of the remaining articles, 2 investigators reviewed abstracts of
all abstracts. Following this, 2 investigators reviewed the full text articles of the
included abstracts. Disputes between the 2 reviewers were settled by discussion.
This 2-reviewer approach to article selection is a further strength of the review.
As emphasised in the results section, no single study set out to measure
inflammatory markers in survivors of critical illness. The inclusion criteria allowed
for any study that had measured a measure of systemic inflammation at any point
starting from ICU discharge. A lack of detail in abstracts meant that even where
inflammatory mediators had been measured sequentially in ICU patients, it was
often not at all clear when measurements had stopped. To prevent the inadvertent
loss of relevant studies during the abstract review stage, an inclusive approach was
adopted so that exclusion could not occur at this stage due to lack of detail in the
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abstract. This added to the workload of full text reviews. However, it reduced the
risk of data loss.
None of the studies identified by the review process had in their reports
enough data to carry out the proposed analysis. For this reason, as agreed at the
protocol stage, the authors of the included studies were contacted by the email and
postal addresses attached to the articles. In some cases, email addresses were
invalid and postal addresses could not be found. For these studies, considerable
effort was made to make contact. This included contact with co-authors and
secretaries. As a result a relatively good response rate was achieved (65%) with
authors very keen to assist with the project. Unfortunately, only about half of them
had access to or were prepared to provide the raw data.
A further challenge of the review was the lack of a widely available
evidence-based validity assessment instruments specific to the particular research
question that could be easily and rapidly applied. A justification of the need for
validity assessment has been given in addition to an extensive account of process of
appraising available tools, and developing a review-specific tool. Criticism has been
levelled at previous investigators who have modified other validity assessment
checklists to suit the needs of a particular research question or disease. However
the major challenge of the current review was the search for data pertaining to a
research question that was not the aim of any of the included studies.
2.6.1 Systemic inflammation during recovery from critical illness
There is reasonable evidence that in survivors of critical illness, there is
significant immune activation when they leave ICU. Despite the variable quality of
the data, this is supported by numerous studies in different subsets of ICU
survivors measuring primarily CRP but also SIRS criteria, IL-6, TNF-alpha, and PCT.
The finding of persistent inflammation at this stage in a patient's illness is
unsurprising.
ICU discharge is an arbitrary point in the patients hospital stay and will vary
from country to country, hospital to hospital and from clinician to clinician. ICU
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discharge often represents the point when the patient no longer requires organ
support as part of their ongoing clinical management. It usually does not signify
full resolution of the disease process. The finding of ongoing systemic inflammation
at this time point therefore does not contribute significantly to medical knowledge.
One might expect that by the time a patient leaves hospital, organ failure
and disease resolution might be nearly complete. A finding of significant elevations
of inflammatory markers, or ongoing SIRS response at this stage might be more
clinically important. Only one study of ICU survivors has measured inflammation
at hospital discharge and this was focused on a very small (10 patients) COPD
cohort that had been admitted to ICU for respiratory failure. The finding that 9 of
these had CRPs above lOmg/L at ICU discharge is impossible to generalize to the
wider ICU survivor population.
Beyond hospital discharge, evidence of inflammation may be even more
significant. Whilst CRP and IL-6 remain elevated in ICU patients who were
anaemic on ICU discharge in one small study, there is no evidence in the literature
that in the wider ICU population, inflammation might be prevalent.
2.6.2 Systemic inflammation and physical recovery
After an extensive literature review process, there really are no studies that
have tested the hypothesis that persistent inflammation after ICU discharge and
recovery of muscle function might be interlinked. Despite the many studies that
link inflammation to muscle function and weakness in other diseases, there is no
previous work that has attempted to examine this link in a critical care cohort. In
order to start to understand whether inflammation is important in recovery after
critical illness, cohort studies testing such associations are required.
2.7 Conclusions
This systematic review marks the first stage in a programme of work
exploring systemic inflammation during the convalescent phase of critical illness
and its potential effects on the recovery of physical function. Whilst it has shown
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without question that there is on-going activation of the innate immune system at,
the point a patient is discharged from the intensive care unit there is no available
data that explains what happens beyond this point. Furthermore, there is no data to
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Chapter 3 - Persistent inflammation and the post-ICU
syndrome: A Cohort Study
3.1 Introduction
The physical, social, and psychological consequences of critical illness place a
real and significant burden on survivors of critical illness and their families. In the
introduction to this thesis, risk factors for poor recovery were reviewed. Notably,
these risk factors relate to patient characteristics, and severity of illness, factors that
are largely un-modifiable. There is a lack of epidemiological study seeking to
identify potentially modifiable risk factors occurring in the post-ICU period.
Low-grade 'chronic' inflammation is associated with poor physical function in
the elderly and patients with chronic inflammatory disease. In addition, systemic
inflammation has been implicated in psychiatric and psychological disease. In
chapter 2, it has been shown that in a majority of patients show biochemical
evidence of persistent inflammation at ICU discharge - but there is little knowledge
about what happens beyond ICU discharge. There is also some evidence that
circulating inflammatory markers may be detrimental to muscle function. It is
therefore plausible that the presence of unresolved inflammation following an
episode of critical illness (characterised by acute inflammation), may impact on
physical, and possibly psychological outcomes.
The 'RECOVER' study is a randomised controlled trial evaluating a
rehabilitation complex intervention for patients following intensive care discharge.
The study protocol has recently been published (T. S. Walsh et al., 2012). Briefly,
two hundred and forty survivors of critical illness were randomly allocated to
receive standard NHS ward care (control group) or standard NHS ward care plus
an enhanced recovery package (intervention group). Various measures of physical
function, psychological comorbidity, and quality of life were measured at 3, 6, and
12 months after ICU discharge with comparisons made between intervention and
control groups.
83
In addition to testing the effects of the RECOVER intervention, this trial
provides a unique opportunity to study 'post-ICU' factors that may hamper
rehabilitation. A blood sampling study was incorporated into the RECOVER trial
design in order to investigate persistent inflammation in survivors of critical illness,
and its relationship with rehabilitation outcomes.
This chapter aims to characterise the inflammatory profiles of ICU survivors
and to investigate the effects of persistent inflammation on recovery from critical
illness.
3.2 Hypotheses
• Systemic inflammation is prevalent in ICU survivors at ICU discharge,
during the post ICU period of hospitalisation, and after hospital discharge.
• The presence of systemic inflammation in recovering ICU patients prevents
physical and psychological recovery and quality of life.
3.3 Research Questions
• What is the prevalence of systemic inflammation in survivors of critical
illness?
• How long does systemic inflammation persist in survivors of critical illness?
• What is the time course of individual biochemical markers of systemic
inflammation after critical illness?
• Is persistent inflammation associated with the physical, psychological, and
quality of life outcomes?
3.4 Patient selection
Patients were eligible for the biomarker study if they were enrolled in the
RECOVER study. Inclusion and exclusion criteria for RECOVER are given in Table
3-1. Patients admitted to ICU for a short period of ventilation were excluded on the
basis that they are not the group that experiences the greatest disability and could
have weakened any observed impact of the trial intervention. Other excluded
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groups included those that would not be able to get the intervention, those unlikely
to survive, or those who could not be followed up.
Inclusion > 48 hours of invasive mechanical ventilation
Consultant in charge of care deems patient fit for ICU discharge
Exclusion Primary neurological admission diagnosis
Palliative care only
Currently receiving or planning to receive home ventilation
Expected to be discharged to a non-study hospital where intervention
could not be received
Could not consent due to communication difficulties
Currently enrolled in another trial with similar endpoints
<18 years old at time of screening
Table 3-1 Inclusion and exclusion criteria for the RECOVER trial.
3.5 Consent
During the consent process for RECOVER, patients were also provided with
information about the biomarker sub-study. Participation in the study was not a
pre-requisite of entry into the RECOVER study, and patients were permitted to
withhold their consent for this part of the study.
3.6 Baseline data collected
Data was collected at baseline that served to describe the patients under
study, track important functional changes, and to allow investigation of potential
confounding and interacting factors. These were determined by the main trial and
were not specific the biomarker component of the trial. This data can be subdivided
into a number of categories and these have been outlined in Table 3-2.
Baseline data category Data fields
Demographics Gender
Age
Evidence of ongoing disease process at
study baseline
Confusion assessment method (CAM) for
the ICU
Sequential Organ Failure Assessment
Score
Severity of illness Acute Physiology and Chronic Health
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Evaluation (II) score (APACHE II)
Use of vasopressors during ICU stay,
Renal Replacement Therapy during ICU
stay
Premorbid disease Functional comorbidity index (FCI)
Function at baseline Rivermead Mobility Index at baseline
Hand Grip Strength at 1 week
Table 3-2 Baseline data collected in the RECOVER trial.
3.7 Blood sampling
Blood sampling was carried out at entry to the study (close to the point of
ICU discharge). Following this, blood samples were drawn on a weekly basis until
hospital discharge, and then a final sample was drawn 3 months after study entry.
3.8 Blood processing and storage
Blood samples were drawn by vene-puncture (or from arterial lines if they
were still in situ to reduce patient discomfort) into pre-treated sample tubes (Serum
Gel 4.7mL, and EDTA 4.9mL (Starstedt AG and Company, Niimbrecht, Germany).
Samples were allowed to sit at room temperature for 30 minutes prior to processing
as per the manufacturers guidance. Samples were then centrifuged at 2500G for 10
minutes at room temperature before being divided into aliquots in pre-labelled
sample tubes. Samples were placed in boxes and stored at -70C until analysis.
Freeze thaw cycles were kept to a minimum.
3.9 Selection of biochemical markers of inflammation
3.9.1 C-Reactive Protein
C-reactive protein (CRP) is an acute phase protein and is a short chain
member of the pentraxin family. It is an extremely sensitive marker of systemic
inflammation. CRP is produced primarily in hepatocytes. Its synthesis is rapidly
up-regulated in response to tissue damage, infection, inflammation, and malignancy.
Up-regulation is caused by inflammatory cytokines - particularly IL-1 and IL-6
originating at the site of injury. Serum concentration rises almost immediately and
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peaks at 48 hours. Elimination half life of CRP is 19 hours (Pepys & Hirschfield,
2003). Baseline levels are very consistent in health. In healthy young adults,
median CRP concentration is 0.8mg/L (90th centile 3mg/L, 99th centile lOmg/L)
(Shine et al., 1981). CRP rises slightly with age. Despite this, CRP concentration in
healthy adults seldom rises above 3mg/L (Ballou et al., 1996; Delongui et al., 2013).
As such is it is an excellent non-specific marker of systemic inflammation.
3.9.2 Human Neutrophil Elastase (HNE)
The granules of neutrophils are distinguished by their relative
concentrations of cytotoxic peptides, and their ability to exocytose (discharge their
cell contents out of the cell). Azurophil granules undergo limited exocytosis and are
defined by the high concentrations of myeloperoxidase (MPO), bactericidal
permeability-increasing protein, defensins, and serine proteases (cathepsin G,
neutrophil elastase (HNE), and proteinase 3) that they contain.
The serine proteases have both intracellular and extracellular actions. They
are involved in the degradation and elimination of microorganisms. In addition,
they contribute to the coordination of the innate immune response, and may have a
role in he development of non-infectious chronic inflammatory disease. These
effects have recently been reviewed (Pham, 2006).,
Neutrophils phagocytose microorgansims and imprison them within a
compartment know as the phagolysosome. Following this, the granules of the
neutrophil exocytose, releasing their cytoxic contents including the serine proteases
that kill the engulfed invading particles. Serine proteases are also a component of
the extracellular fibrous protrusions of activated neutrophils known as neutrophil
extracellular traps (NETs) that kill extracellular bacteria (Brinkmann et al., 2004).
Although the activity of serine proteases are controlled in the extracellular
environment due the presence of protease inhibitors, large amounts can inactivate
those inhibitors leading to damage to the extracellular matrix (ECM) and proteolysis.
In addition, serine proteases can alter the activity of chemokines throught
proteolytic degradation leading to an alteration in leukocyte recruitment. Serine
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proteases can also alter the activation of cytokine precursors such as pro-TNF and
pro-IL-1 (3, modulating the availability of pro-inflammatory mediators (Pham, 2006).
HNE is an important mediator of inflammation-induced tissue injury. The
epithelium is usually protected from damage by proteinase inhibitors such as elafin
and secretory leukocyte protease inhibitor (SLPI) produced by epithelial cells and
cells of the innate response. However other tissues are less well protected and an
imbalance between HNE and inhibitors of serine proteases is implicated in the
pathogenesis of ARDS and the organ failure associated with critical illness.
HNE is therefore an important component of the innate immune response,
and also contributes to the collateral damage of critical illness. Plasma
concentration of HNE may therefore be a useful marker of ongoing neutrophil
driven immune system activation and may also contribute to impaired physical
recovery. In healthy controls HNE concentration is around 77ng/mL (Z. Wang et al.,
2009) and rises to 186 ng/mL in ICU patients with pneumonia (Tagami et al., 2011)
and 640ng/mL in patients with ARDS (Z. Wang et al., 2009).
3.9.3 Myeloperoxidase (MPO)
Myeloperoxidase (MPO) is another leukocyte enzyme found in the largest
quantities in the azurophil granules of neutrophils but is also found in monocytes
and macrophages. It is released from neutrophils during inflammation and allows
hydrogen peroxide conversion in to hypochlorous acid (HOCL). MPO is important
in the pathophysiology of atherosclerotic plaque formation and instability. Elevated
levels have been associated with an increased risk of atherosclerotic disease and
cardiovascular events (Stankovi/a & Majki/a-Singh, 2011). MPO can be measured
by ELISA in the laboratory and has been chosen for use in this study as a second
marker of neutrophil-driven inflammation.
3.9.4 Secretory leukocyte protease inhibitor (SLPI)
Secretory leukocyte protease inhibitor (SLPI) is a serine protease inhibitor
originally isolated from the bronchial secretions of patients with COPD. It is
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secreted from epithelial surfaces of the respiratory and alimentary tracts and acts to
protect them from damaging effects of proteases secreted by inflammatory
leukocytes. SLPI is also produced systemically by macrophages and neutrophils, in
response to bacterial products and increases the production of anti-inflammatory
cytokines. It therefore plays 2 important roles in human inflammation: the localised
protection of host tissue from serine proteases, and the induction of inflammatory
resolution (Grobmyer et al., 2000a).
3.9.5 Pro-inflammatory interleukins
The pro-inflammatory interleukins - interleukin 1 (3 (IL-1|3) and interleukin 6
(IL-6) were chosen as biomarkers of innate immune response activation.
IL-1|3 is a cytokine of the interleukin-1 family. It is produced by monocytes,
macrophages, and dendritic cells in response to various stimuli in the form of
damage-associated molecular patterns (DAMPS) and pathogen-associated
molecular patterns (PAMPS). Membrane associated toll-like receptors (TLRs) or
nucleotide binding and oligomersation domain (NOD)-like receptors (NLRs)
recognise these PAMPS and DAMPS and lead to up-regulation and release of IL-1 (3.
The mechanisms involved in IL-1 (3 release have been recently reviewed (Eder, 2009).
IL-1 (3 is extremely important in the pathogenesis of acute inflammation. It
initiates the pathways resulting in fever, reduced pain tolerance, erythema, and
hypotension - the clinical hallmarks of inflammation. Through its effects on the
vasculature, chemokine and cytokine production, and the bone marrow, IL-1 (3
promotes the infiltration of inflammatory cells into sites of tissue damage or
infections (Dinarello, 2009).
Interleukin-6 (IL-6) is another cytokine important in the innate response to
pathogens. It is released from numerous cells (macrophages, dentritic cells, mast
cells, B cells, T cells, fibrobasts, astrocytes, and epithelial cells). It is produced in
response to IL-1 and tumour necrosis factor a (TNFa). It causes activation of B and
T cells, induction of fever, and it mediates the acute phase response. It also has anti¬
inflammatory effects by inhibiting IL-1 and TNFa release, and increases the
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circulating concentrations of anti-inflammatory molecules (Schulte, Bernhagen, &
Bucala, 2013).
3.9.6 lnterleukin-8 (IL-8)
Chemokines are a group of around 50 small, structurally similar proteins
that attract cells and control cell migration during inflammation. They are sub-
classified according to structural characteristics. The CXC chemokine IL-8 is
produced in tissue macrophages and is released in response to mediators of
inflammation such as TNF and IL-1. IL-8 concentration is another marker of innate
immune response activation.
3.9.7 Complement anaphylatoxin proteins
Complement proteins are involved in the initiation, propagation, regulation,
and resolution of inflammation. Complement is the collective name given to a
group of enzymes and proteins involved in both the innate and adaptive immune
response and act together in the initiation and regulation of inflammation, the lysis
of bacteria and viruses, and the clearance of immune complex from the circulation.
Complement responses can be initiated by the 'alternative' or 'manin-
binding lectin' pathways (innate immune response) or the 'classical' pathway
(adaptive immune response).
Complement is important in the clearance of apoptotic neutrophils during
the resolution of inflammation. Clq deficiency has been shown to be a strong risk
factor for SLE, a disorder characterized by reduced clearance of apoptotic
neutrophils (Rossi book) and there also appears to be a role for 'downstream'
complement proteins in this process. It is therefore reasonable to explore the
association of serum levels of complement proteins in predicting inflammatory
outcome (Doan, Melvold, Viselli, & Wlatenbaugh, 2012).
In this study, C3a, C4a, and C5a were chosen as markers of complement
'activation' to determine whether a dampened complement response during the
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recovery phase of critical illness might be associated with a persistent inflammatory
response.
3.9.8 Transforming growth factor beta (TGF-P)
Transforming growth factor beta (TGF-|3) is an anti-inflammatory cytokine.
It is released from macrophages during neutrophil phagocytosis during the
resolution of inflammation and plays a key role in this process. TGF-|3 inhibits the
secretion of pro-inflammatory cytokines and chemokines. It has been chosen as a
marker of the inflammatory resolution process (M. O. Li, Wan, Sanjabi, Robertson,
& Flavell, 2006).
3.10 Considerations for outcome measures used in the study
The outcome measures used in the RECOVER study were a mixture of
questionnaires and clinical measurements. To consider the relative strength of these
measures, it is useful to consider then in terms of reliability, validity, and
responsiveness. These concepts are described in the following paragraphs.
3.10.1 Reliability
Reliability is the degree to which different independent assessors obtain the
same result using the same measurement instrument (Streiner & Norman, 2008). As
such it is a way of expressing measurement error. Interpretation of the clinical
relevance of a measurement error is only possible in the context of the variability
within the study population. Therefore reliability is typically expressed using the
intra-class correlation coefficient (ICC):
Subject VuriubiliLy
Reliubilily = -r-r-. r?—. —-r: r-
iuir/cti 1- untibtiily + Afeusuremenl brvor
The proportion produced by this calculation represents the proportion of
variance in measurements that can be attributed to true differences between the
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patients under study. It is important to note that reliability is only applicable to the
context in which it was measured. Reliability of a measure in one population does
not mean that it is equally reliable in another population.
3.10.2 Validity
Validity is the degree to which a measurement actually represents the
quality of interest. A prerequisite to validity is reliability. If the reliability of a
measure is only 0.5 (half of the variability between individuals can be attributed to
true differences) then the validity cannot exceed that value. In a similar way to
reliability, a measurement may only be valid in the population and context in which
it was measured. Validity can be assessed by criterion validation (assessment of the
extent to which a measure agrees with a Gold standard measure), content validation
(an expert judgment about whether the content of a measure or scale is relevant or
representative of the quantity being assessed), and construct validation (assessing the
performance of a measure or scale with characteristics or behaviours that reflect
unseen underlying factors known as constructs) (Streiner & Normal, 2008).
3.10.3 Responsiveness
Responsiveness is 'the ability of an instrument to measure a meaningful or
clinically important change in a clinical state'. It has been distinguished from
'sensitivity', which is defined as 'the ability of an instrument to measure change in a
state regardless of whether it is relevant or meaningful to the decision maker' (Liang,
2000). This can be considered part of validity - how much a change in a measure
reflect a change in the characteristic of interest (Streiner & Normal, 2008).
3.11 Measures of physical outcome used in the study
3.11.1 Rivermead mobility index
The Rivermead Mobility Index (RMI) is the primary outcome of the
RECOVER study. It was designed in 1991 by Collen and colleagues in the UK as an
adaptation of the Rivermead Motor Assessment Gross Function Scale (Collen, Wade,
92
Robb, & Bradshaw, 1991). Its purpose was to give rehabilitation professionals a
simple clinical test with which they could assess the effects of rehabilitation
treatments.
The RMI consists of a 15-point scale consisting of 14 functional questions and
1 direct observation (Appendix D). A low score indicates poor mobility. Studies in
stroke patients (Hsieh, Hsueh, & Mao, 2000; Hsueh, Wang, Sheu, & Hsieh, 2003) and
mixed neurological patients (J. M. Walsh et al., 2010) have shown good reliability,
validity and responsiveness. Reliability is consistently good (ICC 0.93, 0.92, and
0.96). Validity has been assessed against various 'gold standards' of mobility
including the 10 minute walk test (r = 0.86) (J. M. Walsh et al., 2010), the Barthel
Index (r = 0.88, 0.6) (Hsieh et al., 2000; Hsueh et al., 2003). It has also been assessed
in patients with lower limb amputation in whom it is less useful (Franchignoni,
Brunelli, Orlandini, Ferriero, & Traballesi, 2003; Ryall, Eyres, Neumann, Bhakta, &
Tennant, 2003).
It is worth noting that the performance of the RMI has not been assessed in
survivors of critical illness but all other measures of mobility are similarly lacking in
validation studies in ICU survivors. RMI was therefore chosen as a pragmatic
measure that has been shown to have very little inter-rater variability. Its simplicity
and ease of use has allowed a very high follow-up rate in the RECOVER study and
therefore extremely complete outcome data.
3.11.2 Hand grip strength
Maximal handgrip strength (HGS) was measured in the non-dominant hand
positioned at the side of the body using a T.K.K. dynamometer 5401 D (Takei
Scientific Instruments, CO., LTD. Tokyo, Japan). Measurements were taken 3 times
and the maximum score was recorded.
Maximum handgrip strength has good concurrent validity with the 6 minute
walk test that is a test of physical function (Enright, 2003; Reuter, Massy-Westropp,
& Evans, 2011). HGS declines with age and is lower in females than in males
(Massy-Westropp, Gill, Taylor, Bohannon, & Hill, 2011). HGS measurements in the
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current study were therefore converted in to percentage predicted scores based on
their age and gender for comparisons. Age and gender stratified measurements
from a recent Australian study were used (Massy-Westropp et al., 2011). Tables
showing age and gender stratified measurements from this study are shown in
Appendix E. In addition, to identify particularly weak patients, we created binary
categories of 'weak' and 'not weak' using 2 different definitions of 'weak' identified
a priori. These were patients > 1 or 2 standard deviations below predicted HGS.
3.11.3 Timed up and go test
The Timed Up and Go test (TUG) (Podsiadlo & Richardson, 1991) is a
modification of the 'Get up and Go' test designed by Mathias et al in 1986 (Mathias,
Nayak, & Isaacs, 1986). It was intended as a simple method of assessing falls risk in
the elderly. Subjects were asked to stand from sitting, walk 3 metres, turn and walk
back and sit down again. The original test was a 5-point subjective observational
rating. However, many observers felt that this scale lacked precision and the timed
version has largely replaced it.
The TUG was initially validated in 60 elderly patients attending a day
hospital (mean age 79.5 years). In this population, it was found to be reliable and
had a high correlation with the Berg Balance Scale, a validated balance scale, and
the Barthel index, a validated measure of mobility and functioning in relation to
activities of daily living.
The TUG has subsequently been validated as a predictor of falls and
physical function in institutionalized adults (Schoene et al., 2013) and Huntingdon's
disease and is responsive to changes in disease severity (Rao, Muratori, Louis,
Moskowitz, & Marder, 2009) but has been found to be a poor predictor of falls in
patients with MS (Cattaneo, Regola, & Meotti, 2006) and non-institutionalised adults
(Schoene et al., 2013).
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3.12 Measures of psychological function used in the study
3.12.1 Davidson's Trauma Scale
The Davidson's Trauma Scale (DTS) is a scale that was developed as a
simple diagnostic test for post-traumatic stress disorder (J. R. Davidson et al., 1997).
The 17 items on the scale correspond to the diagnostic criteria listed in the
Diagnostic and Statistical Manual for Mental Disorders 4th Edition (Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DMS-IV-TR),
2000). Subjects were asked to rate their symptoms in terms of frequency and
severity. It is reliable (test-retest reliability = 0.86), and shows very high validity
when compared to the Structured Clinical Interview for DMS-III-R (SCID) (r=0.83 at
a score of >40) (J. R. Davidson et al., 1997). In this study, DTS is analysed as
continuous variable, the DTS score, and also in binary diagnostic categories
according to a cut-off of 37. The DTS is in Appendix G.
3.12.2 Hospital Anxiety and Depression Scale
The Hospital Anxiety and Depression Scale (HADS) was developed in the
early 1980s as a tool to rapidly screen patients for anxiety and depression in the non-
psychiatric medical outpatient setting (Zigmond & Snaith, 1983). It is a self-
administered questionnaire that consists of 14 questions addressing the domains of
depression and anxiety. Each question is marked on a scale of 0-3 giving a
maximum possible score of 21 for each of depression and anxiety. The scale can be
found in Appendix F.
Since its inception, HADS has been used extensively (Bjelland, Dahl, Haug,
& Neckelmann, 2002). The scale has been widely validated in a large number of
populations (Annunziata, Muzzatti, & Altoe, 2011; Boyes, D'Este, Carey,
Lecathelinais, & Girgis, 2013; Bratas, Gronning, & Forbord, 2013; Castro et al., 2006;
G. Cheung, Patrick, Sullivan, Cooray, & Chang, 2012; Dawkins, Cloherty, Gracey, &
Evans, 2006; Fatt, Atiya, Heng, & Beng, 2007; Golden, Conroy, & O'Dwyer, 2007;
Gough & Hudson, 2009; Helvik, Engedal, Skancke, & Selbaek, 2011; Higashi et al.,
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1996; Hinz, Zweynert, Kittel, Igl, & Schwarz, 2009; Honarmand & Feinstein, 2009;
Julian, 2011; Karimova & Martin, 2003; Kuijpers et al., 2003; Leentjens et al., 2011;
Loosman, Siegert, Korzec, & Honig, 2010; Lowe et al., 2003; McCue, Martin,
Buchanan, Rodgers, & Scholey, 2003; Mitchell, Meader, & Symonds, 2010; Mondolo
et al., 2006; Norton, Cosco, Doyle, Done, & Sacker, 2013; Poole & Morgan, 2006;
Roberts, Bonnici, Mackinnon, & Worcester, 2001; Rodriguez-Blazquez, Frades-Payo,
Forjaz, de Pedro-Cuesta, & Martinez-Martin, 2009; Sagen et al., 2009; Samaras et al.,
2013; Smarr & Keefer, 2011; Snaith & Zigmond, 1986; Sukantarat, Williamson, &
Brett, 2007; Terluin, Brouwers, van Marwijk, Verhaak, & van der Horst, 2009; Untas
et al., 2009; White, Leach, Sims, Atkinson, & Cottrell, 1999; Woolrich, Kennedy, &
Tasiemski, 2006; Zakrzewska, 2012) and has been used to evaluate the psychological
impact of critical illness (Bienvenu et al., 2012; Garrouste-Orgeas et al., 2012;
Kayambu, Boots, & Paratz, 2011; Kowalczyk, Nestorowicz, Fijalkowska, &
Kwiatosz-Muc, 2013; H. Myhren, Ekeberg, Toien, Karlsson, & Stokland, 2010; Peris
et al., 2011; Ringdal, Plos, Lundberg, Johansson, & Bergbom, 2009; Rosendahl,
Brunkhorst, Jaenichen, & Strauss, 2013). Despite this, there has only been 1
validation study in this population and this study compared the HADS to a newer
questionnaire (Sukantarat et al., 2007) without establishing the validity of the F1ADS
that was being used as the gold standard.
A systematic review by Bjelland et al (Bjelland et al., 2002) found that
optimal cut offs for both the depression (FiADS-D) and anxiety (HADS-A)
components to be 8/21 (giving sensitivity and specificity for both HADS-D and
HADS-A of 0.8).
3.13 Measures of quality of life used in the study
3.13.1 SF-12V2
The Medical Outcomes Study Short Form 12 version 2 (SF-12v2) is a short,
generic health status and health outcomes questionnaire containing 12 questions
that can be administered in less than 2 minutes. It is a simplification of the Medical
Outcome Study Short Form 36 (SF-36) which contains 36 items (Ware, Kosinski, &
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Keller, 1996). The SF-12v2 yields physical and mental component summary scores
(PCS and MCS respectively) as well as scores for a range of integrated health status
scales (Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality,
Social Functioning, Role Emotional, and Mental Health). Reliability of the summary
scores is very good (0.89 and 0.86 for PCS and MCS respectively). Raw scores are
calculated according to an algorithm derived from the Medical Outcomes Study and
then converted into norm based scores (Ware et al., 1996). SF-12v2 has been
validated across a vast range of population groups (Ware, Kosinski, Turner-Bowker,
& Gandek, 2008).
3.14 Assays
A summary of the assays used for each biomarker is given in Table 3-3. All
assays were conducted according to manufacturers instructions.
Molecule Assay
type
Kit Company Sample Optimal Dilution
Baseline 3 mo.
CRP ELISA Duoset R and D Serum 1:100000 1:10,000
IL-1 p ELISA Duoset R and D Serum 1:1 1:1
IL-6 ELISA Duoset R and D Serum 1:1 1:1
IL-8 ELISA Duoset R and D Serum 1:1 1:1
C3A CBA Anaphylatoxin BD bioscience Serum 1:1 1:1
C4A CBA Anaphylatoxin BD bioscience Serum 1:1 1:1
C5A CBA Anaphylatoxin BD bioscience Serum 1:1 1:1
MPO ELISA Duoset R and D Serum 1:100 1:100
HNE ELISA ELISA Cambridge Plasma 1:50 1:50
TGF p ELISA Duoset R and D Serum 1:20 1:20
SLPI ELISA Quantakine R and D Serum 1:100 1:100
Table 3-3 Characteristics of the assays used in the study
3.14.1 Sample types
Assays of CRP, interleukins, TFG beta, SLPI, MPO, and complement were
carried out on defrosted serum. HNE was assayed on defrosted plasma.
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3.14.2 Dilutions
IL-1 [3, IL-6, IL-8, and complement assays were carried out undiluted because
concentrations of these molecules in serum were low. All the other assays (all
ELISAs) required dilution. A test analysis was carried out with each assay to
establish the most appropriate dilution (Table 3-3). In some cases, optimal dilution
depended upon the time point being analysed. Following this, each sample was
assayed at the optimal dilution. If the optical density fell above the highest or below
the lowest point on the standard curve, that sample was re-assayed at a higher or
lower dilution.
3.14.3 Quality
All ELISAs were carried out in duplicate. The co-efficients of variation (CV)
for optical density in each duplicate assay were assessed and assays were repeated
where necessary to ensure CV <15%.
3.15 Statistical analysis and reporting
A signed, dated a priori analysis plan for this section was included in the
request for RECOVER trial data. To further explore some of the signals seen on
primary analysis, a number of post-hoc analyses are appended once the primary
analysis had been carried out.
3.15.1 Prevalence of systemic inflammation in ICU survivors
In health, CRP concentration rarely rises above 3mg/L even in elderly
cohorts. In a young adult cohort, a CRP concentration of greater than lOmg/L
represents the 99th centile, and 3mg/L the 90th centile. Persistent inflammation was
therefore defined according to these 2 definitions. The following time points of
interest are arbitrarily defined:
• ICU discharge (study entry)
• Closest sample to hospital discharge (variable time after ICU discharge)
• Community sample (3 month follow up visit)
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The number and proportion of surviving patients with evidence of systemic
inflammation for the 3mg/L and lOmg/L threshold at each of these time points (CRP
>3mg/ L or >10mg/L) was reported.
3.15.2 Characterisation of the inflammatory and inflammatory resolution
profile during recovery from critical illness
The blood markers of systemic inflammation and inflammatory resolution
(CRP, IL-1[3, IL6, IL8, MPO, HNE, TGF beta and SLPI), were reported at 2 time
points - ICU discharge and 3 months after ICU discharge. Serum concentrations of
all biomarkers are non-parametric in distribution and were presented as median
(IQR). Serum CRP concentration, IL-6, IL-1|3, IL-8, and TGF|3 were also reported at
an additional time point (hospital discharge).
In an attempt to characterise the inflammatory resolution trajectory, a
subgroup of ICU survivors who remained in hospital for similar lengths of time
after ICU discharge was selected. Patients that remained in hospital for 1, 2, and 3
weeks after ICU discharge were compared. In these patients, median concentration
of CRP, IL-6, IL-8, and TGF|3 were plotted against time. Serum concentration of IL-
113 was negligible at all time points. Therefore a line chart was not presented for this
cytokine.
Biomarkers with concentrations falling below the level of detection of the
assay were assigned a value of zero.
3.15.3 Physical and psychological outcomes of ICU survivors
Physical and psychological outcome measures were presented for the whole
cohort at both 3 months and 6 months.
Mobility: RMI was reported as median (IQR).
Hand strength: Using age and gender stratified population norms, handgrip
strength (HGS) measurements were converted into percentage predicted HGS and
reported as mean (SD). In addition, 3 outcome groups were identified to identify
patients with particularly poor physical recovery. Patients with a HGS that
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decreases more than 2 standard deviations below mean predicted HGS for age and
gender were considered 'very weak'. Patients with HGS between 1 and 2 standard
deviations below the predicted HGS were considered 'weak'. All other patients
were considered 'normal'. The number and proportions of patients falling into
these categories are reported.
Quality of Life: Total, physical component and mental component scores of
the SF-12v2 were presented as median (IQR).
Anxiety and Depression: Total Hospital Anxiety and Depression Scale
(HADS) were reported as median (IQR). Patients scoring more that 8 points on the
anxiety component were considered to have a positive screening test for anxiety.
The same threshold is used for the depression component. The number and
percentage of patients with a positive screening test for anxiety or depression was
reported.
Post-traumatic stress disorder: Davidson's trauma scale (DTS) was reported as
median (IQR). PTSD is defined as DTS > 37. Number and percentage of patients
with PTSD was reported.
Falls risk: Number of seconds take to complete the timed up and go (TUG)
test was reported as median (IQR).
3.15.4 Association of systemic inflammation with indices of physical and
psychological recovery
A cross-sectional analysis of CRP concentration and indices of physical
recovery at 3 months was performed. Scatter plots were drawn representing the
relationships between CRP concentration and the outcome measures detailed in
section 5. Pearson's correlation coefficients were reported with p values. Kendall's
tau-b correlation coefficients were calculated for non-parametric correlation.
In addition, to explore the association of systemic inflammation and
diagnostic subgroups (depression, anxiety, and PTSD) and patients with
particularly poor physical recovery (lower quartile of RMI, weak HGS category),
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CRP concentration are reported in binary groups and presented as boxplots.
Comparisons are made with Mann Whitney U tests.
3.15.5 Post-hoc analyses
To explore the possibility that pre-morbid inflammation may contribute to
the observation of persistent inflammation during the recovery phase of critical
illness, comparisons were made between subgroups of patients who had pre¬
morbid conditions that could be considered 'inflammatory' diseases and those that
did not. Two such analyses were carried out. The first compared those with a
Functional Comorbidity diagnosis of 'arthritis' to those without. The second
included other possible 'inflammatory' diagnoses (asthma, COPD, obesity, diabetes,
and arthritis) compared to those without. Both median CRP concentration, and
proportion of patients with inflammation were compared across subgroups.
3.15.6 Issues of study power and multiple testing
It is important to emphasise that the biomarker study reported here was an
add-on to an RCT and was not powered to detect differences in inflammatory
biomarkers between groups of patients. Positive results are regarded as hypothesis
generating. Similarly, negative results may indicate lack of statistic power rather
than a lack of affect. It is also acknowledged that multiple statistical tests were
carried out to compare levels of biomarkers between groups and to take this into
account, results are reported and discussed in relation to Bonferroni adjusted p
value thresholds.
3.16 Results
3.16.1 Recruitment and loss to follow up
Figure 3-1 illustrates the recruitment of patients into the study and describes
the small number of patients that dropped out during the study. A number of
patients followed up at 3 months were lost to follow up at 6 months. Reasons for
loss of follow up at 6 months are given in Table 3-4.
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Figure 3-1 RECOVER biomarker study flow diagram up to 3 months
Unable to contact 7
Death 6
Declined 1
Not returned questionnaire / not able to contact 11
Unknown 11
Table 3-4 Reasons for loss of follow up at 6 months
Two hundred and forty patients were recruited to the RECOVER study. Of
these, 193 participated in the inflammation sub-study. Of the 193 patients in the
study, 175 patients were followed up to 3 months, and 157 patients were followed
up to the 6 months. This represents 91% of those surviving to 3 months, and 82% of
those surviving to 6 months. A comparison between those patients available for
follow up at 3 months and those in whom follow up could not be arranged is shown
in Table 3-5.
Follow up blood No follow up blood taken
taken (n=122) (n=71)
Age 60 (13) 62 (15)
Gender (m/f (%m)) 75/47 (62) 42/29 (59)
Functional comorbidity index 2.8 (2.0) 2.5 (1.9)
Functional comorbidity index
subcategories (n (%))
Arthritis 33 (27) 21 (30)
Osteoporosis 7(6) 4(6)
Asthma 23 (19) 10 (14)
COPD 24 (20) 8 (11)
Angina 12 (10) 5(7)
Heart Disease 11 (9) 10 (14)
Heart Attack 14 (12) 4(6)
Neurological 0(0) 4(6)
Stroke 15 (12) 7(10)
PVD 1 (1) 5(7)
Diabetes 22 (18) 8 (11)
Upper Gastro 39 (32) 23 (32)
Depression 36 (30) 19 (27)
Anxiety 30 (25) 16 (23)
Visual 18 (15) 7(10)
Hearing 15 (12) 5(7)
Disc Disease 12 (10) 5(7)
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Obesity 28 (23) 15 (21)
APACHE 2 21 (7) 21 (7)
SOFA score at baseline
Total 3(1,4) 3(1,5)
Cardiovascular 0 (0,0) 0 (0,0)
Respiratory 2 (0,2) 2 (0,2)
Coagulation 0 (0,0) 0(0,1)
Renal 0(0,1) 0(0,1)
Liver 0 (0,0) 0 (0,0)
Neurological 0(0,1) 0(0,1)
ICU stay (days) 11 (4,19) 11 (3,18)
Ventilation (days) 9 (3,16) 6 (3,13)
Vasopressors (n(%)) 50 (70) 91 (75)
RRT (n(%)) 31 (26) 21 (30)
Delirium (n(%)) 19 (16) 10 (14)
RMI 3 (0,6) 2 (0,7)
HGS (kgs) 16 (6,22) 13 (6,20)
Table 3-5 Comparison of those patients followed up and those lost to follow up
expressed as mean (standard deviation) or median (25th centile, 75th centile).
3.16.2 Baseline descriptive data
Table 3-6 illustrates the characteristics of the patients enrolled in the study.
To explore the possibility of selection bias, comparisons were made between
patients enrolled in the RECOVER study who agreed to take part in the blood study,
and those that refused consent.
The mean age of the participants was 61 and a higher proportion were male
that female. Women who were enrolled in RECOVER were less likely to consent to
the blood sampling study than males. Mean APACHE 2 score was 21 and organ
failure (defined by the sequential organ failure score (SOFA score)) was rare at the
point of enrolment. Patients stayed a median of 11 days in the intensive care unit
and were received mechanical ventilation for 8 days. A high proportion (73%
received vasopressors) and just over a quarter (27%) received renal replacement
therapy. Patients had poor mobility (median RMI of 3), and were weak (HGS of 13
kg)-
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Other than the gender differences already mentioned, the patients in the




Age 61 (14) 58 (15)
Gender (m/f (%m)) 117/76 (61) 20/27 (43)
Functional comorbidity index 2.7 (2.0) 2.9 (2.0)
Functional comorbidity index
subcategories (n (%))
Arthritis 54 (28) 8(17)
Osteoporosis 11 (6) 3(6)
Asthma 33 (17) 10 (21)
COPD 32 (17) 5(11)
Angina 17(9) 4(9)
Heart Disease 21 (11) 2(4)
Heart Attack 18 (9) 1 (2)
Neurological 4(2) 2(4)
Stroke 22 (11) 3(6)
PVD 6(3) 1 (2)
Diabetes 30 (16) 7(15)
Upper Gastro 62 (32) 14 (30)
Depression 55 (29) 22 (47)
Anxiety 46 (24) 16 (34)
Visual 25 (13) 9 (19)
Hearing 20 (10) 4(9)
Disc Disease 17(9) 13 (28)
Obesity 43 (22) 10 (21)
APACHE 2 21 (7) 19 (9)
SOFA score at baseline
Total 3(1,4) 2(1,4)
Cardiovascular 0 (0,0) 0 (0,0)
Respiratory 2(1,2) 2(1,2)
Coagulation 0 (0,0) 0 (0,0)
Renal 0 (0,0) 0 (0,0)
Liver 0 (0,0) 0(0,1)
Neurological 0(0,1) 0(0,1)
ICU length of stay (days) 11 (4,18) 12(3,22)
Hospital length of stay (days) 29 (11,43) 35 (10,56)
Days of mechanical ventilation 8 (3,14) 9(3,17)
Received vasopressors (n(%)) 141 (73) 37 (78)
Received renal replacement
(n(%))
52 (27) 12 (25)
Delirium at enrolment (n(%)) 29 (15) 6(13)
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RMI at enrolment 3 (0,6) 3 (0,7)
HGS (kgs) 15(6,21) 12 (0,26)
Table 3-6 - Baseline characteristics of patients in biomarker study with comparison
shown between those that refused consent for the study expressed as mean
(standard deviation) or median (25th centile, 75th centile).
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3.16.3 Prevalence of systemic inflammation
Prevalence of systemic inflammation was measured at 3 points during the
period of recovery from critical illness: at the point of study recruitment when
patients are ready for discharge from critical care, at the point of hospital discharge,
and 3 months after ICU discharge.
3.16.3.1 Inflammation at ICU discharge
Median CRP concentration at the point of ICU discharge was 26.7 mg/L (IQR
11.0-60.7). 141/184 (77%) patients had a CRP greater than lOmg/L. 173/184 (94%)
had a CRP greater than 3mg/L.
3.16.3.2 Inflammation at hospital discharge
Median CRP concentration at hospital discharge was 20.5mg/L (IQR 8.4-41.7).
133/188 (71%) of patients had a CRP greater than lOmg/L. 169/188 (90%) of patients
had a CRP greater than 3mg/L.
3.16.3.3 Inflammation 3 months after ICU discharge
Median CRP concentration at the 3-month follow up was 4.4 mg/L (IQR 1.1-
11.9). 34/123 (30%) of patients had a CRP greater than lOmg/L. 72/123 (59%) of
patients had a CRP greater than 3mg/L.
3.16.4 Characterisation of the inflammatory resolution profile during recovery
from critical illness
Median and interquartile ranges for the concentrations of CRP, IL-1(3, IL-6,
IL-8, TGF(3, MPO, and SLPI in serum and HNE in plasma at ICU discharge and 3
months after ICU discharge are shown in Table 3-7. Median CRP concentration at
ICU discharge was 27 mg/L, decreasing to 20mg/L at hospital discharge, and 3 mg/L
at 3 months. When compared to the normal values noted in section 2.5.6.1, the
median values at ICU discharge and hospital discharge were above the 97th centile
of normal healthy adults. The values at the 3-month follow up stage were at the 90th
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centile of normal healthy adults. Therefore, whilst CRP concentration decreases
drastically during the first 3 months, there remains evidence of significant on-going
inflammation during the months of recovery after ICU discharge.
The pro-inflammatory cytokine IL-113 was detectable in only a small number
of samples at ICU discharge and hospital discharge. IL-6 was detectable. Median
concentration was 27 pg/mL at ICU discharge, decreasing to 16 mg/L by hospital
discharge, and 5 pg/mL at the 3 month follow up visit. These levels are higher than
the upper quartile level of 3.5 pg/L measured in a healthy adult population in a
previous study (see section 0).
The chemokine IL-8 was also detectable at all time points. At ICU discharge,
the median concentration was 28 pg/mL decreasing to 11 pg/mL at hospital
discharge, and 8 pg/mL at the 3 month follow up point. Again, this represents a
higher concentration of IL-8 in the serum of ICU survivors than that seen previously
in a healthy population sample.
Low concentrations of TGF|3 were found at all time points. Median
concentration was 12ng/mL at ICU discharge decreasing to 8 ng/mL at hospital
discharge, then rising to lOng/mL at the 3 month follow up point. When compared
to studies of healthy individuals (median concentration 35ng/mL) by previous
investigators, these levels were extremely low.
HNE concentrations fell from 159ng/mL at ICU discharge to 106 ng/mL at
the 3 month follow up visit. This is elevated in comparison to the 77ng/mL
previously measured in healthy controls. Similarly, MPO concentration fell from a
median of 191ng/ml at ICU discharge to 127ng/mL 3 months later. This is far in
excess of the 951pg/mL (Ing/mL) measured in healthy controls in other studies
indicating significant ongoing neutrophil driven inflammation.
Median SLPI was 59ng/mL at ICU discharge, decreasing to 47ng/mL 3
months later. In a previous study, the mean (SD) plasma concentration of SLPI in
healthy elderly patients was 38 (10) ng/mL. In patients surgical patients with sepsis,
SLPI rises above lOOng/mL, with serum concentration correlating with severity of
illness. In healthy patients with COPD, mean concentration was 51 (6)
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ng/mL(Grobmyer et al., 2000b; Hollander et al., 2007). The values observed at ICU
discharge in the current study are unlikely to be elevated to a physiologically
significant degree compared to the background level seen in the community. By 3
months, levels are almost normal.
Marker / Time point Median IQR n
CRP (mg/L) ICU discharge 27 11-60 184
Hospital discharge 20 8-42 185
3 months 4 1 - 11 123
IL-1 p (pg/mL) ICU discharge 0 0-15 180
3 months 0 0-15 120
IL-6 (pg/mL) ICU discharge 27 7-80 180
Hospital discharge 16 5-65 183
3 months 5 0-31 120
IL-8 (pg/mL) ICU discharge 28 13-64 180
Hospital discharge 11 73-183 183
3 months 8 1 -28 119
TGF(31 (ng/mL) ICU discharge 12 8-16 181
Hospital discharge 6 4-11 182
3 months 10 8-13 120
HNE (ng/mL) ICU discharge 159 116-228 180
3 months 106 88-138 120
MPO (ng/mL) ICU discharge 191 115-292 184
3 months 127 79-213 120
SLPI (ng/mL) ICU discharge 59 45-76 184
3 months 47 37-60 123
Table 3-7 Biomarker concentrations at ICU discharge, hospital discharge, and 3
months after ICU discharge.
Figure 3-2 shows the in-hospital longitudinal trajectory of the acute phase
protein CRP for patients staying for 1, 2 and 3 weeks after ICU discharge. The
sampling points are displayed relative to hospital discharge rather than ICU
discharge. Time point '0' represents hospital discharge; time point '-1' is 1 week
prior to hospital discharge with '-2' and '-3' being 2 weeks and 3 weeks prior to
hospital discharge respectively. In the subgroups presented, CRP resolves linearly
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with time, but does not fall below 20mg/L prior to hospital discharge. This is
supported by the median CRP concentration of 20.5mg/L quoted above for the
whole sample. Interestingly, CRP concentrations are more similar when time points
relative to hospital discharge rather than ICU discharge are studied. For example
patients CRP concentration at ICU discharge in patients that stay in hospital for a
further 2 weeks, is lower than CRP concentration at ICU discharge in patients
staying for 3 weeks. One week after ICU discharge patients who stay for 3 weeks
have CRP concentrations similar to patients that only stay 2 weeks.
Blood sampling point (weeks before hospital discharge)
Figure 3-2 Median (IQR) CRP Concentration after ICU discharge in patients staying
3 weeks (n=17; closed circles), 2 weeks (n=27; squares) and 1 week (n=50;
triangles) after ICU discharge.
Figure 3-3 shows a similar chart for IL-6 concentration over time. As with
CRP concentration the chart is presented with the sampling time points on the x axis
plotted relative to hospital discharge (weeks before hospital discharge), rather than
ICU discharge (weeks after ICU discharge). In the subgroups presented, IL-6
concentration decreases exponentially as patients approach hospital discharge.
Median values of IL-6 concentration are elevated in patients staying 3 weeks in
hospital after ICU discharge when compared to those staying 1 or 2 weeks beyond
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ICU discharge. By one week prior to hospital discharge, median IL-6 concentration
decreases to around 20pg/mL where it remains until hospital discharge. When
compared to other studies of healthy community dwelling adults, this value
represents a significant elevation in IL-6 at the point of hospital discharge (see
upper quartile of 3.5 pg/L noted in section 2.5.4).
Figure 3-3 Median (IQR) IL-6 concentration in patients staying in hospital 3 weeks
(closed circles; n=15), 2 weeks (squares; n=26), 1 week (triangles; n=40) after ICU
discharge.
The time course chart for IL-8 concentration after ICU discharge (Figure 3-4)
is again presented with sampling time point relative to hospital discharge.
Concentration of IL-8 does not follow a clear pattern of resolution. IL-8
concentration fluctuates during the period of hospitalisation after ICU discharge
around a level of 40pg/mL. The 18 patients staying for 3 weeks after ICU discharge
(closed circles) have a median IL-8 concentration that peaks 1 week after ICU
discharge and decreases again towards hospital discharge. At all time points, IL-8 is
significantly elevated when compared to the levels found in healthy community
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dwelling adults in whom the median concentration is about 3.5pg/mL (Boekholdt et
al., 2004).
The TGF|3 time course chart is presented differently to the other 3
biomarkers studied (Figure 3-5). Sampling time points are presented relative to ICU
discharge because TGF|3 concentration decreases exponentially after ICU discharge
regardless of hospital length of stay. This is in direct contrast with IL-6 and CRP.
TGF|3 concentration decreases to around 4ng/mL by about 1 week after ICU
discharge where it remains until hospital discharge. These concentrations are far
lower than the 35ng/mL median seen in other studies of healthy individuals living
in the community (Lin et al., 2009).
Sampling point (weeks before hopsital discharge)
Figure 3-4 Median (IQR) IL-8 concentration in patients staying 3 weeks (closed









Sampling point (weeks after ICU discharge)
3
Figure 3-5 Median (IQR) TGF beta concentration in patients staying 3 weeks (n=17;
closed circles), 2 weeks (n=27; squares), and 1 week (n=50; triangles) after ICU
discharge.
3.16.5 Physical and psychological outcomes of ICU survivors
A summary of the main outcome measures is provided in Table 3-8.
3.16.5.1 Mobility
Patients are immobile at ICU discharge with a median RMI of 3 (IQR 0-6).
Over the first 3 months, this rises to 13 (IQR 11-15) and by 6 months it is 14 (IQR 11-
15). Due to the nature of the RMI, the frequency distribution is positively skewed at
baseline and negatively skewed at the follow up points. The majority of patients at
the follow point have very high scores on the RMI. This disguises the very




Mean (SD) HGS at 3 months is 22 (8). This represents a mean percentage
predicted HGS of 64%. The percentage of patients who would be considered weak
when compared to a population of age and gender matched controls is 53%.
3.16.5.3 Quality of life
According to the SF-12 v2 questionnaire, both physical and mental
components of quality of life are significantly lower than that seen in the US
reference population used to calibrate the scale at both 3 months and 6 months. At 3
months, mean physical component score was 35, 1.5 standard deviations below the
reference population mean. Mean mental component score was 45, 0.5 standard
deviations lower than the reference population. At 6 months, SF-12 scores were
very similar with a PCS of 37 and an MCS of 44.
3.16.5.4 Anxiety and depression
Mean (SD) HADS anxiety and depression scores at 3 months were 7 and 6
respectively. Thirty-three per cent had a HADS anxiety score of greater than 8 and
met screening criteria for anxiety. Twenty-eight per cent had a HADS depression
score of greater than 8 and met screening criteria for depression.
Mean (SD) HADS anxiety and depression scores at 6 months were also 7 and
6 respectively. At this later time point, 36% met screening criteria for anxiety and
31% met screening criteria for depression.
This represents a high proportion of patients suffering from anxiety and
depression that does not resolve over the 6-month time horizon.
3.16.5.5 Post-traumatic stress disorder
At 3 months, the median Davidson's Trauma Scale value was 11 (IQR 0-25).
Using the cut off of 37, 24 patients (18%) would be considered to have PTSD. At 6
months, median DTS was 27 (IQR 6-56). At this time point, 48 patients (39%) would
be considered to have PTSD.
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3.16.5.6 Falls risk
At 3 months, the median time to carry out the 10 metre timed up and go test
was 10 seconds (IQR 8-13 seconds).
Outcome measure Baseline (n=193) 3 months (n=175) 6 months (n=137)
RMI 3 (0,6) 13 (11,14) 14 (11,15)
HGS - 22 (8) -
% Predicted HGS - 64 (21) -
% 'Weak' - 53 (34.6) -
SF-12 PCS - 35 (11) 37 (12)
SF-12 MCS - 45 (13) 44 (13)
HADS A - 7(5) 7(5)
HADS D - 6(4) 6(4)
%HADSA>8 - 50 (33) 48 (36)
%HADSD>8 - 43 (28) 41 (31)
DTS - 11 (0,25) 27(6,56)
%PTSD (DTS>37) 24(18) 48 (39)
TUG (seconds) - 10 (8,13) -
Table 3-8 Physical and Psychological outcomes of critical illness means that the
outcome was not measured at a particular time point) Mean (SD) or median (1st, 3rd
quartile).
3.16.6 Association of systemic inflammation and outcome measures at 3
months
A summary of correlation coefficients and inference testing can be found in
Tables 3-9 and 3-10. To take into account the 8 outcome measured assessed, a
Bonferoni-adjusted p value threshold of p<0.006 was used to infer statistical
significance.
3.16.6.1 CRP concentration and mobility
CRP concentration and RMI exhibit a statistically significant negative
correlation when measured together at the 3-month time point (Kendall's Tau
correlation coefficient = -0.2; pO.OOl). Both RMI and CRP concentration were
severely skewed in their distribution - hence the use of Kendall's Tau. The
relationship between the 2 variables is therefore illustrated using a log
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transformation of the inverted RMI (to normalise the extreme negative skew in this







Figure 3-6 Scatter plot illustrating relationship of RMI and CRP concentration at 3
months
Higher levels of the inflammatory marker are associated with poorer
mobility as measured by RMI. Median CRP concentration in patients with poor
mobility outcomes (lower quartile of RMI) was 9.4 mg/L (IQR 4.8-20) compared to
3.0 (0.8-9.3) in those with good outcomes (upper 3 quartiles of RMI). This
represented a significantly higher CRP concentration in those with poor outcomes
(P=0.002). A box plot illustrating CRP concentration in these 2 groups is shown in
Figure 3-7.
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Upper 3 quartlles of RMI Lower quartile of RMI
RMI group at follow up
Figure 3-7 CRP concentration in patients in the upper 3 quartiles versus the lowest
quartile of RMI at follow up. (p=0.002). Lower quartile n=19; Upper quartile n=102.
3.16.6.2 CRP concentration and hand strength
CRP concentration and percentage predicted HGS are also negatively
correlated at the 3-month time point (Spearman's rho -0.19; p=0.03) but did not quite
reach statistical significance according the Bonferoni adjusted threshold. Weak
patients (HGS >2 SD lower than predicted) also had higher CRP concentration than
those with higher HGS (6.3 versus 3.1mg/L) but this difference did not reach
statistical significance (p=0.10).
3.16.6.3 CRP concentration and falls risk
The Kendall's Tau correlation coefficient for the relationship between CRP
concentration and the number of seconds taken to perform the TUG was 0.11
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(p=0.10). Patients with higher levels of CRP trended towards a longer time taken
doing the TUG test but this did not reach statistical significance.
3.16.6.4 CRP concentration and psychiatric symptoms
Neither HADS anxiety nor HADS depression scores were correlated with
CRP concentration at 3 months (Spearman's rho correlations coefficients of 0.04 (p =
0.70) and 0.03 (p=0.73) respectively). Patients considered to be depressed (HADS-D
>8) had a CRP concentration that was comparable with those who weren't
depressed (3.6 versus 4.4 mg/L p=0.68 respectively). Patients considered to be
anxious (HADS-A >8) had a similar CRP concentration to those that weren't anxious
(4.1 versus 4.4mg/L p=1.0 respectively.
3.16.6.5 CRP concentration and post-traumatic stress disorder
DTS was not significantly correlated with CRP concentration at 3 months
(Kendall's Tau B correlation coefficient -0.07 (p=0.49)). Interestingly, patients with
PTSD symptoms had lower CRP concentration than those without (1.3 versus 5.0
mg/L) a difference that met statistical significance for a single test but does not
account for multiple testing (p=0.05).
3.16.6.6 CRP concentration and quality of life
Spearman's rho correlation coefficients for the relationship between physical








Physical RMI -0.21** 0.00
% Predicted HGS -0.19* 0.03
2m TUG 0.11** 0.10
Psychological HADS A 0.04* 0.70
HADS D 0.03* 0.73
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DTS -0.07** 0.49
Quality of Life SF-12 v2 PCS 0.02* 0.86
SF-12 v2 MCS -0.09* 0.31
* Spearman's rho **Kendall's Tau B
Table 3-9 Relationship between CRP concentration at 3 months and physical,
psychological, and quality of life outcome measures




























Table 3-10 CRP concentration at 3 months according to categorical outcomes
3.16.7 Post-hoc analyses
3.16.7.1 Concentration of other biomarkers at 3 months according to RMI
outcome groups
To further explore the relationship between the innate immune system and
recovery of physical mobility, biomarker concentrations in patients with a good
recovery (upper quartile of RMI) were compared with those with a poor recovery
(lower 3 quartiles of RMI). The median values with 95% confidence intervals and
Mann-Whitney U p values are presented in cross-reference.
Biomarker RMI < 12 RMI >12 P
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IL-1p (pg/mL) 0 (0-0) 0 (0-0) 0.36
IL-6 (pg/mL) 7 (2-14) 3 (1-12) 0.56
IL-8 (pg/mL) 9 (4-14) 6 (4-12) 0.44
TGFp (ng/mL) 99 (84-112) 102 (94-114) 0.46
MPO (ng/mL) 137 (118-177) 107 (88-141) 0.06*
HNE (ng/mL) 114 (105-138) 105 (100-117) 0.02*
SLPI (ng/mL) 48 (40-57) 14 (41-49) 0.48
Table 3-11 Biomarker concentrations at 3 months according to RMI category
3.16.7.2 Biomarker trajectory in patients with good and poor outcome
For this analysis, the subgroup of patients who stayed in hospital for 3
weeks following ICU discharge was studied. The 3-week subgroup was chosen
because it was considered that at least 3 readings after ICU discharge would be
required to plot a meaningful trajectory and after 3 weeks, the number of patients
still in hospital dropped off significantly. Unfortunately, after categorising patients
according to RMI outcome, there were very few patients in each of these categories.
Median concentration of CRP, IL-6, IL-8, and TGF|3 were plotted against time,
however, due to the very small number of patients, the confidence intervals were
widely overlapping. The graphs produced below are therefore of interest but do
not give definitive characterisation of the inflammatory resolution profile. Formal
statistical comparisons between biomarker profiles in patients with good and poor
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Weeks after ICU discharge
Figure 3-8 Median (IQR) CRP concentration in patients staying in hospital for 3
weeks after ICU discharge comparing patients with good recovery (RMI >12 (solid
line; n=6)) and poor recovery (RMI<12 (dashed line; n=9).
Figure 3-8 shows the changes in median CRP concentration over time in
patients staying in hospital for 3 weeks after an ICU discharge. In this very small
sample, there does not seem to be a dramatic difference in CRP trajectory between
people with good recovery and poor recovery.
In this subgroup, IL-6 shows a delayed resolution profile in patients with a
good outcome compared to those with a poor outcome (Figure 3-9). This
observation conflicts with the finding in the whole cohort that patients with poor
RMI scores have a higher IL-6 concentration at 3 months after ICU discharge.
Similarly, IL-8 is higher and resolves more slowly during the hospital stay in
patients good RMI scores (Figure 3-10). There seems to be very little difference in
TGF beta concentrations during the post-ICU hospital stay (Figure 3-11).
122
Weeks after ICU discharge
Figure 3-9 Median (IQR) IL-6 concentration in patients staying in hospital for 3
weeks with good recovery (RMI ^12 (solid line; n=6)) versus poor recovery (RMI>12
(dashed line; n=6)).
Weeks after ICU discharge
Figure 3-10 Median (IQR) IL-8 concentration after ICU discharge in patients staying
in hospital for 3 weeks with good recovery (RMI >12; solid line) (n=6)) and poor
recovery (RMI <12; dashed line (n=9)).
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Weeks after ICU discharge
e 3-11 Median (IQR) TGF beta concentration after ICU discharge in patients staying
in hospital for 3 weeks with good (RMI>12 (solid line; n=9), and poor (RMI<12
(dashed line; n=6) recovery.
3.16.7.3 Pre-existing inflammatory conditions
Patients with a pre-existing diagnosis of arthritis according to the FCI had
similar serum concentrations of CRP at 3 months, compared with those that did not
(3.6 (1.1-14.1) versus 4.4 (1.0-11.9) mg/L respectively (p=0.906)). Similarly, those
with any of the FCI diagnoses considered to be 'inflammatory' (arthritis, diabetes,
asthma, COPD, obesity) compared to those that had none of these conditions were
similar (3.7(1.3-11.9) versus 4.9 (0.8-11.0) mg/L respectively (p=0.929)).
3.17 Discussion
This chapter describes a cohort study, built into a randomised trial and
studied inflammation in ICU survivors and its relationship with patient relevant
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outcomes. It found a high prevalance of systemic inflammation lasting up to 3
months after ICU discharge with a significant relationship with physical recovery.
The systematic review reported in Chapter 2 reported many studies that
have explored inflammation during critical illness. In those that measured
inflammation at the point of ICU discharge, elevation of inflammatory biomarkers
was virtually ubiquitous at this treatment landmark. It was proposed that this was
an unsurprising finding given that ICU discharge is an arbitrary point in an ICU
patient's journey dictated mainly by the successful weaning from organ support,
but not necessarily the point of full resolution of the disease process. It was also
noted that there was a lack of data pertaining to the post-ICU period - either during
hospitalisation or after discharge to the community. Furthermore, there was no
data to support or refute the hypothesis that systemic inflammation during recovery
from critical illness contributes to the post-ICU syndrome.
The analysis carried out in this chapter therefore represents the first specific
exploration of the inflammatory fate of ICU survivors. It documents the prevalence
of systemic inflammation according to pre-specified criteria and the concentrations
of key inflammatory biomarkers at pre-specified time points after ICU discharge. In
addition, it explores for the first time the interplay between persistent inflammation
and the physical and psychological consequences of critical illness.
3.17.1 What is the prevalence and duration of systemic inflammation in
survivors of critical illness
Almost all the patients in the sample had a CRP concentration that was
greater than 3mg/L both at ICU discharge and hospital discharge. Even when a
higher reference threshold was used representing the 97th centile in healthy adults
(lOmg/L), a significant majority of patients (more than 70%) were inflamed at these
time points. By the 3-month follow up visit, median CRP concentration decreases
almost within the normal range. Despite this nearly a third of patients had a CRP
concentration that was greater than lOmg/L and two thirds have a CRP
concentration that was greater than 3mg/L.
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These data were obtained from a cohort of patients enrolled in a randomised
controlled trial. A potential criticism of the work, and a possible barrier to the
generalisability of the data was the use of a target population that was potentially
very selective and one that might not represent ICU patients in general. These
patients were all ventilated for greater than 48 hours and were therefore a sicker
cohort than the 'average' ICU survivor. Despite this, the RECOVER trial excluded
very few patients as a result of its protocol design. Furthermore, very few eligible
patients in the study declined consent, most probably due to the perceived benefits
of the 'enhanced' recovery package. From this cohort 80% of patients were enrolled
in the biomarker study and analysis of the baseline data confirmed that those who
were not enrolled were a very similar group. The population were likely to be a
good representation of the RECOVER target population.
At the earlier time points (ICU discharge and hospital discharge) rates of
subject attrition were very low. At 3 months, there was very complete data for the
functional outcome measures. However, a significant number of patients did not
have blood sampling for reasons of patient refusal or failed venepuncture
introducing a potential source of attrition bias. A comparison of baseline features
between those with complete and incomplete blood sampling was carried out and
this did not reveal any significant differences between the groups at least in terms of
the measured variables. The risk of attrition bias was considered to be minimal.
These data therefore provide convincing evidence of persistence of systemic
inflammation in an inclusive cohort of ICU survivors with low overall risk of bias.
Evidence of inflammation in ICU survivors could represent distinct
pathophysiological possibilities. Patients who are at risk of becoming critically ill
may represent a subgroup that has higher basal levels of circulating inflammatory
mediators. In this study, patients were enrolled in the study only after they had
become unwell and after they had survived an episode of critical illness. It is
therefore impossible to speculate whether they had raised levels of inflammatory
markers or not before they became unwell. However, in the post-hoc analysis
carried out in section 3.16.7.3, CRP concentrations at 3 months after ICU discharge
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was found to be similar in patients with and without pre-existing inflammatory
disease. This provides support for the hypothesis that inflammation persisting
beyond ICU is related to the episode of critical illness.
It is possible that this pattern of inflammatory resolution represents the
normal pattern for all patients following acute illness even if they do not become so
unwell that they require ICU admission. To test this hypothesis, a comparison
between ICU patients and a cohort of comparable hospitalised non-ICU patients
would be necessary. It was not possible to make this comparison in the current
study. Moreover, studies tracking inflammatory markers following hospital
discharge are lacking in the literature except for a small study that looked at CRP
concentration in patients discharged from hospital after an admission for unstable
angina. Of the 53 patients studied, 26 (49%) had an elevated CRP concentration (>
3mg/L) at hospital discharge with the same number having an elevated CRP
concentration 3 months later. The 3-month data from this study are comparable to
59% of patient with CRP >3mg/L seen in the RECOVER patients. However, the 2
samples are not comparable in terms of demographics and are starkly different in
terms of underlying pathophysiological processes.
Another possibility is that the observed immune activation is an appropriate
physiological response to a persistent pathogen or on-going tissue injury that is not
evident clinically. No follow-up imaging, microbiological screening, or other
diagnostic screening was carried out during the follow up of the study sample and
so it it is difficult to address this question.
Chronic inflammation following critical illness could represent recurrent
episodes of infection - secondary and tertiary inflammatory 'hits' in an
immunologically susceptible individual. It is known that down regulation of the
innate immune response, termed 'immunoparalysis', is observed in both adults and
children following critical illness and is associated with morbidity and mortality
(Frazier & Hall, 2008). This immunosuppression could potentially lead to chronic
low-grade activation of the immune system as the body is infected by pathogens
that are incompletely combatted by a weakened innate immune response.
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Immunoparalysis is formally defined as a reduction in the capacity of
monocytes to present antigen (monocyte HLA-DR+ <30%), or less formally as a
reduction in the cytokine production capacity of whole blood in response to a
stimulus. Neither definition was tested in the current cohort of patients therefore it
was not possible to test whether immunoparalysis might be causative in the
inflammatory persistence observed.
Reactivation of latent viral infection is another potential mechanism for
persistent innate immune activation and this topic is explored in chapter 4. A final
potential explanation is that critical illness is associated with delayed or
dysfunctional inflammatory resolution mechanisms that result in the persistence of
acute inflammation in the absence of pathological stimulus. What is the time course
of biochemical markers of systemic inflammation after critical illness?
Serum concentrations of molecules representing distinct aspects of the acute
inflammatory response after ICU discharge were studied. This analysis served 2
purposes. Firstly, it documented for the first time in human survivors of critical
illness, what happens to the blood concentrations of these substances as the body
switches from combating critical illness to the new challenge of recovery and
rehabilitation. Secondly, having identified a high prevalence of systemic
inflammation, study of the individual components of the inflammatory response
helped to explore which parts of the system might be contributing.
The granular neutrophil products HNE and MPO, the chemokine IL-8, the
pro-inflammatory cytokine IL-6, and the acute phase protein CRP were found in
high concentrations both at ICU discharge and 3 months after ICU discharge.
Although there was no control group in the study, the comparison made with other
populations of healthy subjects suggests that these are higher than what would
normally be observed. This suggests that the innate immune system is activated at
multiple levels, and that neutrophil degranulation, or neutrophil necrosis might be a
key characteristic of the on-going inflammatory process.
These findings are interesting but must be interpreted with some caution.
The lack of a control group prevents any formal statistical comparison between
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patients who have experienced an ICU admission, and patients with similar
illnesses who have not required organ support. These observations may represent
the natural history of the diseases studied, and ICU admission 'event' may be of
little consequence.
It was not possible in this study to follow the longitudinal time course of
these inflammatory biomarkers in a rigorous manner. The main limitation to this
was one of study design. Patients only had serial measurements of inflammatory
biomarkers carried out during the post ICU, in-hospital stay. Following discharge,
there were not further blood samples until the follow up point. In addition, a large
number of patients only stayed a week or 2 after ICU discharge. For these reasons,
the scope to plot biomarkers over time was limited.
A compromise was to compare patients who had stayed for a similar length
of time, and this was carried out for patients staying 1, 2 and 3 weeks after ICU
discharge. The interesting and perhaps surprising finding in this analysis was that
biomarker concentration seemed to be dictated by time from hospital discharge and
not ICU discharge. Despite following a very similar trajectory, patients staying for
shorter lengths of time in hospital after ICU discharge, had drastically different
biomarker concentrations at the point of ICU discharge. Assuming that discharge
from hospital is dictated at least in part by clinical status, the fact that the time
course of inflammatory resolution mirrors this is supportive of the theory that
inflammatory resolution is a key 'event' in recovery.
3.17.2 Is persistent inflammation in survivors of critical illness associated
with post-ICU recovery?
Another important finding of the study was that systemic inflammation and
physical function after critical illness were significantly associated. CRP
concentration was significantly correlated with RMI at 3 months with patients with
higher concentrations of CRP having poorer function. The serum concentration of
CRP measured in patients with a good mobility outcome (according to the pre-
specified RMI threshold of greater than 12) was a third of the concentration of those
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with a poor mobility outcome. Furthermore, a significant negative correlation was
observed between hand grip strength and CRP concentration with the weakest
patients (>2 standard deviations below the mean HGS) having a median CRP
concentration that was twice that of the other patients in the sample.
These findings lend support to the hypothesis that a persistent inflammatory
process impedes recovery. Despite this, it is important to stress that such a
conclusion cannot be drawn from this data alone. Using an epidemiological
framework proposed by Bhopal, the case for persistent inflammation as a candidate
aetiological factor in the pathophysiology of delayed physical recovery can be
evaluated (Bhopal, 2008).
Temporality. In epidemiology, temporality refers to the relationship in time
between a proposed risk factor or variable and the outcome of interest. For a risk
factor to be causative, its occurrence must predate the occurrence of the disease or
outcome. In this study, inflammation was significantly associated with both hand
strength and mobility at the same moment in time: 3 months after ICU discharge.
The study design that led to this observation was dictated by the randomised
controlled trial on which the sample was drawn. It was not possible to know with
certainty, which occurred first, the immobility or the inflammation. Patients may
have had significant decrements in their physical function prior to their ICU
admission. Indeed some of these physical impairments may have been
accompanied by chronic inflammation - rheumatoid arthritis being an obvious
example. This possibility was explored in the study with CRP concentration in
patients with potential pre-existing inflammatory conditions being compared to the
rest of the sample. This analysis, though underpowered, did not give any indication
that these patients were different in terms of their inflammatory response.
Alternatively, inflammation may have occurred as a result of muscle
dysfunction, with recovering, regenerating muscle being the focus of a restorative
inflammatory response. The finding of an association between inflammation and
poor recovery may reflect the greater regenerative inflammatory process (higher
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levels of inflammatory molecules) in patients with weaker and more damaged
muscles at study baseline.
Strength of relationship. Provided the other conditions are met, a stronger
relationship between potential risk factor and an outcome, the greater the likelihood
that the relationship is causative. Although there was a significant correlation
between inflammation and physical recovery, the correlation co-efficients and
scatter plots show that the relationship is fairly weak, at least using the chosen
outcome variables.
The RECOVER study was not originally designed to investigate
inflammatory outcomes and therefore aspects of the study design are likely to have
had an impact on the precision of the estimates. For example, the timing of blood
samples was dependent on patient convenience and not standardised by time of
day. In addition, the primary outcome measure of the RECOVER study (RMI)
displayed some ceiling effect - i.e. many patients had scores of 15. Therefore, whilst
RMI was used as a linear scale, lots of information will have been lost at the top end
of the scale. It is possible that a study designed specifically to assess the
relationship between inflammation and recovery addressing these potential flaws
may have improved the strength of the observed relationship.
Dose response. Another indicator of causality is dose response - an increase in
the exposure to or 'dose' of a risk factor (in this case inflammation) should lead to
an increased expression of the disease (in this case poor recovery). This has
certainly been demonstrated in this study. As CRP concentration increases, RMI
and percentage hand grip strength decrease. This observation strengthens the case
for a causative relationship.
Specificity. The case for a causative relationship is strengthened if the risk
factor has an effect that is limited to a narrow number of diseases - so called
specificity. In this situation, specificity is difficult to assess because neither 'critical
illness' nor 'physical disability after critical illness' could be considered to be
'diseases'. If a potential risk factor is associated with a wide range of conditions,
then it is much makes it less likely to be causative. Specificity is difficult to assess,
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especially when studying a phenomena that has not been explored much in the past.
The current study is the first to explore the role of inflammation in post-ICU
comorbidity and was limited to the post-ICU syndrome. It is possible that future
studies will demonstrate associations between post-ICU inflammation and other
diseases - reducing specificity. At this stage, it is probably most accurate to state
that specificity cannot be assessed at this time.
Other considerations are 'consistency' - the repetition of findings in other
studies, 'experimental confirmation', and 'biological plausibility'. So far, the
findings of this study have not been replicated in other studies because no other
studies asking this question have been carried out. No studies have confirmed the
phenomenon in an experimental study design, and doing so, at least in clinical
studies would not be feasible or ethical. Finally, the plausibility of the hypothesis
has been extensively argued above.
In summary, an association between functional outcome, and systemic
inflammation has been observed lending support to the hypothesis of a causative
role of inflammation in the post-ICU syndrome. Further studies will be required to
strengthen confidence or refute this hypothesis.
3.18 Conclusions
CRP concentration is elevated in almost all survivors of critical illness at the
point of discharge from ICU, remains elevated until discharge from hospital, and is
persistently elevated in up to 60% of patients 3 months after discharge from
intensive care unit. Contrary to expectation, CRP concentration does not decrease
exponentially as the patient recovers, but instead fluctuates considerably, in some
cases having an overall downward trend, but in many has an upward or a
persistently elevated course.
The exact mechanisms of CRP production and elimination and therefore the
main determinants of serum concentration in this cohort of patients cannot be
determined from this study. However, it is likely that ongoing release of pro¬
inflammatory mediators drives ongoing synthesis and release and therefore it is
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reasonable to suggest that ongoing acute inflammation or chronic inflammation is at
least partly responsible.
In this study, a significant relationship was observed between CRP
concentration, and measures of physical recovery. As with all observational studies,
it is impossible to determine whether theses relationships signify a causative role of
systemic inflammation on poor recovery after critical illness. However, biological
plausibility, and the lack of confounding influences mean that this is at least a
reasonable line of enquiry for future studies.
In addition, the fact that this study does not demonstrate a relationship
between other measures (in particular measures of psychological illness), does not
rule out the role for these factors in their aetiology and should not deter future
enquiry, but that this study was not powered to detect these relationships.
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Human cytomegalovirus (CMV) is a virus of the Herpesviridae family.
Owing to common biological characteristics such as restricted number of hosts, long
reproductive cycle, slow culture times, sites of latency and its tendency to cause
cytomegalia, CMV is classified in the betaherpesevirinae subfamily which also
contains Muromegalovirus, Roseolovirus, and Proboscivirus (Pellett & Roizman,
2007).
Human transmission is via contact with the infected body fluids of an
infected individual (saliva, breast milk, urine, vaginal secretions, semen). In an
American population sample (Staras et al., 2006), overall sero-prevalence of CMV
IgG was 59% increasing from 36% in 6-11 year olds to 91% in those older than 80
(Table ). Female gender, low household income and certain racial / ethnic groups
(e.g. Hispanics) carry increased risk of sero-positivity.










Table 4-1 Seroprevalence of CMV IgG in a non-institutionalised, civilian US
population (Staras et al., 2006)
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Following entry into the human body, the first line of defence encountered
by a viral pathogen is the innate immune system. Interferons and natural killer cells
(NK cells) are key components of the early defense against infection. Interferons
exert their antiviral effects via a number of pathways that cause blockade of viral
mRNA translation, apoptosis of virus-infected cells, degradation of viral RNA, and
inhibition of viral transcription. In addition, interferons stimulate major
histocompatibility complex (MHC) protein class 1 and 2 expression thus assisting in
the orchestration of the adaptive immune response. Non-specific proliferation of
NK cells is mediated by type 1 interferons and IL-15 in the immediate stages of
infection. NK cells kill virus-infected cells directly via direct cytolysis. However
they also produce interferon gamma that helps protect cells from infection and
activates macrophages.
As infection continues, the adaptive immune responses take over involving
both cell mediated and humoral mechanisms. The interaction of antibody and
complement with viruses and virus-infected cells prevents the spread of virus into
cells and mediates antibody dependent cellular cytotoxicity (ADCC) via NK cells,
macrophages, and neutrophils. In addition, the T cell response is crucial for
mounting a highly effective and specific cytotoxic effect against infected cells (Nash,
2006).
As a result of these immune responses, CMV infection is almost always a
subclinical disease in the immunocompetent host. Rarely, patients develop
symptoms of cytomegalovirus mononucleosis - manifesting as fever, lymph node
swelling, sore throat, rash, and spleno- or hepatomegaly. Even more rarely, patients
develop a severe multisystem disease (Pellett & Roizman, 2007).
In patients lacking a fully functioning immune system, unabated CMV
replication can lead to severe life-threatening CMV infection. Acute CMV illness is
classically recognised in 2 specific situations - vertical transmission from infected
mother to unborn foetus causing foetal damage; and reactivation (and rarely
primary infection) in patients with AIDS or following solid organ or bone marrow
transplantation. In these scenarios CMV infection can cause pneumonitis, retinitis,
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hepatitis, and colitis. Pneumonitis in particular is associated with high mortality
(>80%).
The replication phase of viral infection is dependent on the host cell. After
cell entry, a complex series of events leads to replication of the viral genome.
Following this, the virus particle is packaged within a protein and released from the
host cell. This process leads to death or 'lysis' of the host cell and this phase is
therefore known as the 'lytic' phase of viral infection. Some viruses are able to enter
cells and stop in a static or latent phase. All herpes viruses including CMV are able
to do this (Traylen et al., 2011).
4.1.2 CMV latency and persistence
Once infected, CMV is a life-long infection persisting in the human host in 2
states. These states are best described as viral latency -'the maintenance of the viral
genome in the absence of production of infectious virions' (Sinclair, 2008) and
chronic infection, where viral replication continues at low levels but does not cause
disease due to the surveillance and killing functions of host T cells.
The most studied site of HCMV latency is the myeloid cell lineage (Sinclair,
2008), a site that gained considerable interest following the discovery that
transfusion of leukocyte-depleted blood reduces the risk of transfusion-related CMV
disease (de Graan-Hentzen et al., 1989). There are likely to be other sites of CMV
latency but so far, these have been not been consistently demonstrated.
The precise mechanisms by which herpes viruses evade detection and
elimination by the host immunes system remain largely a mystery. However, it has
been recently shown that cells containing latent CMV virus secrete an increased
quantity of the chemokine CCL8 that recruits CMV specific T cells and inhibit their
cytotoxic function (Mason, Poole, Sissons, Wills, & Sinclair, 2012). In addition the
CMV genome encodes IL-10 production within myeloid cells inhibiting the function
of CD4 cells (A. K. Cheung et al., 2009).
Although CMV reactivation and its consequences have historically been
considered a phenomenon isolated to those with immune-compromise particularly
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organ transplant recipients and patients with the acquired immunodeficiency
syndrome (AIDS), reactivation also occurs in immune-competent individuals in
certain situations including critical illness (Chiche et al., 2009; Cook et al., 2003;
Cook et al., 1998; Desachy et al., 2001; Heininger et al., 2011; Heininger et al., 2001;
Jaber et al., 2005; Kutza et al., 1998; Limaye et al., 2008; von Muller et al., 2006).
It is known that the lytic phase of CMV infection is critically dependent on
immediate early (IE) gene expression. IE genes are the first viral genes expressed
following infection with CMV. In latent myeloid cells there is evidence of IE gene
suppression. Virus-encoded genes including the CMV IE gene promoter control the
switch from a latent to a lytic replication phase of CMV infection. NF-kappa B and
C-Jun (both stimulated by cytokines and stress-related proteins during critical
illness) up-regulate the production of these genes leading to CMV reactivation
(Traylen et al., 2011).
4.1.3 CMV infection and reactivation in ICU patients
Various aspects of CMV infection have been studied in populations of ICU
patients over the past 20 years. These studies have attempted to describe the rates
of previous CMV exposure, the incidence of active CMV infection, the potential
clinical consequences of active and latent infection, and the risk factors for CMV
reactivation.
4.1.3.1 Evidence ofprevious CMV exposure
In healthy community dwelling adults, evidence of prior CMV exposure
(presence of IgG antibody to CMV) is widespread and rates rises steadily with age
(Staras et al., 2006) (Table 4-1). In ICU patients, prevalence rates are similarly high
(up to 94%), and although direct age based comparisons have not been done, they
are likely to reflect the background prevalence rates of the population (Table 4-2).
In an early study of 34 surgical ICU patients with sepsis, 33 were screened
for CMV IgG on the day of sepsis onset and 31 (94%) were CMV IgG positive at this
time (Kutza et al., 1998). Of 104 patients in an observational study of surgical ICU
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patients with a length of stay of more than 5 days, 76 patients (73%) were CMV IgG
positive (Cook et al., 2003). In another study of 242 immuno-competent medical
ICU patients that were mechanically ventilated for at least 48 hours, 194 patients
(80%) were CMV IgG positive at the point of ICU admission (Chiche et al., 2009).



















Ventilated > 48 hours
242 194 (80%)
Table 4-2 Baseline CMV IgG seropositivity of ICU patients
4.1.3.2 Evidence of CMV reactivation
Some investigators have examined the incidence of active CMV infection in
ICU patients with evidence of prior CMV exposure (CMV IgG positive). These
studies are summarised in Table 4-3. Whilst it is possible that these patients have
experienced newly acquired CMV infections, due to the presence of dormant
infections, these patients are usually described as patients experiencing CMV
'reactivation'.
In a series of 23 immuno-competent critically ill mechanically ventilated
patients, CMV DNA was not detected in the peripheral blood leukocytes or in the
cells of broncheo-alveolar lavage (BAL) samples from any of the patients (Stephan et
al., 1996). This was an observational study and the sampling regimen was not
standardised. Only half of the patients had BAL sampling, and whilst all the
patients had blood sampling, it was not clear how often this was carried out.
Certainly, it appears that only 8 of the 23 patients had sequential blood sampling.
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There is therefore a high likelihood that active CMV infection if it had been present
could have been under-diagnosed.
In another study, this time of severely ill surgical intensive care unit
patients, 36% of CMV IgG positive patients were found to have active CMV
infection defined by CMV detection by PCR or viral culture of plasma, leukocytes,
or respiratory tract secretions (Heininger et al., 2001). Limaye and colleagues found
a reactivation rate of 33% measured by CMV plasma DNA PCR in their study of 120
CMV IgG seropositive ICU patients (Limaye et al., 2008). Finally, in 86 immuno¬
competent CMV seropositive patients with sepsis, 35 patients (41%) had evidence of
CMV reactivation (CMV DNA detected by PCR in leukocytes, plasma, or tracheal
secretions)(Heininger et al., 2011).



















































Table 4-3 CMV reactivation in CMV IgG positive ICU patients
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4.1.3.3 Evidence of active CMV infection
Other investigators have described active CMV infection regardless of IgG
status. These studies are summarised in Table 4-4. In a study of patients with
sepsis, found that 11 out of 34 patients (33%) had CMV DNA in their leukocytes and
6 (17%) had CMV antigen in their leukocytes (Kutza et al., 1998). In another study
of patients with multiple organ dysfunction syndrome (MODS), CMV infection was
detected in only 1 of the 96 ICU patients studied using a similar definition. The
authors of this study conceded that the likely explanation for the disparate result
was the single sampling point early during the ICU admission (mean 1.8 days after
ICU admission) in contrast to the serial sampling regimen undertaken in other
studies (Desachy et al., 2001). In a surgical ICU population, Cook and colleagues
cultured CMV in the respiratory samples of 15% of patients and found CMV
viraemia in 5.8% using a weekly sampling regimen (Cook et al., 2003). In a
heterogenous ICU population of 242 patients ventilated for greater than 48 hours, 38
(16%) of patients had active CMV infection. Diagnosis was based on the presence of
CMV pp65 antigenaemia, positive bronchoalveolar lavage (BAL) viral culture, a
histological diagnosis of CMV, or signs and syptoms of lung disease combined with
CMV detected in BAL fluid.
In a highly selective population, Jaber and colleagues studied 237 patients in
whom CMV infection was suspected on clinical grounds and in whom CMV pp65
antigen was measured in peripheral blood leukocytes. Of these patients 40 patients
(17%) had evidence of active CMV infection (Jaber et al., 2005).












































































Table 4-4 CMV infection in ICU patients
4.1.3.4 CMV infection and mortality
Few of the observational studies exploring the effects of CMV infection in
critical illness on mortality have employed statistical techniques to take into account
potential confounders. Heininger reported higher mortality in patients with active
CMV infection (55% versus 36% p=0.17) (Heininger et alv 2001). This may reflect the
greater proportion of CMV positive patients that had sepsis (50% versus 17%). In
Cook's study, an excess mortality was seen in CMV positive patients (50% versus
27% p=0.15) (Cook et al., 2003). Jaber and colleagues also reported excess ICU
mortality (50% versus 28% p=0.02). Chiche and colleagues reported a greater
proportion of patients with CMV infection in those that died during ICU stay
(Chiche et al., 2009).
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Limaye and colleagues performed a multivariable analysis to examine the
effect of CMV infection on the composite endpoint of death or hospitalisation at 30
days (Limaye et al., 2008). In univariable analysis, mechanical ventilation, serious
infection, ventilator days and CMV viraemia but not age, type of intensive care unit,
race, severity of illness, or blood transfusion were associated with the composite
outcome. In their multivariable model including intensive care unit, mechanical
ventilation, major infection, ventilator days, and various quantitative measures of
CMV load, all variables were independently associated with the composite endpoint.
On the basis of this analysis, it would seem plausible that CMV infection is
associated with mortality or prolonged hospital length of stay. Unfortunately the
presence of multiple potentially interacting variables introduces the risk of a type 1
error so the results of this regression must be interpreted with caution.
Heininger and colleagues used Cox proportional hazards modelling to
explore the relationship of CMV reactivation with hospital mortality. They found
severity of illness, presence of septic shock, and CMV reactivation had significant
bivariate relationships with hospital mortality. After adjustment for measured
potential confounders (SAPS II score, presence of septic shock, length of ICU stay
before enrolment, and HSV detection in respiratory secretions), CMV reactivation
did not have a significant association with hospital mortality (Heininger et al., 2011).
4.1.3.5 CMV infection and other outcomes
Similar to the data reported for mortality, most of the studies examining
other outcomes in CMV-infected ICU patients did not adjust for potential
confounding factors. Heininger and colleagues noted a longer ICU length of stay in
patients with CMV infection. This observation is likely to be confounded by the
preponderance of septic patients in the CMV group who may have had a longer
length of stay (Heininger et al., 2001). Cook and colleagues also found that patients
who developed CMV infections had a longer length of ICU stay, in addition to
longer hospital lengths of stay, and longer duration of ventilation (Cook et al., 2003).
Jaber and colleagues reported longer length of stay, longer hospital length of stay
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after ICU, longer duration of ventilation, and a greater number of nosocomial
infections. Chiche and colleagues reported longer ICU length of stay, greater
number of ventilator-associated pneumonia (and other bacteraemia) in patients
with active CMV infection (Chiche et al., 2009).
In the only study to perform multivariable analysis on outcomes other than
mortality, Heininger and colleagues found CMV reactivation had a significant
association with ICU length of stay. This association remained significant after
adjustment for SAPS II, septic shock, ICU stay before enrolment, and HSV detection
in respiratory secretions (Heininger et al., 2011).
4.1.3.6 CMV infection after ICU discharge
No studies were found that measured CMV infection in patients after ICU
discharge. It is therefore unclear, how many of the large proportion of CMV
infected patients have on-going CMV infection.
4.1.3.7 Risk factors for CMV infection
Several studies have explored potential risk factors for CMV infection
during critical illness. Investigators have done this by comparing patient
characteristics between patients who do and do not subsequently develop CMV
infections. In some cases, multivariable analyses have been conducted to adjust for
measured confounders.
In risk factor analysis such as this, temporality is important - i.e. the
characteristic must exist prior to the onset of the disease. For baseline
characteristics such as age, gender, and pre-existing comorbidity, this is
straightforward. However for illness-related factors such as severity of illness and
drug treatments given during an illness, temporality is difficult to demonstrate.
Any risk factor analysis examining these factors should therefore be interpreted
with caution.
Using a case-control study design where patients were matched for gender,
age, severity of illness, pre-ICU hospital length of stay, and ICU diagnosis, Jaber
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and colleagues found that patients with suspected CMV infection who had the
diagnosis confirmed were more likely to have renal failure requiring renal
replacement therapy, or receive corticosteroids during their ICU stay (Jaber et al.,
2005). Whilst no analysis of confounding was carried out in this study, the matched
design suggests that these differences were independent of the matched factors. It
is not known whether these differences contributed to or were a consequence of
CMV infection.
In Heininger's study of severely septic patients, there were no differences
noted in terms of age, gender, diagnosis, or severity of illness at baseline (Heininger
et al., 2011).
Kutza and colleagues study of septic patients (Kutza et al., 1998) noted
higher rates of severe sepsis in those patients who subsequently developed CMV
infections (73% versus 44%).
In Heininger's study of surgical patients, gender, age, severity of illness
(SAPS II), presence of malignant disease, pre-ICU treatment duration, and a
diagnosis of sepsis were compared between CMV infection groups. The group who
subsequently developed CMV infections had higher proportions of patients with a
diagnosis of sepsis and pre-existing malignant disease. More of these patients had
pre-ICU treatment of longer than a week. When SAPS II score, age, female gender,
malignant disease, and acute sepsis were entered into a multivariable logistic
regression equation with CMV infection as the outcome, malignant disease and a
diagnosis of sepsis had a statistically significant association with CMV infection
status and could therefore be considered potential independent risk factors
(Heininger et al., 2001).
In a heterogenous group of ICU patients, those that subsequently
experienced CMV reactivation were more likely to be male, more likely to have
received a blood transfusion and be mechanically ventilated prior to study entry.
Severity of illness (APACHE 2) race, age, type of ICU were similar in both infection
groups. In a multivariable logistic regression analysis including type of ICU, and
gender, male gender remained independently associated with subsequent CMV
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reactivation. Patients in cardiac ICU were less likely to be become reactivated
(Limaye et al., 2008).
In Chiche and colleagues' ventilated medical ICU cohort, age, gender,
severity of illness, ICU diagnosis, and prior comorbidities were compared. Patients
who subsequently developed CMV infection were slightly older (68 versus 62 years
p=0.018). They were more likely to have a diagnosis of pneumonia and more likely
to have pre-existing chronic renal failure, COPD, or have taken corticosteroids in the
preceding 1 month. No multivariable analyses were carried out to adjust for
potential confounders and therefore these observations are speculative (Chiche et al.,
2009).
Cook and colleagues tested the associations of various baseline
characteristics with CMV infection as the outcome in a multivariable logistic
regression model (Cook et al., 2003). Of the variables included in the model
(APACHE 2 score, age, female gender, previous CMV exposure, steroid exposure,
multiple blood transfusions, ICU length of stay, and bacterial pneumonia), female
gender, previous CMV exposure, steroid exposure, and bacterial pneumonia were
significantly associated with CMV infection (Cook et al., 2003).
4.1.4 Effect of CMV infection on the immune system
CMV infection is associated with elevated levels of inflammatory cytokines
and induces systemic inflammation that persists beyond the acute infection and into
viral latency (van de Berg et al., 2010). It is therefore plausible that patients who
have evidence of active CMV infection during the recovery phase of critical illness
will have inflammatory consequences. In addition, the mere presence of latent
CMV infection might increase a patient's risk of persistent inflammation, and by
extension, worsened physical outcome as a consequence.
4.1.5 Other viruses in critically ill patients
The reactivation of other viruses (Herpes Simplex Virus (HSV), Ebstein Barr
Virus (EBV), and torque teno virus (TTV) is also observed during critical illness.
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Studies of these viruses have shown possible association with patient relevant
outcomes such as secondary bacterial infections, and prolonged ICU length of stay
(Bruynseels et al., 2003).(Walton et al., 2014). CMV was chosen as the virus that has
most frequently been studied in a critical care population, has shown the strongest
associations with clinical outcome including mortality, and also has been shown to
have an impact on the inflammatory profile of again patients. Thus as a potential
aetiological factor in the pathogenesis of inflammatory persistence in ICU survivors,
it carries the most promise.
4.1.6 Summary and outline of aims
In summary, the majority of ICU patients are likely to have been previously
exposed to cytomegalovirus and a significant proportion of these will experience
viral reactivation during critical illness. The consequences of CMV infection in
critical illness requires further investigation as most observational studies do not
control for confounding variables. CMV infection is associated with longer ICU
length of stay and possibly also increased mortality.
No studies have explored CMV infection in ICU survivors. Specifically, it is
not known how many ICU patients (who have high rates of reactivation) still have
evidence of active infection at ICU discharge and at later time points.
This study therefore aimed to document the prevalence of active CMV
infection at ICU discharge and at 3 months after ICU discharge in a heterogeneous
population of 193 survivors of critical illness. Furthermore, the author aimed to
study the characteristics of patients with evidence of active infection, and compare
them to non-infected patients. Finally, the authors set out to explore the
associations between CMV status and markers of inflammatory resolution and
physical recovery.
4.2 Hypotheses
• A high proportion of ICU survivors have evidence of prior CMV
exposure.
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• In some patients, it may be possible to detect evidence of CMV
reactivation at ICU discharge.
• Prior CMV exposure is associated with persistent inflammation and
dysfunctional inflammatory resolution after ICU discharge.
• CMV reactivation is associated with persistent inflammation and
dysfunctional inflammatory resolution after ICU discharge.
• CMV status at ICU discharge is associated with post-ICU complications
such as depression, anxiety, PTSD, and poor physical function.
4.3 Research Questions
• What is the proportion of ICU survivors that have evidence of prior
exposure to CMV at ICU discharge?
• What proportion of patients in the sample has evidence of active CMV
infection at ICU discharge?
• What are the characteristics of these patients?
• How long does CMV infection persist after ICU discharge?
• Is CMV infection associated with resolution of inflammation?
• Is CMV infection associated with the post-ICU syndrome?
4.4 Methods
This chapter analyses CMV reactivation on the same cohort of patients
described in chapter 3. The reader is therefore directed to the methods section of
this chapter for information on patient selection, consent, and blood sampling. In
addition, the methods employed for processing and storage of the blood samples is
identical.
4.4.1 Diagnosis of active CMV infection
To establish exposure to CMV prior to ICU discharge, stored serum samples
were analysed using a quantitative indirect anti-globulin enzyme immunoassay
(VIDAS CMV G, Biomeuryx, Lyon, France), CMV antibody was quantified in
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arbitrary units/mL (aU/mL). As per the manufacturers instructions, patients with <4
aU/mL were considered to have negative CMV IgG serology. Patients with CMV
titres of greater than or equal to 4aU/mL or less than 6aU/mL were considered
equivocal. Those with titres of greater than or equal to 6aU/mL were considered to
have positive serology.
Those patients with positive or equivocal CMV IgG titres had quantitative
PCR carried out on stored plasma samples.
4.4.2 Systemic inflammation and inflammation resolution
The inflammatory biomarkers measured in RECOVER have been justified
previously (section 3.9).
Serum concentrations of CRP, complement enzymes, IL-1|3, IL-6, IL-8, TGF
beta, SLPI, MPO, and HNE were determined using the methodology described in
chapter 3.
4.5 Statistical Methods
A signed, dated a priori analysis plan for this section was included in the
request for RECOVER trial data (Appendix Ef).
4.5.1 Evidence of previous CMV exposure and active CMV infection
The number and percentage of patients with previous CMV exposure was
reported. Previous CMV exposure was defined as a positive test for CMV IgG
antibody at ICU discharge.
The number and percentage of patients with evidence of CMV reactivation
was reported. CMV reactivation was defined as the number of patients with
previous CMV exposure that had detectable CMV DNA in plasma at ICU discharge.
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4.5.2 Investigation of factors associated with evidence of prior CMV
exposure
Baseline data was presented for patients with evidence of prior CMV
exposure at ICU discharge. Comparison was made with patients that did not have
evidence of prior CMV exposure using the Student's t-test for parametric data and
Mann-Whitney U Test for non-parametric data.
4.5.3 Investigation of factors associated with evidence of CMV reactivation
at ICU discharge
Baseline data was presented for patients with evidence of CMV reactivation
at ICU discharge. Comparison was made with patients that did not have evidence
of CMV infection at this time using the Student's t-test for parametric data and
Mann-Whitney U test for non-parametric data.
4.5.4 Duration of CMV infection
In those patients who did have evidence of CMV infection at ICU discharge,
the number and percentage of patients of those patients that still had CMV DNA in
plasma at 3 months was reported.
4.5.5 Association of prior CMV exposure / active infection and inflammatory
resolution
Comparisons CRP, IL-1|3, IL-8, IL-6, TGFp, MPO, HNE, and SLPI,
concentration at 3 months grouped according to previous CMV exposure and active
CMV infection are presented. Groups were compared with Mann Whitney U tests.
These comparisons represented cross-sectional analyses of 2 groups of patients. As
such an un-paired statistical test was chosen.
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4.5.6 Association of CMV status with indices of physical recovery,
psychological sequelae, and quality of life outcomes
Outcomes of physical (RMI, % predicted FIGS, 2 minute timed up and go),
psychological (HADS A, and D; DTS), and quality of life (SD12 v2 PCS and MCS)
were compared according to previous CMV exposure group. In addition these
outcome measures were compared according to CMV reactivation group. The
Mann-Whitney U test was used for non-parametric data and Student's t-test was
used to compare parametric data.
4.5.7 Association of CMV status and other outcomes
The association of CMV status with post ICU hospital length of stay was
explored using Student's t-test.
4.5.8 Issues of study power and multiple testing
As with chapter 3, this study was an add-on to an RCT and is also likely to
be underpowered to detect differences between study groups. To take into account
issues of multiple testing, results are reported and discussed in relation to
Bonferroni adjusted p value thresholds.
4.6 Results
4.6.1 Patients
For details of patients enrolled in the blood sampling study see Figure 3-1.
At study baseline (ICU discharge) CMV serology was carried out on 183 of the 184
patients (99%) in RECOVER that had blood sampling. One patient had an
insufficient quantity of remaining sample due to previous testing to carry out the
CMV assays.
At study follow up (3 months after ICU discharge) CMV serology was




At ICU discharge, 115/183 (63%) had positive CMV serology indicating prior
CMV infection and 1 patient had equivocal CMV serology.
Three months later, 77/122 (63%) had positive serology and 1 patient had
equivocal CMV serology. Of the 77 CMV IgG positive patients at 3 months, 74
patients had CMV IgG measured at ICU discharge. Seventy-two patients were IgG
positive at ICU discharge, 1 patient had equivocal serology. Only 1 patient had
negative CMV IgG at baseline and represented a single case of CMV sero¬
conversion during the 3 month follow up period.
4.6.3 CMV reactivation
CMV PCR was carried out on 114 (99%) of the patients with positive CMV
serology at ICU discharge. In one case, there was inadequate sample to perform
PCR analysis. Of these, 13 patients (11.4% of IgG positive patients or 7.2% of all ICU
survivors) had detectable CMV on PCR consistent with reactivation of latent CMV
infection.
4.6.4 Characteristics of patients with evidence of prior CMV exposure
The baseline characteristics of ICU survivors who had positive CMV IgG
were compared with those who were IgG negative (Table 4-5). Patients in these
groups were similar in terms of age, gender distribution, previous comorbidity, and
severity of illness. IgG positive patients spent a similar period of time in ICU and
received mechanical ventilation and vasopressors as often as IgG negative patients.
IgG positive patients were more likely to receive renal replacement therapy than
IgG negative patients (30% versus 22% p=0.25). This difference did not reach
statistical significance, however given the wide confidence intervals around the
percentage, it is possible that this represents a type 2 error resulting from the
secondary analysis of trial data that was not powered to demonstrate such a
difference.
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Similarly, IgG positive patients were twice as likely to have on-going
delirium at ICU discharge (19% versus 9% p=0.06) and had worse scores on the RMI
(2 versus 4 (p=0.07). Whilst these results also fail to reach statistical significance,
they provide a potentially interesting signal that may warrant future exploration.
CMV IgG + CMV IgG - p***
(n=115)* (n=68)*
Age 61 (14) 61 (13) 0.97
Gender (m/f (%m)) 69/46 (60) 43/25 (63) 0.66







Osteoporosis 37 (32) 16 (24) 0.21
Asthma 7(6) 3(4) 0.75
COPD 20 (17) 13 (19) 0.77
Angina 20 (17) 12 (18) 0.97
Heart Disease 12 (10) 5(7) 0.49
Heart Attack 13 (11) 8(12) 0.93
Neurological 13 (11) 3(4) 0.11
Stroke 4(3) 0(0) 0.30
PVD 14 (12) 7(10) 0.70
Diabetes 3(3) 3(5) 0.67
Upper Gastro 17 (15) 10 (15) 1.00
Depression 37 (32) 20 (30) 0.69
Anxiety 32 (28) 21 (31) 0.66
Visual 25 (22) 20 (30) 0.24
Hearing 16 (14) 9(13) 0.90
Disc Disease 12 (10) 7(10) 0.98
Obesity 9(8) 6(9) 0.81
27 (24) 14 (21) 0.65
APACHE 2 21 (7) 21 (8) 0.98
SOFA score at
baseline
Total 3 (2,5) 2 (2,4) 0.18
Cardiovascular 0 (0,0) 0 (0,0) 0.69
Respiratory 2(1,2) 2(1,2) 0.39
Coagulation 0 (0,1) 0 (0,0) 0.26
Renal 0 (0,1) 0 (0,0) 0.36
Liver 0(0,1) 0 (0,0) 0.12
Neurological 0(0,1) 0 (0,1) 0.56








83 (72) 49 (72) 0.91
Received renal
replacement (n(%))
34 (30) 15 (22) 0.25
Delirium at
enrollment (n(%))
22 (19) 6(9) 0.06
RMI at enrollment 2(1,6) 4(1,5) 0.07
HGS (kgs) 16(8) 16(8) 0.99
Table 4-5 Baseline characteristics of CMV IgG negative/equivocal versus IgG
positive CMV ICU survivors. *Expressed as mean (sd), median (25th, 75th centile)
or n (%) unless otherwise stated. **For continuous data, mean difference and 95%
confidence intervals are presented. For percentage data, percentage differences
and 95% confidence interval for the differences are presented. *** p values: T test
for parametric data, Mann Whitney U for non-parametric data, Chi-squared test for
proportion unless any cell value <5 in which case Fishers exact test was employed.
4.6.5 Characteristics of patients with active CMV infection
The baseline characteristics of those IgG seropositive patients who had
evidence of active CMV infection (CMV PCR positive) at ICU discharge are
compared with IgG seropositive patients without evidence of CMV infection in
Table 4-6.
CMV PCR + CMV PCR- p***
(n=13)* (n=101)*
Age 61 (13) 61 (13) 0.93
Gender (m/f (%m)) 9/4 (69) 60/41 (59) 0.71
FCI 2.8 (2.0) 2.4 (2.6) 0.47
FCI subcategories (n (%))
Arthritis 4(31) 32 (32) 1.00
Osteoporosis 1 (8) 6(6) 0.58
Asthma 2(15) 18 (18) 1.00
COPD 2(15) 18 (18) 1.00
Angina 2(15) 10 (10) 0.63
Heart Disease 3 (23) 10 (10) 0.17
Heart Attack 1 (8) 12 (12) 1.00
Neurological 0(0) 12 (12) 1.00
Stroke 0(0) 4(4) 0.36
PVD 0(0) 3(3) 1.00
Diabetes 1 (8) 16 (16) 0.69
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Upper Gastro 5 (39) 32 (32) 0.62
Depression 2(15) 30 (30) 0.35
Anxiety 2(15) 23 (23) 0.73
Visual 0(0) 16 (16) 0.20
Hearing 1 (8) 11 (11) 1.00
Disc Disease 1 (8) 8(8) 1.00
Obesity 4(31) 23 (23) 0.50
APACHE 2 20 (11) 21 (6) 0.65
SOFA score at baseline
Total
Cardiovascular 3 (2,6) 3 (2,5) 0.50
Respiratory 0 (0,0) 0 (0,0) 0.65
Coagulation 2(1,2) 2(1,2) 0.48
Renal 0 (0,2) 0(0,1) 0.60
Liver 0(0,1) 0(0,1) 0.75
Neurological 0 (0,2) 0(0,1) 0.47
0(0,1) 0(0,1) 0.63
ICU length of stay (days) 16 (10,28) 11 (6,18) 0.06
Days of mechanical 11 (4,26) 8(5,13) 0.51
ventilation
Received vasopressors 10 (77) 72 (72) 1.00
(n(%))
Received RRT (n(%)) 3 (23) 31 (31) 0.75
Delirium at enrolment (n(%)) 4(31) 18 (18) 0.27
RMI at enrolment 1 (0,2) 2(1,6) 0.06
HGS (kgs) 12(6) 17(8) 0.03
Table 4-6 Baseline characteristics of CMV PCR positive versus CMV PCR
negative/equivocal CMV seropositive ICU survivors. *Expressed as mean (sd),
median (25th, 75th centile) or n (%) unless otherwise stated. **For continuous data,
mean difference and 95% confidence intervals are presented. For percentage data,
percentage differences and 95% confidence interval for the differences are
presented. *** p values: T test for parametric data, Mann Whitney U for non-
parametric data, Chi-squared test for proportion unless any cell value <5 in which
case Fishers exact test was employed.
Patients with evidence of CMV infection were of a similar age but were more
likely to be male. Small differences were noticed between the 2 groups in FCI
subcategories reflecting small differences in pre-existing comorbidity. Due to the
small sample size, it is impossible to determine whether these would translate to
significant differences in a larger samples size. Overall FCI score was the same in
the PCR positive and PCR negative groups indicating a similar level of pre-existing
comorbidity.
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Severity of illness as assessed by APACHE 2 score was the same in both
groups. SOFA scores at ICU discharge were also the same in both groups. PCR
positive patients trended towards a longer stay in ICU (16 days versus 11 days
p=0.059), and were ventilated for longer (11 days versus 8 days p=0.511).
Of note, physical function at baseline was reduced. Despite the highly
skewed distribution of RMI data at this time point, with most patients having vary
poor function, RMI was a point higher in CMV PCR negative patients compared
with CMV PCR positive patients (RMI 1 versus 2 p=0.06) (Figure ). In addition,












Figure 4-1 Comparison of RMI at ICU discharge across CMV reactivation groups




CMV f>CR negative CMV PCR positive
CMV PCR status
Figure 4-2 HGS across CMV reactivation groups (p=0.03). PCR positive n=11; PCR
negative n=69.
As discussed in the introductory section (4.1.3.7), potential risk factors for
CMV reactivation and infection are sepsis, severity of illness, blood transfusion,
corticosteroid use, organ transplantation, and other causes of immunosuppression.
A case note review was therefore carried out to further assess these potential risk
factors. Case notes were available for 11/13 (85%) of the patients in whom CMV
reactivation was diagnosed. A summary of this review is presented in Table 4-7
and Table 4-8.
Risk factor n %
Blood transfusion 2/11 18
Organ transplant 2/11 18
Blood borne virus 1/11 8
Sepsis 4/11 36
Corticosteroids 2/11 18
Other immunosupression 2/11 18
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Table 4-7 Summary of risk factors from ICU survivors with evidence of CMV
reactivation
Six out of 11 (55%) of patients had 1 or more of the risk factors described in
Table 4-7. Two of the 11 patients (18%) received a blood transfusion during their
ICU admission. Two patients (18%) of the patients had received an orthotopic liver
transplant and were receiving immunosuppression. One patient had a diagnosis of
hepatitis C - potentially putting them at risk of other blood borne viruses and
particularly HIV. Four patients (36%) had an admission diagnosis of sepsis, and 2
patients (18%) had received systemic corticosteroids whilst in ICU. One patient had
had a splenectomy. Five patients (45%) had no known risk factors for CMV
reactivation other than critical illness.












56 M 22 Y N N N N N N
4 Out of hospital
cardiac arrest
78 M 26 Y N N N N N N
5 Post op repair
mycotic
aneurysm






44 F ND Y N N N N N N
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Case Diagnoses Age Sex APACHE2 Vasopressors RRT Steroids BBV Organt/p Transfusion Otherimmunosuppress
oesophageal
varices
7 Hepatic abscess 83 F 24 Y Y Y N N Y N






























70 F 22 N N N N N N N
Table 4-8 Summary of case note review of ICU survivors with CMV reactivation
(ND=no data)
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4.6.6 Time course of CMV infection following ICU discharge
Of the 13 patients that were CMV PCR positive at ICU discharge, only 6 had
repeat sampling at 3 months. The research team was unable to contact 2 patients,
one of who was known to have moved abroad. Four patients received a home visit
but the research nurses were unable to obtain a blood sample due to difficulties
with venepuncture.
Of the 7 patients in whom a sample was obtained, none had on-going
evidence of persistent CMV viraemia.
There were no cases where patients tested PCR negative at ICU discharge
and PCR positive at 3 months after ICU discharge.
4.6.7 CMV status and systemic inflammation
4.6.7.1 Systemic inflammation and CMVIgG
Comparison of biomarker concentrations between ICU survivors who were
CMV IgG positive and those that were negative are shown in Table 4-9 (see page
164). CRP concentration at baseline was similar in both groups (28 versus 25mg/L
p=0.90). At the 3-month follow up point, IgG positive patients had a CRP
concentration that was nearly twice that of the IgG negative patients (5mg/L versus
3mg/L p=0.07) with the difference not reaching statistical significance (Figure 4-3).
Given that this was an exploratory analysis that was not powered to detect such
differences, there is a reasonable chance that this represents a type 2 error and that




CMV IgC negative / equivocal CMV IgC positive
CMV IgC status
Figure 4-3 CRP concentration at 3 months according to CMV IgG status. IgG
positive n=76; IgG negative/equivocal n=41.
At ICU discharge, HNE (Figure 4-4), IL-6 (Figure 4-5), and IL-8 (Figure 4-6)
were elevated in IgG positive patients, reaching statistical significance in the case of
HNE, even accounting for a Bonferoni adjusted p value of p<0.004. IL-6 almost
achieved statistical significance according to this threshold. TGF|3 on the other hand
was found in lower concentrations in the serum of IgG positive patients and had a p
value that was almost significant to the Bonferoni adjusted threshold (p=0.01)
(Figure 4-7). IL-1[3 was virtually undetectable in the serum of ICU survivors. No
differences in concentration were observed in the concentrations of MPO or SLPI.
However, the median MPO concentration of 192ng/mL across the entire sample is
significantly greater than the upper limit of normal of 951pg/mL (0.9ng/mL) seen in
























CMV IgC positiveCMVIgC negative / equivocal
CMV IgG status
Figure 4-4 HNE concentration at ICU discharge according to CMV status p=0.00.
















CMV IgC negative / equivocal CMV IgC positive
CMV IgG status
Figure 4-5 IL-6 concentration at ICU discharge according to CMV IgG status p=0.05.


























Figure 4-6 IL-8 concentration at ICU discharge according to CMV IgG status p=0.06.


























Figure 4-7 TGF beta concentration at ICU discharge according to CMV IgG status
p=0.01. IgG positive n=113; IgG negative/equivocal n=67.
At the 3-month sampling point, the biomarker patterns observed at ICU
discharge were preserved. Patients who were CMV IgG positive had higher
concentrations of HNE, IL-6, and IL-8 and lower concentrations of TGF beta in their
serum. There were not differences in the concentrations of SLPI or MPO but as at
ICU discharge, the levels of MPO were significantly elevated compared to the
observations made by others in healthy adults.
In summary, ICU survivors with evidence of previous CMV exposure had
elevations in their inflammatory markers when compared to patients without prior
exposure. Given that these 2 groups were similar in terms of their severity of illness,
demographics, and prior comorbidity, it is possible that latent CMV infection does
have some impact on inflammatory resolution.






























































Baseline 36 (24-36) 24 (17-29) 0.07
3 months 9 (5-16) 5 (1-10) 0.06
TGFp (ng/mL)
Baseline 11 (10-12) 14 (12-15) 0.01
3 months 9 (9-10) 11 (10-12) 0.01
Table 4-9 Comparison of inflammatory biomarkers according to serum IgG at ICU
discharge.
4.6.7.2 Effect of latent CMV infection on biomarker recovery trajectory
To further explore this hypothesis, a post hoc analysis was carried out on a
subgroup of patients that remained in hospital for at least 3 weeks after ICU
discharge. It was considered necessary to have at least 3 samples after ICU
discharge to plot a 'trajectory' and three weeks was the time point with the
maximum number of patients fulfilling this criterion. These patients had weekly
blood sampling during their post-ICU hospital stay and line charts of median
concentration were constructed to depict the recovery trajectory of several of the
inflammatory biomarkers - CRP (Figure 4-8), IL-6 (Figure 4-9), IL-8 (Figure 4-10),
and TGF-beta (Figure 4-11).
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Weeks after ICU discharge
Figure 4-8 Median (IQR) CRP concentration after ICU discharge according to CMV
IgG status. IgG positive n=10; IgG negative n=5.
Weeks after ICU discharge
Figure 4-9 Median (IQR) IL-6 concentration after iCU discharge according to CMV
IgG status. IgG positive n=8; IgG negative n=5.
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Weeks after ICU discharge
Figure 4-10 Median (IQR) IL-8 concentration after ICU discharge according to CMV
IgG status. IgG positive n=10; IgG negative n=4.
Weeks after ICU discharge
Figure 4-11 TGFp concentration after ICU discharge according to CMV IgG status.
IgG positive n=9; IgG negative n=5.
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In this subset of patients with prolonged post-ICU length of stay (3 weeks),
CRP concentration remained elevated in IgG positive patients compared to IgG
negative patients at all time points and decayed at a similar rate. Due to the small
sample size (10 patients and 5 patients respectively), statistical inference testing was
not carried out and the values observed have widely overlapping confidence
intervals (median (95% CI) CRP concentration at baseline in this subgroup was 50
(5-17) in the IgG positive group versus 70 (6-91). It is therefore possible that this
observation was made purely as a result of chance. However, given the elevations
seen in other biomarkers at baseline and follow up time points, it is also possible
that this signals a difference in inflammatory resolution in the IgG subgroups.
Similar differences were noted in the IgG subgroups when 11-6 and IL-8 were
examined.
As in the whole sample population, TGF beta concentration was higher in
the IgG negative patients compared to the IgG positive patients at the point of ICU
discharge. During the first week after ICU discharge, serum concentration of TGF
beta dropped in both IgG positive and IgG negative patients, reaching a plateau of
4-6 ng/mL for the remaining weeks of the hospital admission. As a substance that is
released during resolution from inflammation, its suppression in CMV IgG positive
patients who have elevations in pro-inflammatory cytokines some 3 months after
ICU discharge may represent an inflammatory resolution defect.
4.6.7.3 Systemic inflammation and CMVPCR
In this section, only patients who were CMV IgG positive were included in
the analysis. Patients with evidence of CMV reactivation (CMV IgG positive
patients who were also PCR positive) were compared with those without evidence
of CMV reactivation (CMV IgG positive patients that were PCR negative). This
analysis is summarised in Table 4-10 (see page 168). There was no difference in CRP
concentration between these 2 groups at baseline (24 versus 27mg/L p=1.00) or at 3
months (6 versus 5mg/L p=1.00).
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Due to the small number of events, the differences in the concentrations of
the other biomarkers were difficult to interpret. There were small differences in the
median values of some of the biomarkers that had widely overlapping confidence
intervals. It is therefore impossible to draw many conclusions from this data. There
is no evidence in this sample that patients with latent CMV infection that have
evidence of CMV reactivation at ICU discharge are different in terms of their
















































































Table 4-10 Comparison of inflammatory biomarkers between CMV IgG positive
patients with evidence of CMV reactivation (CMV PCR positive) and those without.
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4.6.7.4 Effect of CMV reactivation on biomarker recovery trajectory
Of the 10 patients identified who were CMV IgG positive who stayed in
hospital for at least 3 weeks after ICU discharge, only 2 had evidence of CMV
reactivation. It was not therefore possible to make a meaningful comparison of
biomarker recovery trajectories in this subgroup.
4.6.7.5 Complement proteins
As was the case in the main RECOVER analysis, complement proteins were
analysed using a cytometric bead array technique. Due to technical difficulties with
this assay, and the resulting loss of sample, no interpretable results are available for
complement and as such are not included in the analysis.
4.6.8 Association of CMV status and the post-ICU syndrome
4.6.8.1 Recovery after critical illness and CMV IgG
Measures of physical function, psychological comorbidity and quality of life
3 months after ICU discharge were compared between patients with and without
evidence of prior CMV infection (CMV IgG positive versus CMV IgG negative
patients). TUG was 10 seconds in IgG negative patients versus 11 seconds in IgG
positive patients (p=0.03).
There was a clinically small but statistically significant difference in the time
taken to perform the Timed Up and Go test. RMI was 1 point lower in IgG positive
patients compared to IgG negative patients (p=0.09) and % predicted HGS was also
slightly lower (63% versus 65% p=0.42). Neither of these met the pre-specified
threshold for statistical significance. Otherwise there were no differences between
the 2 groups. There was therefore no definitive evidence that CMV IgG positivity
on its own has a negative impact on physical recovery after critical illness, although
there were perhaps some signals that physical function might be poorer.
Psychological outcome as measured by the HADS score showed no
difference between the 2 groups. IgG positive patients scored almost twice the
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number of points on the DTS signalling a potential increased risk of PTSD
symptomology at the 3 month follow up stage.
Finally physical and mental quality of life as measured by SF-12 version 2
were no different between the 2 groups.
CMV IgG + (n=115) CMV IgG - (n=68) P
mean* or median** (95% mean* or median** (95%
CI) CI)
Physical
RMI 13 (11-14)** 14 (12-15)** 0.09
HGS (kg) 21 (19-23)* 23 (20-25)* 0.28
2 m TUG (seconds) 11 (10-12)** 10 (8-10)** 0.03
Psychological
HADS A 6 (5-8)** 6 (4-8)** 0.66
HADS D 7 (5-7)** 6 (4-8)** 0.99
DTS 12 (5-1)** 6 (3-14)** 0.40
Quality of Life
SF12 v2 PCS 35 (33-37)* 35 (32-38)* 0.85
SF12 v2 MCS 45 (43-48)* 45 (41048)* 0.82
Table 4-11 Comparison of physical, psychological, and quality of life outcomes in
ICU survivors according to CMV IgG status
4.6.8.2 Recovery after critical illness and CMV reactivation
There were no significant differences between the patients who had
evidence of CMV reactivation when compared to those that didn't (Table 4-12). The
number of IgG patients who had evidence of active CMV infection was small and
the follow up incomplete therefore rendering this analysis grossly underpowered.
It is therefore difficult to draw any meaningful conclusions about the effects of CMV











RMI 11 (7-14)** 13 (12-14)** 0.76
HGS (kg) 66.0 (50.8-78.1)* 52.6 (42.2-63.0)* 0.09
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2 m TUG (seconds) 13 (9-23)** 11 (10-12)** 0.31
Psychological
HADS A 5 (2-10)** 6 (5-8)** 0.63
HADS D 7 (5-7)** 6 (1-9)** 0.71
DTS 16 (0-19)** 11 (4-15)** 0.73
Quality of Life
SF12 v2 PCS 37 (32-42)* 35 (33-37)* 0.50
SF12 v2 MCS 43 (34-53)* 46 (43-48)* 0.63
Table 4-12 Comparison of physical, psychological and quality of life outcomes in
CMV IgG positive patients according to CMV PCR status
4.6.8.3 CMV status and hospital length of stay
Hospital length of stay was increased in CMV IgG positive patients who had
evidence of CMV reactivation (median of 57 days versus 28 days p=0.05). To further
explore this, the number of post-ICU days in hospital was compared to test whether
CMV PCR positive patients had a more protracted course following ICU discharge
that could explain the prolonged hospital length of stay. Patients with evidence of
CMV reactivation at ICU discharge stayed in hospital twice as long (median 26 days
versus 13 days p=0.02).
4.7 Discussion
In chapter 3, significant correlations between serum markers of
inflammation and measures of physical recovery were reported. Thus it was
speculated that inflammatory outcome and recovery of physical function might be
inter-related. Understanding why inflammation is evident in the blood of ICU
survivors months after ICU discharge may therefore be of crucial importance if
reductions in post-ICU morbidity and enhanced post-ICU recovery are to be
realised.
One mechanism that could explain the presence of chronic inflammation in
this cohort is the reactivation of latent viral infection either through direct activation
of the innate immune system, or by increasing susceptibility to inter-current
infections and illnesses.
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Numerous studies have reported reactivation of latent CMV infection in ICU
patients assumed to have normal immune systems and these have been extensively
discussed in the introduction (page 137). These patients spend longer in ICU,
longer in hospital, and seem to require a longer duration of mechanical ventilation.
They may also be more likely to die. The mechanisms linking CMV reactivation to
these adverse clinical outcomes are a matter of speculation at the present time.
However as a relatively common occurrence with known clinical consequences,
studying CMV reactivation as a potential contributor to inflammatory outcome
and/or rehabilitation outcomes is a reasonable line of enquiry.
It could be argued that the ideal study design to explore this hypothesis
would be to identify all seropositive patients within an ICU cohort that go on to
develop reactivated CMV infection and then follow them up after ICU discharge.
As this study was limited to the post-ICU period, it was not possible to do this. On
the other hand, by limiting the analysis to ICU survivors only, it is possible to limit
the survivor bias attributable to ICU mortality. The fact that very few of the
patients in this cohort died subsequent to ICU discharge reduces the risk of this
kind of bias - and is a notable strength of the study.
4.7.1 What is the proportion of ICU survivors that have evidence of prior
exposure to CMV at ICU discharge?
This study has shown that sixty-three percent of critically ill adults who are
ventilated for more than 48 hours have evidence of prior CMV exposure (CMV
latency) at the point of ICU discharge. Referring back to the American population
described in Table where prevalence rates raise from 65% in 40-49 year olds to
nearly 90% in 70-79 year olds, this finding most likely represents that background
sero-prevalence rate.
This is lower than the rates seen in a severe sepsis cohort (Kutza et al., 1998)
that had a prevalence rate of 94%, a surgical ICU cohort (Cook et al., 1998) that had
a prevalence rate of 73%, or a medical ICU cohort (Chiche et al., 2009)that had a
prevalence rate of 80%. This is likely to reflect pathological and demographic
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differences in these cohorts. From the current study data, there is no reason to
suspect that ICU patients have higher rates of prior CMV exposure although it is
acknowledged that this statement is speculative only.
4.7.2 What proportion of ICU patients has evidence of CMV reactivation after
ICU discharge?
Of the 65% of ICU survivors that had positive CMV IgG serology, 11.4% had
evidence of CMV infection at ICU discharge and were considered to have CMV
reactivation. This represented 7.2% of the whole sample.
When compared to the studies that examined samples from patients still in
ICU, the prevalence of CMV reactivation is low. In 120 IgG positive ICU patients'
patients in a mixed unit, 39 (33%) of patients had evidence of CMV reactivation
determined by CMV DNA in plasma (Limaye et al., 2008).
None of the previous investigators have sought to determine the duration of
CMV infection in their studies. The observation of 11.4% reactivation prevalence at
ICU discharge is therefore interesting. Although from the available data in the
current study, it is impossible to determine the total number of patients who
experience reactivation during their ICU stay, from the work of others, it may be as
high as 30%. One explanation for the low rates of CMV infection found at ICU
discharge is that most patients with CMV reactivation during critical illness, resolve
that infection whilst they are in ICU. For some, the battle to curtain viral replication
lasts longer. Another explanation is that patients with CMV reactivation are more
likely to die in ICU and the low rates observed reflect this.
From the case note review carried out on CMV PCR positive cases, it is
known that only in the case of 1 patient, CMV infection had been suspected and a
diagnosis made. In this case, antiviral treatment (Gancyclovir) was given. In all the
other cases, the clinical team did not know about the CMV infection. Despite this,
all the patients followed up managed to resolve their CMV infection over the
following 3 months without receiving specific treatment.
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4.7.2.1 What were the characteristics ofpatients with evidence of prior
exposure to CMV?
ICU survivors with evidence of prior CMV exposure did not differ
significantly from the other patients in the sample. Patients were of a similar age,
and gender distribution, had similar levels of pre-existing comorbidity, and had
experienced critical illness of a similar severity.
The finding that patients were in receipt of RRT more commonly if they
were IgG positive is worth noting, particularly because patients with renal failure
have been observed to have higher circulating levels of inflammatory mediators (Raj
2003). Renal replacement therapy is therefore a potential confounder of any
relationship between IgG status and inflammation. Given the very small difference
observed, and the lack of statistical significance, it is unlikely to have had a major
impact in the current analysis.
Another difference observed was that CMV IgG positive patients had rates
of delirium that were more than twice those observed in CMV IgG negative patients.
Whilst it is difficult to ascertain the significance of this observation, delirium has
been associated in previous studies with prolonged hospital length of stay and
increased mortality. The causative relationship between delirium and these
outcomes has not been established and some have argued that delirium is really a
marker of severity of illness. It is therefore possible that the increased rates of
delirium observed in the IgG positive patients in the current study are a subtle
indicator of a more severe illness in this group - therefore raising another potential
(unquantifiable) confounder of the relationship between inflammatory outcome,
and CMV latency.
In a study where most patients had a very low RMI at study baseline, it was
interesting to observe that the RMI at ICU discharge was 2 in the CMV IgG positive
patients when compared with and RMI of 4 in the CMV IgG negative patients.
Although the difference did not quite meet statistical significance, the difference
was striking. If the observed difference does reflect a true difference within the
population, there are several possible explanations.
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Firstly, patients who have previously been exposed to CMV might have
poorer pre-existing physical function. Secondly, prior CMV exposure might
predispose patients to a more severe illness that results in a greater insult to
physical function. Thirdly, the IgG positive patients, a proportion of whom may
have experienced CMV reactivation during critical illness, are more likely to have
experienced damaging pulmonary insults (caused by CMV pneumonitis) and
therefore have a cardiopulmonary reason for poor baseline mobility. It is
impossible to determine which of these is the explanation and it warrants further
exploration in future studies. The first 2 are probably more likely than the third due
to the relative rarity of CMV pneumonitis.
4.7.2.2 What were the characteristics of ICU survivors with evidence of CMV
reactivation at ICU discharge?
Before considering the differences in the patients with and without evidence
of CMV reactivation at the time of blood sampling, it is worth considering the
possible circumstances that could have led to these 2 states.
The most likely sequence of events given the findings of the previous
literature is that a proportion of patients previously exposed to CMV at an earlier
stage in their life, reactivated latent CMV infection during critical illness. These
reactivations are likely to have been triggered by pro-inflammatory stimuli in
susceptible individuals. Following reactivation, the immune system responds
firstly by activation of the innate immune response, and secondly by adaptive
responses. In the majority of patients, these responses bring the reactivation under
control so that by ICU discharge - the point at which organ failure has resolved,
only a minority of patients still have evidence of on-going viral replication - the
CMV PCR positives in this study. Those patients who are CMV negative are likely
to represent 2 groups of patients. One group may consist of patients that have
reactivated their CMV and in whom the immune response has curtailed viral
replication. The other group may consist of patients that never reactivated. Those
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patients in the CMV negative group may therefore represent patients at the end of
distinct pathological processes.
The other less likely explanation for the observation is that the arbitrary
single sampling time point at ICU discharge picks up patients at different stages of
their CMV reactivation. Assuming that all ICU patients resolve an episode of CMV
reactivation over a similar time frame (and this is unlikely to be the case), this
theory would mean that positives and negatives represent patients that have
reactivated earlier and later in their ICU stay. This is unlikely due to the sampling
point at ICU discharge where patients could be considered to be at the same stage of
their recovery from acute illness.
Patients who had evidence of CMV reactivation (CMV IgG positive patients
that were CMV PCR positive) did not differ significantly from the other patients in
the sample. Patients were of a similar age, and gender distribution, had similar
levels of pre-existing comorbidity, and had experienced critical illness of a similar
severity according to APACHE 2 score after 24 hours, vasopressor use, and use of
renal replacement therapy.
Patients with CMV reactivation had a longer length of ICU stay and had
poorer physical function at ICU discharge as indicated by a lower score on the RMI
and a lower HGS. These findings suggest that patients with evidence of CMV
reactivation had a more protracted illness, and it is possible that this had a negative
impact on physical function. There is no evidence of any difference in prior
functional comorbidity in the reactivation group making it possible, but unlikely
that pre-existing functional deficits explain this observation. Unfortunately the
current study cannot answer this question definitively.
In the present study, active CMV infection was observed in 11.4% of IgG
seropositive ICU survivors at the point of ICU discharge. Other than the criteria
imposed by the RECOVER study, the sample included all ICU patient groups.
Patients with risk factors for CMV reactivation were not identified in advance and
excluded. Despite this, in only 55% of cases of CMV reactivation were specific risk
factors found on case note review - the most common of these being sepsis, present
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in 36% of the cases studied. Other risk factors identified were blood transfusion (2
cases), organ transplant (2 cases), corticosteroids (2 cases) and splenectomy (1 case).
4.7.3 Is CMV infection associated with resolution of inflammation?
Perhaps the most interesting observations made in this study were the
differences in inflammatory biomarkers in ICU survivors depending on whether
they were CMV IgG positive or negative. At ICU discharge, HNE, IL-6, and IL-8
were all elevated in IgG positive patients and whilst IL-6 and 11-8 could only be
considered to have achieved borderline statistical significance, the highly significant
elevation in HNE lends support to a more severe on-going inflammatory process in
the IgG positive patients. Furthermore, the highly significant difference in pro-
resolution biomarker TGF beta concentration at the same time point with lower
levels in the IgG positive patients supports the theory that there is delayed
switching from a pro-inflammatory to a pro-resolution state.
Three months after ICU discharge, the persistent activation of the immune
system of the ICU survivor is more pronounced in IgG positive patients. Again IL-6,
IL-8 and HNE are found in greater concentrations and TGF beta is found in lower
concentrations in these patients. In addition, a small difference in CRP
concentration is evident with IgG positive patients having a CRP that is almost
twice that of IgG negative patients. This strongly suggests that CMV IgG positive
patients resolve inflammation at a different rate to IgG negative patients.
The exploratory longitudinal analysis of inflammatory biomarkers whilst
statistically underpowered also supports this hypothesis.
The limitations of this analysis should be emphasised. Firstly, it is
acknowledged that issues pertaining to multiple testing may have affected the
analysis. Despite this, the difference in HNE concentration observed both at ICU
discharge and 3 months later would have achieved significance at a Bonferormi
adjusted p-value threshold of 0.004. Moreover, this analysis was pre-specified and
strongly hypothesis driven both of which add considerable strength to the analysis
and its findings.
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Another weakness is one that is shared by all studies of an observational
design - that of confounding. This feature contributes a significant limitation to the
interpretation of the results. From the measured baseline characteristics, there are
very few indications that IgG positive patients are a different group to those who
are IgG negative. There are more patients that received RRT during their ICU stay
in the IgG positive group and it is conceivable that this could contribute to a
prolonged ICU state. However, the subgroup analysis carried out in chapter 3 does
not support this.
Finally, it should be recognised that this is a study of ICU survivors and
some patients that have CMV disease may have died in ICU before study
recruitment. This limits the external validity of our findings to ICU survivors and
should not be applied to all ICU patients.
4.7.4 The effect of CMV reactivation on inflammatory profile
In a subgroup of IgG positive patients (114 patients), inflammatory markers
were not significantly different at any of the time points studied between patients
with or without evidence of CMV reactivation. In these comparisons, there were
subtle differences in the median values of biomarkers but the wide confidence
intervals made their interpretation impossible.
The most likely explanation for this observation is that the sample size
simply wasn't large enough to give an accurate impression of the biomarker
behaviour. The number of patients with reactivation was only 13. In addition, the
large number of patients without evidence of CMV reactivation could represent 2
separate groups of patients (see also pi 75) - those who have not reactivated, and
those who have reactivated, but the immune system has managed to curtail viral
replication. To properly assess the impact of CMV reactivation during critical
illness as a risk factor for persistent inflammation, serial sampling designed to
capture all episodes of CMV reactivation with a prolonged post-ICU longitudinal
study of biomarkers would be more suitable.
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4.7.5 Is latent CMV infection associated with recovery from critical illness?
There were some small signals that CMV latency might be a risk factor for
physical but not psychological comorbidity 3 months after and episode of critical
illness. CMV IgG positive patients scored 1 point less on the RMI (p=0.09) and were
1 second slower in performing the 2-minute timed up and go test (p=0.03). Despite
the apparently small difference in 2m TUG, a 1 second difference is likely to
represent a significant difference in frailty. In the case of RMI, the majority of
patients in RECOVER had very high scores on RMI at 3 months despite
experiencing significant disability. The observation of even this small difference
may therefore be of some clinical significance.
The other observation of relevance was that IgG positive patients had a
significantly longer post-ICU length of stay. This observation may be the key to
understanding the observed inflammatory resolution defect. These patients may be
more at risk of recurrent infections that may prolong hospital stay, and lead to
prolonged elevations in inflammatory biomarkers.
4.7.6 Is CMV reactivation associated with recovery from critical illness?
The question of whether CMV reactivation is associated with recovery from
critical illness has not been adequately addressed by this study. As was the case
with the exploration of inflammatory resolution in this subgroup, the small number
of reactivation events detected limited the analysis. A further limitation was the
possibility that the negatives might represent 2 different pathophysiological groups
as outlined above.
There were some small differences noted. Median RMI was lower in the
patients with evidence of reactivation and the 2m timed up and go took 2 seconds
longer. Mean HGS was slightly higher in the CMV reactivation patients. None of
these differences were supported by significant p values, and confidence intervals
were widely overlapping. It was therefore difficult to draw any conclusions from
this analysis.
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The most significant finding in this analysis was that post-ICU hospital
length of stay as far longer in patients with CMV reactivation.
4.8 Conclusions
A large proportion of ICU survivors have evidence of prior CMV exposure
when tested at the point of ICU discharge. Despite being similar in terms of
severity of illness, demographics and prior comorbidity, prior CMV exposure is
associated with differences in serum concentrations of both pro-inflammatory and
pro-resolution biomarkers in a pattern that would support the theory of a defect in
inflammatory resolution caused by latent CMV. Furthermore, there are signals in
the data that suggest that CMV latency may also be a risk factor for delayed
functional recovery after ICU discharge - a finding that warrants further
exploration.
A small but significant proportion of these patients also have evidence of
active CMV infection (CMV reactivation) at ICU discharge. Many of these patients
do not have obvious risk factors for reactivation, and may represent up to a third of
patients who have reactivation triggered by an episode of critical illness. The
significance of this subgroup in terms of post-ICU outcome remains unclear.
These patients experienced longer ICU stays and more prolonged hospital
stays than seropositive patients that did not have evidence of CMV reactivation.
Levels of physical function were poorer at baseline but this did not translate into
statistically significant differences in function at follow up.
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Chapter 5 - Derivation of a predictive tool to identify
patients at risk of delayed physical recovery after
critical illness
5.1 Introduction
An increasing awareness of the physical, psychological and social problems
faced by ICU survivors has led to a surge in research activity in this area - the
RECOVER study being a good example. The hope is that some of these studies will
identify therapeutic interventions that could improve the overall quality of life for
ICU survivors.
Intensive care research is limited by the heterogeneity of its patients, and the
illnesses that result in a critical care admission. Some patients may benefit from a
certain intervention, and some may not. In some cases, these competing effects may
cancel each other out - therefore failing to demonstrate overall benefit for the
population studied. Even in studies that do demonstrate benefits to patients, it is
likely that certain groups of patients may benefit more than others. Subgroup
analysis is an important component of trial design that can enable greater
understanding of the effects of an intervention, particularly when a trial fails to
show a significant overall result.
In the case of functional recovery after critical illness, some patients may
have a good functional outcome regardless of the treatment that they receive.
Investment in a complex rehabilitation package for these patients may therefore be
an unjustifiable expense as well as an unnecessary burden.
There is an urgent need to be able to identify at an early stage in a patient's
illness their likely recovery trajectory and individual need for enhanced
rehabilitation. Despite the widespread recognition of the post-ICU syndrome,
surprisingly little is known about risk factors for persisting disability. The
following paragraphs summarise previous studies in this area.
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5.1.1 Risk factors for persisting disability after ICU discharge
In a Canadian follow up study of acute lung injury (ALI) patients, a number
of patient characteristics were associated with decrements in physical function
(greater number of organ failures, longer ICU stay, surgical admission diagnosis,
lower blood glucose concentration, lower doses of sedative, depression at follow
up). However, only depression remained significantly associated when
multivariable adjustment was carried out to control for the effects of known
confounding factors (Bienvenu et al., 2012).
Another observational study of 194 American cardiothoracic ICU patients
measured predictors of persistent dependency as defined by a Karnofsky score of
less than 80 points (Gersbach et al., 2006; Grieco & Long, 1984). This study
identified the occurrence of a peri-operative neurological event as the major risk
factor for long-term disability - relevant in an a post cardiac surgery setting, but not
useful in a general adult ICU population.
In a study of 516 survivors of severe sepsis, an American group
demonstrated significant increases in cognitive impairment and functional
limitations as a result of an episode of severe sepsis. This study did not
demonstrate that severe sepsis provided an increased risk of these problems in
addition to the effects of critical illness (Iwashyna, Ely, Smith, & Langa, 2010).
Patients who have pre-existing deficits in physical function cannot be
expected to recover to the pre-illness functional levels of fitter patients. Therefore
pre-illness characteristics are of vital relevance to the prediction of function in the
months following ICU discharge. The functional comorbidity index (FCI) was
developed in a cohort of nearly 40,000 individuals drawn from 2 databases in the
USA and Canada (Groll, To, Bombardier, & Wright, 2005). The index consists of 18
comorbidity categories each of which has been shown to be strongly associated with
physical function (as measured by the physical component of the Medical Outcome
Study SF-36 (P-SF36)). This score has subsequently been validated in 73 survivors
of ARDS (Groll, Heyland, Caeser, & Wright, 2006). It has never been evaluated in
an unselected ICU cohort. This study also had a relatively small sample size, and
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the linear multivariable model used to evaluate the FCI also included 10 other
variables (age, gender, APACHE2 score, P/F ratio, baseline SOFA score, ICU and
total hospital length of stay, cause of lung injury, and smoking status). Whilst none
of these other factors were associated with physical outcome as measured by the P-
SF-36 it is likely that the analysis was underpowered.
5.1.2 Clinical prediction tools
Clinical prediction tools can be derived using multivariable data to allow
identification of patients who are at risk of a certain outcome. These rules assist and
in some cases improve the decision-making ability of clinicians (Adams & Leveson,
2012). As described by Adams et al (Adams & Leveson, 2012), rule development
requires a number of mandatory steps, all of which are necessary for a rule to
become useful in the clinical context. These steps are development, validation,
impact analysis, and implementation and are summarised in Table 5-1.
Step Description
Development Identification of risk factors from an observational study
Validation Testing of the tool in another clinical setting to ensure
reliability
Impact Measure clinical usefulness in terms of cost benefit, patient
satisfaction, and time resource allocation
Implementation Widespresad acceptance and adoption of the tool
Table 5-1 Stages of clinical prediction rule design as described by Adams et al
5.1.3 Available clinical prediction tools for post-ICU outcome
A literature search carried out in the MEDLINE database returned 1 study
that had attempted to develop a clinical prediction tool for the purpose of
identifying patients at risk of post-ICU complications (Schandl, Bottai, Hellgren,
Sundin, & Sackey, 2013). The investigators reported the development of a
prediction tool for psychological comorbidity after critical illness and represented a
component of a research degree thesis that also described the development of a
clinical prediction tool for physical disability (Schandl, 2013).
183
The author reported a process of selecting candidate variables for both
prediction models using a combination of literature review and multidisciplinary
input. Eighteen risk factors were selected for consideration in both the
psychological and physical prediction tools. Additional specific risk factors were
added as a result of expert opinion. These risk factors were assessed individually in
univariable logistic regression models for binary outcomes of psychological
complications (anxiety, depression, or PTSD) and physical complications (physical
dependency according to the ADL staircase).
Major pre-existing disease, having young children, previous psychological
problems, being agitated in ICU, pre-morbid unemployment, and depressive
symptoms in ICU were predictors of PTSD, anxiety or depression and were
included in the final psychological prognostic tool. Education level, reduced core
stability at ICU discharge, fractures, and ICU length of stay >48 hours were
identified as independent risk factors for physical dependency and were included in
the final physical prognostic tool. Both tools performed well from a statistical point
of view. The predictive ability of the psychological and physical prediction tools
were measured by area under the receiving operator characteristic curves of the
derived indices and were 0.72 and 0.82 respectively.
Despite being impressive statistically, these scores have yet to be validated
in other patient groups. In addition there were a number of methodological
problems, some of which were acknowledged by the author that limit their
applicability. Firstly, there were a large number of patients who were excluded
from the derivation cohort for reasons that may have introduced selection bias. Of
389 eligible ICU survivors studied over a 6 month period, 137 patients (35%) were
excluded. 41 (11%)) were excluded on the basis of language, and 10 (3%) were
excluded on the basis of pre-existing cognitive impairment.
In addition, there was a high drop out rate leading to a high risk of attrition
bias. One hundred and two patients (41%) were lost to follow up. Nineteen of these
were deaths. However, 83 patients were non-responders. Although there were no
statistically significant differences in this group of non-responders compared to the
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study population, bias introduced by this level of loss of follow up cannot be
excluded and will make generalisation difficult.
There were also some issues with the model derivation. Following the work
by Peduzzi et al that demonstrated problems with inference testing and estimation
of coefficients at low numbers of events per variable (EBV) in logistic regression
analysis, it has been recommended that an EBV of 10 is the minimum required to
make the model function appropriately (Peduzzi, Concato, Kemper, Holford, &
Feinstein, 1996). In the derivation of the psychological prediction tool, there were 46
'events' and 7 variables were included in the multivariable analysis. This gives an
EBV of 6 that makes the model at high risk of this sort of problem. In the thesis, the
author does not report the physical event rate so one cannot comment on EBV in
this case.
A final limitation of the work is the lack of a clear definition for physical
dependence. The author states the use of the ADL ladder to diagnose dependence.
However there are varying degrees of dependence described by this score and the
level of dependence is not stated in the thesis text.
Overall this single prognostic rule derivation study has derived strong
diagnostic tests for physical and psychological disability within the limitations
described. Importantly, it has identified some potential candidate risk factors for
future work. Further exploration of risk factors and derivation of a new prognostic
scale whilst taking into account the limitations of previous studies can now be
justified.
5.1.4 The RECOVER study sample - an opportunity to derive a clinical
prediction tool for post-ICU complications
The RECOVER study investigators collected a rich database of baseline
variables relating to pre-existing patient factors (age, gender, Functional
Comorbidity Index), critical illness (diagnosis, severity scoring, duration, organ
support), and clinical data (delirium scoring, muscle strength, and baseline
mobility).
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As already discussed, some of these factors have been tested as risk factors
for physical disability after critical illness. Some have not been previously tested.
The availability of such a complete and rich dataset in a heterogeneous ICU
population presented an opportunity for the development of a predictive model
that might be useful for the detection of patients with good and poor function after
critical illness.
In previous chapters, it has been shown that inflammatory outcome and
latent CMV infection is associated with physical function after critical illness. It is
therefore reasonable to suspect that measurement of inflammatory biomarkers and
CMV IgG status at the point of ICU discharge could add additional strength to a
prognostic tool.
The aim of this chapter was to identify potential risk factors for poor
physical recovery after critical illness and attempt to incorporate them into a clinical
prediction tool. The performance of this tool was evaluated with and without the
addition of blood biomarkers data.
5.2 Research Questions
• Which risk factors for post ICU physical immobility can be identified
from the RECOVER study baseline data?
• Can physical recovery after critical illness be predicted using readily
available data at ICU discharge?
• Can prediction of physical outcomes be improved by the addition of




As with chapters 3 and 4, patients participating in the RECOVER study were
approached for consent to participate in the biomarker study. Consenting patients
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who were not lost to follow up and did not have missing data in the target variables
were included in the analysis.
5.3.2 Analysis plan
In order to minimize the risk of researcher bias creeping in during the
analysis stage, a signed and dated analysis plan (Appendix H) was produced prior
to the trial outcome data being made available to the author. For various reasons
this analysis plan required modification. This analysis plan and modifications are
described below
5.3.3 Number of candidate variables
To minimise problems with bias errors in coefficient calculation, the rule of 1
variable per 10 cases was used. In the original analysis plan, this allowed for the
assessment of a maximum of 15 candidate variables in a linear regression model on
a projected sample size of 150 patients.
In the RECOVER biomarker study, the final sample size was 175 patients.
This allowed for the testing of a maximum of 17 candidate risk factor variables.
The study aimed to produce 2 tools, one using the available clinical data,
and the other adding inflammatory biomarker concentrations to the available
clinical data, to assess whether this improved predictive ability. The author wished
to assess 7 biomarkers and CMV IgG status in the second tool. For this reason, a
maximum of 9 clinical data variables were permitted in the first tool, and 17 in the
second.
5.3.4 Identification of candidate independent variables
The design of the original analysis plan pre-dated the publication of the
prognostic model work by Schandl and colleagues (Schandl et al., 2013). This
selection of candidate clinical variables therefore followed a pragmatic approach. It
was hypothesised that physical outcome at 3 months might be predicted by pre¬
existing characteristics, characteristics of critical illness, duration of critical illness,
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evidence of the physical consequences of critical illness at ICU discharge, and
inflammatory biomarker concentrations at ICU discharge. Clinical data available at
ICU discharge were evaluated, looking for variables that represented each of these
potential contributing factors.
5.3.4.1 Pre-illness characteristics
FCI and age were included in the original analysis plan. In the modified
model, social deprivation category was also included to take into account the
association found between education level and functional outcome in Schandl's
study (Schandl, 2013). Although social deprivation category and education level are
not the same thing, social deprivation is one of the strongest predictors of
educational attainment and is therefore a valuable surrogate (Perry & Francis, 2010).
In chapter 4, it was found that latent CMV infection was associated with
higher concentrations of pro-inflammatory mediators, poorer mobility, and reduced
muscle strength (Schandl, 2013). CMV IgG was therefore included as an
independent variable. Another variable, worst sequential organ failure score (SOFA
score) was initially considered. Although this variable was included in the original
analysis plan, due to a protocol change, it was not actually recorded as part of the
RECOVER dataset and was excluded.
Diagnosis was not considered in the original model due to the limitations
placed by the proposed sample size. Flowever due to the increase in the final
sample size, and the loss of the worst SOFA variable, diagnosis of sepsis was tested
in the revised model to reflect the importance placed on sepsis as a cause of reduced
function described by Iwashyna et al (Iwashyna et al., 2010). A surrogate indicator
of sepsis was derived from the available data using the following method. ICU
admission diagnoses were obtained from the Scottish Intensive Care Society Audit
Group codes obtained at study baseline. Codes associated with infection (e.g. septic
shock - respiratory) were grouped into the binary categorical variable 'infection'.
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5.3.4.2 Evidence of the detrimental effects of critical illness at ICU discharge
Physical function at ICU discharge was assessed by means of the Rivermead
mobility index (described in detail in section 3.10.1) and was included in the
proposed analysis. Another physical assessment carried out at this timepoint was
the physical examination component of the Subjective Global Assessment tool
(SGA). This SGA was originally described in the late 1980s and is a validated tool
for assessing nutritional status (Lawson et al., 2013). The physical component of
SGA was included in the RECOVER study as a screening tool for the physical
affects of protein malnutrition. Although not included in the initial proposal, due to
the limitations imposed by the projected sample size, this is one of the additional
variables tested in the modified model due to the larger actual sample size.
5.3.4.3 Biomarkers of inflammation and inflammatory resolution
A prognostic model was built and assessed initially using the 8 variables
described in the first 3 sections. Following this, a further model was built by adding
7 biomarkers of inflammation, and CMV IgG status.
These variables were CRP (section 3.9.1), IL-6 (section 3.8.4), IL-8 (section
3.9.6), TGF beta (section 3.8.8), MPO (section 3.8.3), neutrophil TINE (section 3.8.2)
and SLPI (section 3.8.7). Their use as markers of inflammation and inflammatory
resolution has been justified in the indicated sections.
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Table 5-2 - details of the proposed and revised independent variables.
5.3.5 Outcome variable
The primary outcome measure was Rivermead Mobility Index (RMI)
discussed in detail in section 3.10.1. RMI is a 15 point scale consisting of 14
functional questions and 1 direct observation (see also appendix C).
5.3.6 Choice of regression technique
The choice of technique for deriving a prognostic model is determined by
the characteristics of the data to be modelled, the sample size, and the desired ease
of use of the final prognostic tool. Binary outcomes such as mortality can be
modelled using linear regression techniques. However, because the outcome can
only take 2 levels (e.g. alive or dead), the resulting models are difficult to interpret.
Logistic regression models circumvent this issue by converting the outcome into the
Togit' - the natural logarithm of the odds of an outcome. The linear relationship
between a particular variable and the logit is then modelled. An additional benefit
is the derivation of odds ratios to describe the influence of particular variables.
Odds ratios are conceptually easier to interpret clinically. As alluded to in the
introduction, because logistic regression relies on probabilities, if the event rate is
very low, or the number of modeled variables is high resulting in a low EBV,
logistic regression models become biased. Therefore for small samples, linear
models are preferable if the data will support it.
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Linear outcome variables are best modelled using linear regression
techniques. Linear regression is not subject to the same issues relating to sample
size and event rates that logistic regression suffers from. Therefore, a greater
number of independent variables can be tested.
The Rivermead Mobility Index (RMI) was the chosen outcome measure for
this study. The RMI is a categorical variable with 15 levels and therefore does not
lend itself to either a logistic regression or a linear regression technique. The
potential options were to dichotomize RMI into good and poor categories as was
carried out in 3.14.4 and apply logistic regression. However, given the loss of
power that would result from this categorisation and the reduction in the permitted
number of independent variables, a linear regression approach was adopted. This
approach is considered acceptable practice provided that the data meet the model
assumptions imposed by a linear regression technique.
5.3.7 Choice of independent variable selection method
Various automatic variable selection methods have been proposed to reduce
a list of candidate variables into a smaller number of variables in multivariable
model. Generally speaking, their use is discouraged, particularly when
investigating the effects of known or suspected confounding factors in risk factor
analysis. However, the development of a prognostic model is one situation where
variable selection methods can be useful. Reducing the number of variables in a
model can be useful to reduce the complexity of a prognostic score and by doing so
increasing the likelihood that the model will be used in clinical practice.
All automatic variable selection techniques include or exclude independent
variables depending on various pre-set statistical conditions. Two examples of
automatic variable selection techniques are forward selection, and backward
selection. In forward selection, the model starts with no variables in it. Bivariate
associations are tested and the variable that is most significantly associated with the
outcome variable is included first provided it meets a pre-specified level of
significance. Following this the variable that has the greatest association with the
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outcome variable taking into account the effects of the first variable is entered into
the model. Again, entry of the second variable depends on it reaching a pre-
specified level of significance. The process continues until there are no more
variables that have a significant association with the outcome variable.
Backward selection starts from the position of having all variables in the
model. Variables that have significance levels above a pre-specified value are
assessed. The variable that has the weakest association with the outcome variable is
then removed from the model. This process continues until none of the included
variables have a significance level above the pre-specified value.
Variable selection methods do not always end up drawing the same
conclusions and consistency of results between methods has been used as an
indicator of model strength. The forward method tends to produce more restrictive
models with fewer variables. The backward selection technique is considered to be
more inclusive. For this reason a backward selection technique was chosen for use
in this study. This differs from the stepwise technique originally proposed.
5.3.8 Conduct of the multivariable regression
Having defined a list of candidate variables for inclusion in the
multivariable linear regression model, bivariate relationships with RMI were
assessed. Variables with a p value of less than 0.25 were taken forward for
assessment in the multivariable models. The first multivariable model tested only
the non-serological variables using data readily available at ICU discharge.
Following this, any biomarkers considered significant on bivariate testing were
added to those tested in the first model to determine whether the addition of
biomarkers to the model could increase its prognostic significance.
As discussed in section 6.3.6, variable selection was carried out using
backward selection with a p value for removal of 0.1.
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5.3.9 Checking model assumptions
The reliability of a linear regression model depends on the extent to which
the data meets the assumptions of the chosen technique. Accepted linear regression
model assumptions are:
1. The relationship between the independent variables combined in the linear
regression equation and the outcome variable is linear in nature.
2. The regression equation defines the mean value of the outcome variable for a
set of independent variables.
3. Predicted values of the outcome variable are normally distributed around
the regression line.
4. The variance around the regression line is the same for each independent
variable.
5. The independent variables included in the model are not related to each
other.
5.3.9.1 Linearity
To assess linearity within the fitted model, residual analysis was undertaken.
A residual is the distance between the mean value of the regression equation and
the observed value of the outcome variable. The standardised residual is the
residual divided by the standard error of the residual. To test the assumption of
linearity, standardised residuals were plotted against each of the independent
variables and the predicted value of the outcome variable. Linearity was assumed if
the spread of residual values was similar at all levels of each independent variable.
5.3.9.2 Normal distribution ofpredicted values of the outcome variable
around the regression line
Q-Q plots and histograms were used to assess normal distribution of the
data points of the residuals around the regression line. Q-Q plots present quantiles
of a theoretical normal distribution for a variable against the observed data points.
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Normal distribution can be assumed if the coordinates of the Q-Q plot closely fit (or
'hug') the reference line.
5.3.9.3 Equal variance
Equal variance was assessed from the plots of the standardised residuals
against predicted outcome. Equal variance was assumed if the spread of the
residuals was even above and below zero.
5.3.9.4 Collinearity
Collinearity was assessed using a scatter plot matrix, and calculating the
correlation coefficients. If the correlation coefficient between 2 variables exceeded
0.7, collinearity would be suspected. The effect on the model standard error of
including the 2 variables to the other variables in the model will be observed. If
there is no increase in standard error, the impact of any colinearity was assumed to
be negligible and both variables were included in the model. If significant effects on
the model were detected, only one of the variables was included.
5.3.10 Analysis of outlying and potentially influential data points
Plots of standardised residuals against case number were used to identify
potential outliers. Any residuals exceeding 2 standard deviations were examined to
check for errors in data entry. Leverage values were calculated and any values
greater than 3(p+l/n) (where p = number of variables in the model including the
constant and n = number of subjects in the sample) were examined as potential
influential data points. To test the actual effects of potentially influential data points,
Cook's distances were calculated. Any points with a Cook's distance greater than 1
were considered influential.
5.3.11 Assessing goodness of fit
As a method for comparing regression models, goodness of fit was
compared by use of the R2 statistic. The R2 statistic is a measure of how much of the
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observed behaviour of an outcome variable is explained by the regression equation.
An R2 statistic is a numeric value ranging from 0 to 1. A value of 0 indicates that
none of the observed behaviour can be explained by the regression equation
indicating that it is of no value. A value of 1 indicates a perfect fit - where all the
behaviour is explained by the regression equation. A value of 0.5 indicates that half
of the behaviour is explained by the regression equation. To provide some context
from intensive care research, the APACHE 2 score had an R2 value of 0.319 (Knaus,
Draper, Wagner, & Zimmerman, 1985).
5.3.12 Assessing the clinical utility of the linear regression model
One potential application of a prognostic index is the prediction of ICU
survivors that will have very good functional outcomes regardless of intervention.
Complex rehabilitation interventions for these patients may be expensive,
unnecessary, and an unwanted burden. To assess the potential clinical impact of
the prediction tools, a group of patients deemed to have 'good' outcomes was
defined. The current practice for triaging patients to rehabilitation within NHS
Lothian was identified. Following this, the performance of each index was
compared to current practice.
5.3.12.1 Identifying patients with good outcomes
The RMI describes the full range of physical disability describing patients
with minimal functional limitation right through to patients who are entirely bed
bound. Patients scoring less than 4 are likely to be bed bound. Patients scoring less
than 6 are unlikely to be able to stand and are limited to bed and chair. Patients
scoring less than 8 are unlikely to be able to walk with our without an aid. Patients
scoring less than 10 are likely to be limited in function to such an extent that they
are unlikely to be able to function independently. Patients with an RMI above 10
whilst possibly exhibiting deficits in physical function are likely to be able to
function independently in their home environment provided climbing stairs is not a
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pre-requisite. For the current analysis, patients who had returned to independence,
defined by an RMI of greater than 10 were considered to have a 'good' outcome.
5.3.12.2 Identifying current practice for triaging patients to rehabilitation
The physiotherapy department at NHS Lothian was contacted, and
information regarding rehabilitation triage was discussed. Current practice within
NHS Lothian is to determine through history taking a patients prior level of
function. When a patient's function differs significantly from normal, they are
considered to require rehabilitation. Because there is no formalised mechanism for
making this assessment the reality is that all ICU patients are seen in ICU before
they leave and are subsequently followed up on the ward. In the RECOVER trial,
this process was formalised so that in the intervention arm, treatments were
triggered based on an assessment of prior function, and a patient's deviation from
this normal.
In essence, an assessment of function at ICU discharge is used as to predict
function 3 months later. For this reason, RMI at ICU discharge was used as a
surrogate for current practice and compared with the derived prognostic indices.
5.3.12.3 Comparing triage methods
Observed RMI at 3 months was dichotomised according the threshold score
of 10 to identify 2 groups of patients - those with good outcomes, and those with
poor outcomes. Receiver operating characteristic (ROC) curves were constructed
using RMI at ICU discharge (current practice), and each of the derived prognostic
indices. Prognostic accuracy was determined by calculating the area under the
curve (AUC) for each of the ROC curves. AUC is equal to the probability that in
individual with a particular condition of interest (in this case good functional
outcome) has a higher (or lower) value of a measurement than an individual
without (Altman & Bland, 1994)
For any diagnostic test, a trade off must be made between sensitivity and
specificity. Sensitivity is defined as proportion of true positives (those identified by
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the test who actually have the condition of interest) that are identified by the test.
Specificity is the proportion of true negatives (those identified by the test as not
having the condition who actually do not have the condition of interest).
The author was interested in identifying patients with particularly good
outcome - those patients in whom rehabilitation may be less important. To
accurately identify these patients, a test with good sensitivity was required. To
prevent exclusion of patients in whom rehabilitation might be beneficial, a high
level of specificity was required. To explore the potential utility of each model,
different cut-off values for each mode were selected according to pre-defined levels
of specificity (60%, 70%, 80%). Cut-off values were determined using the coordinate
points on the ROC curves. The sensitivity achievable at these cut-offs was assessed.
Using cut-off values corresponding to a specificity of 80%, pre-test and post-
test probabilities for a negative and positive test result were compared for different
triage methods. Pre-test probability was defined as the prevalence of good physical
recovery (proportion of patients with RMI<10). Post-test probability was calculated
using likelihood ratios (Deeks & Altman, 2004).
5.4 Results
5.4.1 Bivariate relationships of candidate predictive variables with RMI
A summary of bivariate relationships between RMI and each of the
candidate independent variables is presented in Table 5-3. The clinical variables
significantly associated with RMI at a p value of less than 0.25 were age, FCI,
ventilator days and baseline RMI. These were taken forward for assessment in the
first multivariable model. The serological markers associated with RMI at a p value
of less than 0.25 were CMV IgG status, CRP, and SLPI. These were added to the
variables considered in the first model to assess whether a model with greater
predictive accuracy could be derived using serological markers in addition to
clinical variables.




SIMD Quintile 0.08 0.63
CMV IgG status -0.79 0.12
APACHE 2 -0.02 0.56
Ventilator days -0.05 0.02
Diagnosis of Sepsis -0.40 0.39
Baseline RMI -0.33 0.00








Table 5-3 Bivariate relationship of candidate baseline variables with RMI. Variables
taken forward for consideration in the multivariable models are shaded.
5.4.2 Multivariable analysis testing baseline clinical variables only
The results of the multivariable analysis using a backwards variable
selection technique (as proposed in the modified analysis plan) including age, FCI,
baseline RMI, and ventilator days are presented in Table . Ventilator days, baseline
RMI, and FCI were significantly associated with RMI at 3 months and were
included in the final model (Model 1)
Variable Beta coefficient Significance
Constant 12.444 -
Ventilator Days -0.047 0.02
Baseline RMI 0.301 0.00
FCI -0.231 0.03
Table 5-4 Results of the multivariable model using clinical data only (Model 1)
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5.4.3 Multivariable model testing clinical variables and serological markers
Interestingly, the serological markers (CRP, SLPI, and CMV IgG status) that
had p values below the inclusion threshold on bivariate testing were not associated
with RMI at 3 months when the confounding effects of the clinical data were taken
into account. The model yielded a multivariable model was identical to that
produced in section 5.4.3.
5.4.4 Testing linear regression model assumptions for Model 1
On an initial assessment of the data, it was noted that the outcome variable
RMI was very severely skewed. This is illustrated in Figure 5-1. As a result, there
was considerable concern that the model produced in section 5.4.2 might not be











RMI at 3 months
10 15
Figure 5-1 Distribution of RMI at 3 months
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5.4.4.1 Linearity
Plots of standardised residuals of the regression equation against the
included independent variables and the predicted value of the regression equation
are shown in the figures below. The spread of residuals is consistent across all
levels of ventilator days and FCI. However, the spread of residuals is inconsistent
across levels of baseline RMI, suggesting non-linearity in the relationship between
RMI at baseline and RMI at 3 months. Furthermore, the graph depicting residuals
plotted against the predicted value of the regression equation is extremely abnormal
suggesting that the relationship between the independent variables combined in the
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Figure 5-4 Standardised residuals of Model 1 plotted against FCI
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Predicted value from the regression equation of Model 1
Figure 5-5 Standardised residuals of Model 1 plotted against the value predicted by
the regression equation
5.4.4.2 Normal distribution around the regression line
The Q-Q plot and histogram of the residuals of model 1 are presented below.
This plots demonstrate that the residuals deviate significantly from a normal
distribution - hence violating the assumption of normal distribution of predicted
values around the regression line.
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Residuals of Model 1




The residual plots in section 5.3.9.1 show that the spread of residuals above
and below zero is not equal for any of the independent variables suggesting a
violation of the assumption of equal variance in the model.
5.4.4.4 Collinearity
The scatter plot matrix and correlation coefficients for the independent
variables included in Model 1 are presented below. There was no collinearity
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Figure 5-8 Scatter plot matrix for Model 1 independent variables (rmiO = Baseline
RMI; fcitot = FCI; ventdays = Days of mechanical ventilation).
Ventilator Days FCI Baseline RMI
Ventilator Days - -0.2 -0.1
FCI -0.2 - -0.0
Baseline RMI -0.1 -0.0 -
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Table 5-5 Correlation coefficients to assess colinearity of included variables in
Model 1.
5.4.4.5 Conclusions from linear model assumption testing of Model 1
The assumption testing carried out in this section demonstrated violations of
the assumptions of linearity, equal variance, and normal distribution of predicted
values around the regression line. For these reasons, it was considered that there
was a moderate to high risk that the estimation of coefficients was biased, and
therefore a possibility that important variables were not included or unimportant
variables had been included in Model 1.
Model 1 was therefore not considered further, and the analysis was repeated
after transformation of the severely negatively skewed outcome variable (RMI at 3
months), and the severely positively skewed independent variable (RMI at baseline).
5.4.5 Outlier assessment of model 1
Outlier analysis was not carried out for model 1 because the model violated
the assumptions of linear regression.
5.4.6 Transformations
The negatively skewed outcome variable RMI at 3 months was transformed
using a base 10 logarithm transformation of the inverted RMI score which is a
recognised method for normalising negatively skewed data. The formula for this
transformation is shown below. This transformed outcome variable was named
tRMI, and the improved normal distribution of this variable is illustrated in Figure
5-9.












.0 .2 .4 .6 8 1.0 1.2
Transformed 3 month RMI
Figure 5-9 Histogram showing frequency distribution of tRMI with an improvement in
normality after transformation.
This frequency distribution can be compared with the distribution of RMI
illustrated in Figure 5-1.
The positively skewed independent variable RMI at baseline was
transformed by adding 1 and then applying a base 10 logarithm transformation
which improved normality (Figure 5-10).
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Figure 5-10 Histogram of the transformed baseline RMI showing an improvement in
normal distribution
5.4.7 Bivariate relationships of candidate predictive variables with the
transformed RMI
A summary of the bivariate relationship of candidate predictive variables
and the transformed outcome variable tRMI are presented in Table 5-6. The clinical
variables age, FCI, SIMD quintile, LoglO(l+Baseline RMI), and physical component
of SGA and the serological variables CMV IgG status, CRP, and SLPI all had
significant associations with tRMI and were considered further as candidate
variables in the multivariable analysis.
Candidate variable Beta Coefficient P
Age 0.00 0.07
FCI 0.03 0.02
SIMD Quintile -0.03 0.06
CMV IgG status 0.09 0.09
APACHE 2 0.00 0.58
Ventilator days 0.00 0.17
Diagnosis of Sepsis 0.01 0.87
Log10(1+RMI) -0.37 0.00
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Table 5-6 Bivariate association between candidate predictive variables and the
transformed outcome variable tRMI. Shaded variables were tested in the
multivariable models.
5.4.8 Multivariable analysis using clinical variables only and the transformed
outcome variable tRMI - Model 2
In this analysis, age, FCI, SIMD quintile, ventilator days, loglO(l+RMI), and
physical component of the SGA were tested in the multivariable model. The results
are presented in Table 5-7. SIMD quintile, LoglO(l+Baseline RMI), and FCI were the
variables that met criteria for inclusion in the model using a backwards selection
technique and were included in the final model.




SIMD Quintile -0.030 0.08
Table 5-7 Results of the multivariable model using clinical data only and the
transformed variables - Model 2.
5.4.9 Multivariable analysis using clinical and serological variables and the
transformed outcome variable tRMI - Model 3.
In this analysis, CMV IgG status, CRP, and SLPI were added to the clinical
variable above and tested in another multivariable model. The results of this model
are presented in Table 5-8. The resulting model included Logio(l+RMI), FCI, and
SLPI concentration.






Table 5-8 Results of the multivariable model using clinical and serological variables
and the transformed outcome variable tRMI - Model 3
5.4.10 Testing linear regression model assumptions for Model 2
5.4.10.1 Linearity
Plots of standardised residuals of the regression equation against the
included independent variables and the predicted value of the regression equation
are shown in the figures below. The spread of residuals is reasonably consistent
across levels of the both the independent variables and the predicted outcome
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Figure 5-13 Standardised residuals of Model 2 plotted against SIMD quintile
210
i i I I
Predicted Value
Figure 5-14 Standardised residuals of Model 2 plotted against the value predicted
by the regression equation
5.4.10.2 Normal distribution around the regression line
The Q-Q plot of the residuals of Model 2 is presented in Figure 5-15. The
distribution much more closely represents a normal distribution than the Q-Q plot
of residuals for Model 1 (Figure 5-6). The histogram is shown in Figure 5-16. Both
of these indicate better adherence to the assumption of normal distribution of
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Figure 5-15 Q-Q plot illustrating the relationship of Model 2 residuals to a theoretical
normal distribution
Residuals of Model 2
Figure 5-16 Histogram of the residuals of Model 2 demonstrating normal distribution
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5.4.10.3 Equal variance
The residual plots in section 5.4.10.1 show that the spread of residuals above
and below zero is relatively equal suggesting adherence to the assumption of equal
variance in the model.
5.4.10.4 Collinearity
The scatter plot matrix and correlation coefficients for the independent
variables included in Model 2 are presented below. There was no evidence of
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Figure 5-17 Scatter plot matrix for Model 2 independent variables (fcitot = FCI;
tRMIbase = Log10(1+RMI at baseline)_; SIMD_2012_quintile = SIMD quintile)
FCI Log10 (1+RMI) SIMD Quintile
FCI - -0.0 -0.2
Log10 (1+RMI) -0.0 - -0.1
SIMD quinitile -0.2 -0.1 -
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Table 5-9 Correllation coefficients to assess colinearity in Model 2
5.4.10.5 Conclusions from linear model assumption testing of Model 2
Assumption testing of Model 2 suggested good adherence of Model 2 to the
assumptions of linear regression modelling. This model showed a significant
improvement on Model 1, supporting the use of the transformed outcome variable
tRMI, and the transformed baseline RMI as an independent variable. The author
had reasonable confidence in the accuracy of the coefficient estimates and variables
included in this model.
5.4.11 Outlier analysis of Model 2
Figure 5-18 is a plot of the standardised residuals for Model 2. Six of the
residuals fell outwith 2 standard deviations and were considered potential outliers.
The data for each variable was examined to help identify any data errors. No errors





I I I I I
0 50 100 150 200
Case Number
Figure 5-18 Standardised residuals of Model 2 plotted against case number
Leverage values were calculated to assess the potential impact on outlying
data points on the regression equation. Leverage values for Model 2 are plotted
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against case number in Figure 5-19. Only 1 outlier - case 25 was considered to be a
leverage point because it had a leverage value of greater than 3 ((p+l)/n). This case
represented an ICU survivor that had particularly high levels of previous
















Figure 5-19 Leverage values of Model 2 plotted against case number
Leverage points do not always have a significant impact on the fitting of the
regression line. To determine this, the effect of deleting each variable on model fit
can be assessed using the Cook's distance. Cook's distances greater than 1 were
considered to have a significant influence on the regression analysis. Cook's
distances for Model 2 are illustrated in Figure 5-20..
The Cook's distances were low. The outlier identified by the leverage values
was also the most influential data point in the analysis. However, the Cook's
distance of less than 1 indicated that this data point did not have a significant
















Figure 5-20 Cook's distances for Model 2
5.4.12 Testing linear regression model assumptions for Model 3
5.4.12.1 Linearity
Plots of standardised residuals of the regression equation against the
included independent variables and the predicted value of the regression equation
are shown in the figures below. The spread of residuals is reasonably consistent
across levels of the both the independent variables and the predicted outcome
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Figure 5-24 Standardised residuals of Model 3 plotted against the value predicted
by the regression equation
5.4.12.2 Normal distribution around the regression line
The Q-Q plot and histogram of the residuals of Model 2 are presented in
Figure 5-25 and Figure 5-26. As with model 2, the distribution closely represents a
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normal distribution. This indicates good adherence to the assumption of normal
distribution of predicted values around the regression line.
Standardised Residual for Model 3




























Figure 5-26 Q-Q plot illustrating relationship of Model 3 residuals to a theoretical
normal distribution
5.4.12.3 Equal variance
The residual plots in section 5.4.12.1 show that the spread of residuals above
and below zero is relatively equal suggesting adherence to the assumption of equal
variance in Model 3.
5.4.12.4 Collinearity
The scatter plot matrix and correlation coefficients for the independent
variables included in Model 3 are presented below. There was no evidence of













































Figure 5-27 Scatter plot matrix for independent variables in Model 3
FCI Log10 (1+RMI) SLPI
FCI - -0.0 -0.0
Log10 (1+RMI) -0.0 - -0.1
SLPI -0.0 -0.1 -
Table 5-10 Correlation coefficients for the assessment of collinearity in Model 3
5.4.12.5 Conclusions from linear model assumption testing for Model 3
Assumption testing of Model 3 suggested good adherence of Model 3 to the
assumptions of linear regression modelling.
5.4.13 Outlier analysis of Model 3
The scatter plot of standardised residuals against case number is shown in
Figure 5-28. Six of the residuals fell outwith 2 standard deviations and these are
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labelled in Figure 5-29. These data points were checked for errors in data entry and




























Figure 5-28 Standardised residuals of Model 3 plotted against case number
Leverage values were calculated for Model 3 and these are plotted against
case number in Figure . Six of the points were considered to be leverage points
because they have a value that was greater than 3 ((p+l)/n). The cases representing



















Figure 5-29 Leverage values for Model 3
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Cook's distances were calculated and these are plotted in Figure 5-30. There
were 2 outlying points. Neither of these were greater than 1. Therefore, none of the
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Figure 5-30 Cook's Distances for Model 3
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5.4.14 Assessment of model fit
R2 values for Models 2 and 3 alongside p values (calculated from the F
statistic) are presented in Table 5-11. The independent variables included in Model
2 account for 17.5% of the variation in the outcome variable tRMI. Model 3
improves on this slightly with an R2 value of 0.193 (accounting for 19.3% of the
variation). Both regression models were significantly better than chance for




Table 5-11 Goodness of fit assessment
5.4.15 Assessing the diagnostic accuracy of the linear regression models
As described in the methods, ROC curves were constructed using the
predicted values from the two regression equations and the binary outcome
variable 'Good Outcome'. Good outcome was defined as an observed RMI of
greater than 10 after an interval of 3 months after ICU discharge. The accuracy of
the 2 regression models created was compared using the area under curve (AUC)
statistics. Similarly, RMI measured at baseline (a surrogate of current practice) was
plotted against the binary outcome measure 'Good Outcome' and an AUC statistic
calculated to determine any improvement in prognostic accuracy over clinical
observation.
To recap, Model 1 was a linear regression model that did not meet the
assumptions of linear regression modelling and was therefore not considered
further. Model 2 was a linear regression model constructed using clinical variables
only. Model 3 was a linear regression model constructed testing clinical and
serological variables. In contrast to Model 1, Models 2 and 3 used transformed
variables to improve the compliance of the regression model with linear regression
modelling assumptions. Model 2 included the independent variables FCI,
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Logio(l+RMI), and SIMD quintile. Model 3 included the independent variables FCI,
Logio(l+RMI), and SLPI.
The ROC curves for Model 2 and 3, and for RMI at baseline are shown in the
figures below. The regression models have moderate accuracy in predicting the
rehabilitation outcome after 3 months and both are better than chance at doing so
(AUC of 0.76 and 0.73 respectively). The AUC for model 2 that incorporates clinical
variables (RMI, SIMD quintile, and FCI) is greater than that for model 3 that
substitutes SIMD quintile for SLPI, suggesting that the addition of a blood test did
not assist in mobility prediction. Furthermore, the use of RMI alone has an AUC
that is only slightly lower than that produced by Model 2 suggesting that a
structured clinical assessment may be an adequate triage tool in itself.
X - Specificity
Figure 5-31 ROC curve illustrating the accuracy with which regression model 2
predicts RMI >10 at 3 months. (AUC=0.759).
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1 - Specificity
Figure 5-32 ROC curve illustrating the accuracy with which regression model 3
predicts RMI >10 at 3 months. (AUC = 0.725).
1 - Specificity
Figure 5-33 ROC curve illustrating the accuracy with which RMI at baseline predicts
RMI >10 at 3 months (AUC = 0.734).
The sensitivity achieved for each triage tool at different cut-offs is show in
Table 5-12. Model 2 (clinical data only) outperforms Model 3 at all the cut-offs. At a
specificity of 80%, a sensitvity of 63.9% was achieved with this tool.
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Triage tool Cut-off Specificity Sensitivity
Model 2 0.54 60.4 78.5
0.49 71.0 69.4
0.46 80.6 63.9






Table 5-12 Sensitivity at different test cut-off values. *Given the small number of
data points for RMI; there was no available cut-off value on the RMI ROC plot that
corresponded to a specificity of 60%.
5.4.16 Assessing the clinical utility of the triage tools
Based on the above analysis, cut-off values corresponding to specifities of
80% were chosen, and the change in pre-test to post-test probability of having a RMI
at 3 months of greater than 10 was calculated to demonstrate the diagnostic utility
of each tool. In the absence of any previous work in this area, pre-test probability
was set as prevalence of RMI greater than 10 3 months after ICU discharge in the
reference population (0.82). Positive and negative post-test probabilities were


















Model 2 0.46 0.82 3.29 0.45 0.94 0.67
Model 3 0.39 0.82 2.22 0.69 0.91 0.76
RMi 2.5 0.82 3.08 0.50 0.93 0.70
Table 5-13 Results of Likelihood analysis for each triage method
A positive test result based on regression model 2 altered the probability of
having an RMI of greater 10 3 months after ICU discharge from 82% to 94%. This
was no better than could be achieved by measuring RMI at baseline alone (82% to
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93%). A negative test result based on regression model 3 had a poorer performance
still. Probability of a good functional outcome was increased from 82% to 91%.
Thus clinical prediction of good functional outcome was improved using a
structured assessment of mobility at ICU discharge. This probably reflects current
practice. The use of other baseline data including biomarker concentration does not
improve on this.
5.5 Discussion
The aim of this chapter was to identify risk factors for physical disability
after ICU discharge and incorporate them into an a predictive model In doing this, it
was hoped that a simple clinical tool could be created that could identify patients
that would see the greatest potential benefit from novel rehabilitation programmes.
The work was carried out using data from the RECOVER study database,
supplemented with the results of blood tests taken at the point of ICU discharge.
A review of the literature was carried out to identify risk factors for physical
disability after intensive care unit discharge and also to identify and appraise
previous attempts at predicting physical outcome. The aim of the review was to
identify potential candidate variables for use in a predictive score. The results of
this review have been summarised in the introduction to this chapter.
Very few studies have managed to identify these risk factors. Characteristics
related to severity of illness such as illness severity scores, organ failure, and ICU
length of stay are associated with physical outcome. However in previous studies,
these associations have not been evident after adjustment for confounding has been
incorporated into the analysis. There is a strong association between symptoms of
depression and physical recovery however a causal pathway has not been
confirmed. It is therefore not clear whether depressive symptoms prevent physical
recovery, or whether poor physical function leads to depression. In the previously
derived predictive score, education level, reduced core stability, at discharge,
fractures, and ICU length of stay were important predictors of ICU recovery.
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The selection of the candidate variables for the multivariable model was
informed by the literature review, the available data fields in the RECOVER trial
database, and the perceived practicalities of obtaining such data in a real life setting.
With a plethora of potential data fields available for inclusion in the model, it was
recognised that indiscriminately testing all available variables might result in the
identification of spurious associations that would weaken the final prognostic
model. An analysis plan was therefore designed in advance of receiving any data to
prevent this potential problem.
5.5.1 Which risk factors for post ICU physical immobility can be identified
from the RECOVER study baseline data?
This study adds to the understanding of risk factors for physical disability
after ICU discharge. Perhaps unsurprisingly, the level disability at the point of ICU
discharge is the most important risk factor. Patients with the lowest RMI scores at
ICU discharge are more likely to be the patients who have poor RMI scores 3
months later. In some respects, this finding is reassuring since in the current
healthcare model, at least in the UK, allocation of rehabilitation is likely to be
directed by the perceived needs of patients as determined by physical assessment.
Less reassuring is the finding that poor physical function at ICU discharge is not the
only predictor of functional outcome. This is important because currently patients
who are not considered to be the most severely disabled may be not be identified at
ICU discharge and may therefore miss out on potential beneficial rehabilitation
interventions.
Patient characteristics that precede ICU admission are of particular
importance. This study has shown that functional comorbidity (as measured by the
FCI), and social deprivation category (as measured by SIMD quintile) are significant
risk factors for post-ICU physical disability.
High scores on the FCI are likely to indicate patients who have struggled
with physical disability prior to ICU admission, and potentially may have less
rehabilitation potential in terms of improvement of physical function. Despite this,
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FCI seems to be associated with poor outcome irrespective of the observed
functional deficits seen at ICU discharge. It is therefore feasible that the
accumulation of comorbidities described by the FCI could be important in
preventing full recovery after critical illness. For patients with pre-existing
disability, small changes in function could lead to a big change in quality of life. For
example a change in an RMI score of just 2 points could mean the difference
between being unable to stand to being able to walk with an aid around the house.
Social deprivation category was included in the analysis as a surrogate for
education level, a variable that had been found in a previous study to be associated
with poor physical recovery. Patients living in more deprived areas of Edinburgh
had more significant levels of physical disability after 3 months. This suggests that
regardless of comorbidities, duration of illness, and level of function at ICU
discharge, deprivation has a significant role to play in the recovery of ICU survivors.
The reasons for this association are likely to be multifactorial and the analysis is
likely to have omitted important potential confounders such as smoking status and
diet.
In keeping with previous studies of risk factors, traditional measures of
severity of illness were not significantly associated with disability. Duration of
illness as measured by days of mechanical ventilation did show an association on
bivariate testing. However after adjustment for FCI, baseline RMI and SIMD
quintiles, these factors were not significantly associated with RMI at 3 months.
With regard to disease-specific risk factors, sepsis was singled out as a
potential risk factor for post ICU disability, based on the literature. In the current
study, a diagnosis of sepsis as defined by consensus diagnostic criteria was not
recorded. The presence or absence of the admission diagnosis of 'infection' did not
make any difference to physical outcome. Whilst there were problems with the
definition in this study that may limit its generalisability to other populations, the
lack of any association between a diagnosis of an admission diagnosis of infection
and post-ICU disability makes it unlikely that septic patients are at increased risk of
long-term disability compared to other ICU survivors.
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A number of other factors were considered for inclusion in the multivariable
models but were not found to be significant independent risk factors for disability.
Age was one such factor. An association was suggested on bivariate testing, with
increasing age being associated with poorer function 3 months after ICU discharge.
This association was not evident when adjusted for prior comorbidity, ICU length of
stay, and baseline RMI. This suggests that the relationship between age and
disability is confounded by at least one of these other factors. This too is an
important finding. Firstly, triaging patients into rehabilitation pathways based on
age is unlikely to identify those most at need. Secondly, it strengthens the argument
that treatment limitation decisions, and access to critical care should not be
informed by the chronological age of the patient.
Another factor that was considered was the physical component of the
subjective global assessment score - a surrogate marker of nutritional status. This
test is simple and quick to carry out but has not previously been validated in an ICU
survivor cohort. Interestingly there was a trend towards poorer functional outcome
with greater scores on the SGA physical examination. One potential explanation for
this is the challenge of carrying out this assessment on patients that have significant
oedema - a feature of many patients recovering from critical illness.
5.5.2 Risk factors for physical disability after 3 months - the role of
inflammatory biomarkers
In chapter 3, a significant association as found between RMI and CRP
concentration in a cross sectional analysis at a time point 3 months after ICU
discharge. This supported the hypothesis that inflammation and physical function
are related. One possible explanation for this finding is that inflammatory
persistence after ICU discharge hampers physical recovery in some way. It is
further hypothesised that the active process of inflammatory resolution might be
dysfunctional in some patients, making them more likely to have persistence of the
inflammatory response, and therefore make them more at risk of physical disability.
It therefore seemed feasible that patterns of inflammatory molecules measured at
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ICU discharge might be able to extra information to a clinical parameter based
prediction tool and improve its performance.
A number of markers of the inflammation, inflammatory resolution, and
chronic inflammation were measured at ICU discharge and their relationship with
physical disability 3 months after ICU discharge was tested. Higher CRP
concentration at ICU discharge was associated with physical disability at 3 months
although the associated p value was 0.1. This association was no longer evident
when adjusted for ICU length of stay, FCI, baseline RMI, and SIMD quintile.
Higher serum concentration of SLPI was significantly associated with increased
levels of physical disability 3 months after ICU discharge and remained significant
after adjustment for confounders.
5.5.3 Can physical disability be predicted using clinical data available at ICU
discharge?
A rigorous prognostic model development procedure was carried out in
order to make best use of the available data to predict physical outcome after ICU
discharge. A linear regression technique was used for reasons of statistical power.
Transformation of the outcome variable and one of the independent variables was
necessary to satisfy the assumptions of the regression technique. Using clinical
variables alone, FCI, baseline RMI, and SIMD quintile were significantly associated
with RMI 3 months after ICU discharge. These variables were combined in a
regression equation that performed well statistically as a predictor of post-ICU
recovery. Furthermore, the regression model included 2 variables that represented
characteristics of the patient prior to ICU admission, and a physical assessment at
the time of ICU discharge that fitted well with factors hypothesised to be important
during the study design stages.
To test the clinical utility of the tool, a potential application was explored. It
was considered important to be able to distinguish patients that had particularly
good outcomes (who may have good outcomes regardless of intervention) from
patients who had poor outcomes and would require rehabilitation. A RMI cut-off
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was defined, and the outcome variable was dichotomised according to this cut-off.
ROC analysis was then carried out to determine the prognostic accuracy of the
regression equation in differentiating 'good' from 'bad' outcome. Again,
statistically, the model performed well and moderately good accuracy (assessed by
AUC which was 0.76). On the basis that current rehabilitation triage practices are
essentially an assessment of immobility at ICU discharge, analogous analyses were
carried out using RMI at ICU discharge at a triage tool. The ROC curve and
likelihood ratio analyse suggested that RMI alone provided as much prognostic
information as the triage tool based on the regression model.
In summary, there is evidence from this study that both comorbidity
preceding critical illness, social class, and physical function at ICU discharge are
important determinants of subsequent physical recovery. Despite this, assessment
of physical disability at the point of ICU discharge emerges as the most important
factor. The data suggest that very few (if any) patients would be miss-identified if
social class or FCI were not known.
5.5.4 Can prediction of physical outcomes be improved by the addition of
markers of inflammation and inflammatory resolution measured at ICU
discharge?
Previous chapters of this thesis have suggested that both inflammation and
CMV IgG status might be important variables in post-ICU physical recovery. It was
therefore considered perceivable that both these factors might be useful in
predicting physical recovery after ICU discharge.
If either of these factors significantly improved prognostic ability, a blood
test at the point of ICU discharge might be justified. However, if the additional
prognostic information is limited, an additional blood test might become a burden.
For this reason, prediction tools were developed sequentially. Firstly, the tool
described above including only clinical variables was developed. Following this,
biomarker data and CMV IgG status were incorporated.
233
Only SLPI, CMV IgG and CRP met statistical criteria for consideration in the
regression model. Only SLPI was retained in the model after inclusion of clinical
variables and this was at the expense of SIMD quintile. This regression model
explained slightly more of the variation in the outcome variable than the model
containing only clinical variables as determined by a slightly higher R2 statistic.
However, the ROC curve and likelihood ratio analyses suggested that clinically, the
tool was inferior to both the clinical predictive model, and RMI measured at ICU
discharge.
There was therefore little to support the addition of biomarker
measurements, or CMV IgG titre to clinical data when assessing patients for
rehabilitation especially given the extra cost and burden to patients that additional
blood testing might impose.
5.5.5 Further Reflection
. The current study has suggested a number of risk factors identified at ICU
discharge that were associated with poor physical mobility 3 months later. These
were current level of function, previous comorbidity, and social class. The
identification of these risk factors supports the assertions made by other studies that
pre-morbid function and level of education influences physical outcome, regardless
of the level of function at the time of the assessment.
Whilst these findings are interesting, several points of caution relating to
study design and conduct should be emphasised. Firstly, the analysis was an
opportunistic use of data from the RECOVER trial database. The baseline data
fields were originally chosen by the trial steering group to allow comparison of
baseline characteristics between the 2 arms of the RCT. For this reason the variables
available for consideration in the multivariable models were limited by the design
of the RECOVER study. Despite this, careful literature review, and consideration of
biologically plausible risk factors for on-going disability after ICU suggest that most
of the important known confounders were included. In some cases (diagnosis of
sepsis, education level) compromises had to be made and these may have
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influenced the analysis. On balance, it would appear that attempts to control for
known confounders are likely to have been adequate. However, as in all
observational studies, this does not rule out the impact of unknown confounders.
Secondly, it should be emphasised that the associations observed within this
cohort can only be generalised to patients who are similar to the patients in the
current sample. These were general ICU patients who were ventilated for longer
than 48 hours who by definition stayed longer in ICU, and had more significant
degrees of organ failure than general adult ICU patients as a whole.
Thirdly, it should be remembered that this analysis was based on an
interventional study aiming to improve physical outcome through a coordinated in-
hospital rehabilitation package. Whilst the allocation to control or intervention was
randomised, and outcome assessment was blinded, it is possible that within this
setting both control and intervention patients received care that was better than the
ward standard. Indeed a significant majority of patients had 'good' and many
patients, regardless of randomisation, had maximum RMI scores at the 3 month
follow up visit.
This point raises 2 issues. Firstly, that physical outcome may have been
influenced by participation in the trial, leading to bias. Secondly, the sensitivity of
the outcome measure RMI was likely to be affected by the 'ceiling effect' of the
outcome measure. This issue was certainly apparent statistically and required
transformation of the data to make it suitable for linear regression modelling.
With regard to the development of the clinical prediction tools, significant
effort was made to ensure that the regression models were statistically robust.
There was therefore confidence that the regression equations were better than
chance at predicting outcome but no better than an assessment of mobility at ICU
discharge. The explanation for this is probably a simple one. Disability observed at
ICU discharge is likely to the major determinant of recovery and whilst statistically
significant, the clinical importance of the other components of the score is small.
It was disappointing that biomarker concentrations were of little clinical
utility in predicting post-ICU recovery. None of the pro-inflammatory molecules
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measured at ICU discharge had significant bivariate associations with RMI at 3
months. CRP did have show a weak association that lacked statistical significance
on bivariate testing but after adjustment in the model this relationship was
weakened further.
Of note, elevated levels of SLPI were significantly associated with RMI at 3
months and this relationship remained important even after adjustment for baseline
function. This would tend to support the hypothesis generated in chapter 3 that
suggested that inflammatory resolution, and particularly serum concentrations of
substances that dampen down and neutralise systemic inflammation might be
important in the pathogenesis of delayed recovery from critical illness.
It is possible that a shift of focus away from serum concentrations of pro¬
inflammatory markers to substances critical to inflammatory resolution might give
clues to the inflammatory fate of patients, and by extension, their ability to recover
physical function.
An important point to note, and one that has not been addressed by this
study is the concept of rehabilitation potential. Current practice in the NHS, at least
in Lothian is to triage patients by making an assessment of the degree to which
function at ICU discharge differs from the normal function for an individual patient.
Patients assessed, as having significantly poorer function than normal would be
considered to have a rehabilitation requirement. This is a sensible approach. It
would be completely unrealistic to expect a patient with severe pre-existing
disability to return to near normal function after an episode of critical illness.
Conversely, patients with minor degrees of disability may have life changing
decrements in their quality of life.
The regression models in the current study worked on the assumption that a
low score on the RMI scale represented a poor outcome for an individual. In fact,
low RMI scores at 3 months may actually represent a return to normal function that
would be considered a favourable outcome. This is a significant limitation of the
work. It should be remembered therefore that the regression models produced are
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robust in predicting absolute levels of function after ICU discharge, but not
rehabilitation potential or favourable outcome for individual patients.
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Chapter 6 - Overall conclusions and future avenues
6.1 Prevalence of systemic inflammation after critical illness
The systematic review reported in chapter 2 presents all available data
relating to inflammatory markers in the post-ICU period. Whilst many studies
reported high proportions of patients with elevated markers at ICU discharge, there
were no studies of patients at or beyond hospital discharge.
The observational work presented in chapter 3 of this thesis confirms that
the majority of patients surviving critical illness have biochemical evidence of
systemic inflammation at ICU and hospital discharge and that many have on-going
inflammation 3 months after ICU discharge.
The causes and consequences of this long lasting inflammatory process are
yet to be fully appreciated. As a potentially relevant risk factor for post-ICU
morbidity, it provides a long duration of exposure, and is also a potential avenue for
pharmacological intervention in the future. Despite the previous failures in
immunomodulation in the acute phase of critical illness, it is possible that
addressing the redundant immune activation in the recovery phase might have
greater impact.
The limitations imposed by the observational nature of the study design
were extensively discussed in chapter 3, and to some extent in chapter 2. These
issues make it difficult to attribute critical illness as the cause of the observed
elevations in inflammatory markers, particularly at the later time point. It is
possible that many of the patients with raised inflammatory markers had similar
elevations prior to the acute illness. The post hoc analyses carried out in this study
does not suggest this, but in patients it almost certainly plays a part.
Future studies of this issue are likely to be challenging and would require
and epidemiological population based approach. Identification of inflammation in
ICU patients before they become unwell is awkward and data from animal studies
is difficult to extrapolate to human critical illness. A compromise would be an
observational study that rigorously identified and excluded patients with chronic
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diseases or conditions known to cause elevations in inflammatory markers.
Unfortunately such a study could be similarly criticised for not addressing the
'unknown' causes of systemic inflammation in healthy adults that may make them
more susceptible to critical illness.
6.2 Association between inflammation recovery from critical
illness
Biochemical markers of inflammation measured 3 months after ICU
discharge have a significant association with physical comorbidity but not
psychological comorbidity after critical illness.
This conclusion was drawn from the cross sectional analysis carried out 3
months after ICU discharge and reported in chapter 3. As noted in the systemic
review in chapter 2, no previous studies have examined the association between
physical recovery and post-ICU inflammation and this work therefore represents
the first report of this finding.
Whilst the current work has demonstrated that inflammation and recovery
are inter-related in this population, it is not yet clear whether inflammation hampers
physical recovery, or whether recovering damaged muscles are in themselves an
inflammatory focus. Before attention turns towards therapy, this issue must be
resolved.
Two potential future avenues of research might clarify this issue. Firstly, an
experimental approach employing animal models of critical illness might allow the
study of subjects without a prior inflammatory lesion. A previous study of sterile
and bacterial lung injury in mice has shown accelerated inflammatory resolution
and improvement in organ failure using drugs that target inflammatory cell
apoptosis (Lucas et al., 2013). Experimental manipulation of the inflammatory
response during recovery from critical illness in mice might allow the longitudinal
study of muscle function in mass under different inflammatory conditions.
A second potential avenue is to make attempts to localise inflammatory foci
in patients recovering from critical illness. This would help clarify the role of the
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muscle as source, or target of systemic inflammation in these patients. Recent
advances in magnetic resonance imaging (MRI) may permit this line of enquiry. A
clinically available MRI contrast agents contains ultra-small super-paramagnetic
particles of iron oxide (USPIO) that when administered systemically are engulfed by
macrophages and are then transported to sites of inflammation. Subsequent MRI
imaging can then identify these sites. This technology has been employed in the
prediction of aortic aneurysm growth by the uptake of USPIO, and studies of the
myocardium following acute myocardial infarction but it may also be possible to
identify sites of inflammation in recovering skeletal muscle (Alam et al., 2012;
Richards et al., 2011).
6.3 CMV infection and its role in post-ICU inflammation and
recovery from critical illness
The majority of ICU patients show serological evidence of prior CMV
infection at ICU discharge, reflecting the known background prevalence of CMV
latency. It is known from previous studies that during critical illness, CMV
reactivation occurs in up to 38% of CMV IgG positive patients. In the current study,
11% of IgG positive patients were found to have active infection (reactivated CMV)
at ICU discharge, and none had evidence of on-going viral replication at 3 months
after ICU discharge.
The low rates of CMV reactivation detected in this study might reflect a
lower incidence of critical illness induced reactivation in the study population. A
more logical explanation is that by ICU discharge, a much later sampling point than
previous studies, human immune responses have brought any CMV infection under
control in the majority of patients. This is a reassuring finding because it would
suggest that despite potentially high rates of viral reactivation, in those that survive
to ICU discharge CMV infection does not persist. This may explain why previous
studies have failed to demonstrate any effect of CMV reactivation on mortality in
ICU patients. Certainly it would suggest that intervening with antiviral therapy (e.g.
Gancyclovir) in the post-ICU period would be unlikely to confer any advantage.
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In the current study, patients previously exposed to CMV were very similar
to unexposed patients. Despite this, there were some clinically relevant differences
in how they responded to critical illness. These patients were more immobile, and
had increased rates of delirium at ICU discharge. Most notably, they stayed in
hospital nearly twice as long after ICU discharge as patients with no evidence of
previous CMV exposure. Whilst the potential for a unrecognised confounder of the
relationship between CMV IgG status and post-ICU length of stay cannot be ruled
out, based on the baseline data studied, it is likely that this relationship is real.
The impact of CMV latency on systemic inflammation confirms the findings
of previous studies. Patients who have previously been exposed to CMV infection
have a different inflammatory marker profile compared to unexposed patients
during recovery from critical illness. They had higher concentrations of circulating
pro-inflammatory cytokines and granular neutrophil products. Furthermore, they
have lower concentrations of TGF beta 1, a substance important for inflammatory
resolution.
The clinical significance of these biochemical differences requires further
elucidation. Statistically significant differences in physical outcome measures were
observed between IgG positive and IgG negative ICU survivors supporting the
hypothesis that CMV latency has important clinical effects.
The relevance of CMV reactivation was more difficult to establish in this
study. The small number of patients identified at ICU discharge with CMV
reactivation meant that comparisons of inflammatory markers and clinical outcomes
were statistically underpowered. Furthermore, it is reasonably likely that a
proportion of patients who had experienced CMV reactivation were not detected
due to the late sampling time point. This group of 'misclassified' patients are likely
to have further undermined the analysis.
Patients identified as having CMV reactivation had a more severe illness.
They stayed longer in ICU and were weaker and more immobile at ICU discharge.
They also stayed much longer in hospital after ICU discharge. Very little difference
was noted between concentrations of inflammatory markers and there was no
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difference in measures of physical or psychological comorbidity, or quality of life in
patients with CMV reactivation.
In conclusion, CMV latency is likely to be important factor in inflammatory
resolution in ICU survivors. It may also impact on physical recovery. This study
has not fully addressed whether CMV reactivation is also relevant.
This study was an opportunistic exploratory study and as such was not
designed to fully characterise CMV disease in ICU patients and its impact on post-
ICU recovery. Further observational study is required to establish the natural
history of CMV reactivation in critical illness, its effects on inflammatory resolution,
and its impact on post-ICU recovery.
6.4 Prediction of functional outcome after ICU discharge
This thesis describes the most rigorous exploration of the ability of clinical
and biochemical variables to predict functional outcome in the months following
ICU discharge carried out to date. Despite a number of methodological limitations,
the presence of pre-existing comorbidity, and social class appear to be important
risk factors for post-ICU disability. Both of these factors are difficult to modify.
Interestingly age was not associated with poor outcome.
The most important predictor of post-ICU disability was the level of function
observed in patients at the point of ICU discharge. Rivermead mobility index
measured at ICU discharge was so important that the other significant covariates
added little to RMI used on its own as a means of identifying patients likely to
regain independence in the months following critical illness.
The regression models produced showed reasonable accuracy. However,
the R2 values for the regression equations were modest at best suggesting that there
were many unmeasured factors at play.
The current study was an opportunistic use of trial data in combination with
biomarker data collected during an ancillary study. To fully explore risk factors for
poor functional outcome after intensive care further observational studies are
required. Any future study will need to consider a much more targeted panel of
242
exploratory variables. Furthermore, the insensitivity of the RMI and its distribution
were major limitation of the work. More sensitive outcome measures may allow a
better characterisation of the key events.
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CINAHL Plus 1 ((((((((MH "Intensive Care Units"))) OR (((MH "Critical
Care"))) OR (((MH "Critical Illness"))) OR (((MH
"Respiratory Care Unit"))) OR (("critical care")) OR
(("intensive care")) OR (ICU) OR (ITU) OR (("critical
illness")) OR (("critically ill")))) AND (((CRP) OR (("C-
reactive protein")) OR (SIRS) OR (("Systemic
Inflammatory Response Syndrome")) OR (Interleukin*)
OR (tnf*) OR (("tumour necrosis factor")) OR
(((MH"lnterleukin 1") OR (MH "Interleukins"))) OR (((MH
"Tumor Necrosis Factor"))) OR (((MH "Inflammation")))




1 Topic =(CRP* OR ""C-reactive protein" OR Interleukin*
OR IL1 * OR IL6 OR IL8 OR TNF* OR SIRS OR
"Systemic Inflammatory Response Syndrome") OR
Title==(CRP* OR ""C-reactive protein" OR Interleukin*
OR IL1* OR IL6 OR IL8 OR TNF* OR SIRS OR
"Systemic Inflammatory Response Syndrome")
2 Topic=(lntensive care OR critical care OR ICU or ITU or
Critical illness OR critically ill) OR Title=(lntensive care
OR critical care OR ICU or ITU or Critical illness OR
critically ill)
3 1 AND 2
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Appendix B: Example data request for Systematic Review
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David Griffith. RoomW2.03
MRC Centre for Inflammation Research
Queen's Medical Research Institute
University of Edinburgh
47 Little France Crescent
Edinburgh, EH16 4TJ, Scotland, UK
Tel: (44) 131 242 6662
Fax: (44) 131 242 6578
email: d.qriffith(anhs.net
Dr N Al-Subai
General Intensive Care Unit
St George's Hospital, London
SW17 OQT
UK
n a Isubaieta g mail.com
2 November 2012
Dear Dr Al-Subai,
Request for further information in relation to your study:
Al-Subai et al C-reactive protein as a predictor of outcome after discharge from the
intensive care: a prospective observational study. BJA. 2010 September 105(3):318-25
Background information
Our research group is pursuing several research avenues exploring the role of
persistent inflammation in survivors of critical illness, and relating this to physical
recovery. We are currently undertaking a large randomized controlled trial testing a
complex rehabilitation intervention on physical outcomes after critical illness (RECOVER
study) and as part of this, we are exploring the role of inflammation in preventing
physical recovery. In addition we are conducting smaller clinical study (DIGRESS)
examining immune cell dysfunction in critical illness survivors (see links below).
We are also undertaking a systematic review of the literature to answer the following
questions:
1. What is the prevalence of systemic inflammation in survivors of critical illness?
2. What is the relationship between systemic inflammation in survivors of critical illness
and markers of physical recovery?
We wish to collate the available data from the literature in order to provide evidence of
an ongoing inflammatory process in ICU survivors, and where possible, to relate this to
markers of physical recovery.
We are particularly interested in the values of inflammatory parameters at the following
time points:
1. The point of ICU discharge
2. The period between ICU discharge and hospital discharge.
3. After hospital discharge.
Our request
Our request
In your study, you recorded CRP concentration in survivors of critical illness at the point
of ICU discharge. You present these data as median (IQR) for your 2 groups of interest.
We are interested in absolute values of CRP for those patients surviving to ICU
discharge so that we can evaluate variability of the results, and calculate the proportion
of patients who have ongoing systemic inflammation at the point of ICU discharge.
1. What were the absolute values of CRP concentration for your ICU survivors?
2. If you cannot provide absolute values, are you able to provide us with the following
summary data?
a) The mean (with standard deviation) and/or median (with interquartile range)
for CRP in those patients (combining both of your groups of interest) at the
point of ICU discharge.
b) How many patients had a CRP >5mg/L at the point of ICU discharge?
c) How many patients had a CRP >10mg/L at the point of ICU discharge?
We would be very grateful if you could fill in the form attached and where relevant,
send us the requested data.
If you are unable to help
Even if you are unable to provide data, we are interested to know the reason for this.
We would be extremely grateful if you could respond by filling in and returning in the
attached form indicating whether or not you are able to help and giving reasons if this
is not possible.
Thanks for helping us with our study.
Yours Sincerely
Dr David Griffith Prof Adriano Rossi Prof Timothy Walsh
Further information:
Our research group:












































Appendix D: The Rivermead Mobility Index
Ask the patient each question. Observe for question 5. Score 1 for 'yes', 0 for 'no'.




Can you turn over from your back to your side
without help?
Lying to sitting From lying in bed, do you get up to sit on the
edge of the bed on your own?
Sitting balance Do you sit on the edge of your bed without
holding on for 10 seconds?
Sitting to standing Do you stand up from any chair in less than 15
seconds and stand there for 15 seconds, using




Observe standing for 10 seconds without any aid
Transfer Do you manage to move from bed to chair and
back without any help?
Walking in side
(with and aid if
necessary)
Do you walk 10 meters, with an aid if necessary,
but with no standby help?
Stairs Do you manage a flight of stairs without help?
Walking outside
(even ground)




Do you walk 10 meters inside, with no caliper,
splint, or other aid (including furniture or walls)
without help?
Picking up off floor Do you manage to walk five meters, pick




Do you walk over uneven ground (grass, gravel,
snow, ice etc) without help?
Bathing Do you get into/out of a bath or shower and wash
yourself unsupervised and without help?
Up and down four
steps
Do you manage to go up and down four steps
with no rail, but using an aid if necessary?
Running Do you run 10 metres without limping in fours
seconds (fast walk, not limping, is acceptable)?
TOTAL
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Appendix E: Hand grip strength population norms
MALE FEMALE
Age Right Left Right Left
20-29 47(9.5) 45(8.8) 30(7) 28(6.1)
30-39 47(9.7) 47(9.8) 31(6.4) 29(6)
40-49 47(9.5) 45(9.3) 29(5.7) 28(5.7)
50-59 45(8.4) 43(8.3) 28(6.3) 26(5.7)
60-69 40(8.3) 38(8.0) 24(5.3) 23(5)
70 + 33(7.8) 27.2 (3.9) 20(5.8) 19(5.5)
Age and gender stratified hand grip strength in kilograms (Massy-Westropp et al.,
2011)
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AppendixG:Davidson'sTraumaScale
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Appendix H: SF-12v2
- This survey asks for your views about your health. This information will keep track of how
you feel and how well you are able to do your usual activities. For each of the answers, please
mark an X in the one box that best describes your answer.





Good □ Fair □ Poor □
2. The following questions are about activities you might do during a typical day.
Does your health now limit you in these activities? If so, how much?
a. Moderate activities, such as moving a table, pushing a vaccum cleaner,
bowling, or playing golf:
Yes, limited a
iota Yes, limited a little □
b. Climbing several flights of stairs:
Yes, limited a v ,. .. . ...., „
I t q Yes, limited a little □
No, not limited at all □
No, not limited at all □
3. During the past 4 weeks, how much of the time have you had any of the following
problems with your work or other regular daily activities as a result of your physical health?






















4. During the past 4 weeks, how much of the time have you had any of the following
problems with your work or other regular daily activities as a result of any emotional
problems (such as feeling anxious or depressed)?























5. During the past 4 weeks, how much did pain interfere with your normal work
(including both work outside the home and housework)?
otatal|N A little bit □ Moderately Quite a bit Extremely
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Edinburgh Critical Care Trials Group
University of Edinburgh
6th August 2013
Cc. Tim Walsh, Julia Boyd, Ashma Krishan
Enc. Analysis plan including data request.
Dear Steff,
I am writing to request data from the RECOVER trial database to undertake
analysis of the RECOVER biomarker study titled 'Persisting Inflammation
following critical illness: prevalence, relationship to physical recovery, and
exploration of defects in inflammatory resolution pathways'.
I enclose a detailed request and analysis plan for the study. This serves as a
justification for the database fields requested.
I understand that at this stage, 12-month follow up is not complete and the
study has not been reported. I therefore do not request trial group allocations
at this time. I am keen to perform additional analysis using this data after
RECOVER has concluded and will send a further request for data at this time.
Please contact me if you have any queries regarding this data request
Yours sincerely,
Dr David Griffith
Research Fellow in Critical Care
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ANALYSIS PLAN - RECOVER BIOMARKER STUDY
Author: David Griffith.
Date: 6th August 2013
Brief Description of Study
The RECOVER study is a randomised controlled trial testing the hypothesis
that a complex rehabilitation intervention can improve physical outcome in
survivors of critical illness. To investigate the role of persistent systemic
inflammation in recovery from critical illness, a blood sampling sub study was
incorporated into the trial design. Blood samples were taken at ICU
discharge, weekly whilst patients were in hospital, and then at the 3-month
follow up point. Blood was analysed for a panel of inflammatory biomarkers
and markers of inflammatory resolution. As a further analysis, patients were
screened for reactivation of cytomegalovirus (CMV) to determine whether
active CMV infection inhibits inflammatory resolution and therefore physical
recovery.
The a priori analysis plan is described in the following sections. Further
explorative analysis will be carried out depending on the findings of this
analysis. Requested data fields can be found in section 14.
1. Description of the study sample
2. Prevalence of systemic inflammation in ICU survivors
3. Characterisation of the inflammatory and inflammatory resolution
profile during recovery from critical illness
4. Physical and psychological outcomes of ICU survivors
5. Association of systemic inflammation with indices of physical and
psychological recovery
6. Evidence of previous CMV exposure and active CMV infection
7. Investigation of factors associated with evidence of CMV reactivation at
ICU discharge
8. Duration of CMV infection
9. Association of prior CMV exposure / active infection and inflammatory
resolution
10. Association of prior CMV exposure / active infection and indices of
physical and psychological recovery
11. Prediction of physical recovery using clinical information available at
ICU discharge
12. Addition of inflammatory biomarkers to clinical information to predict
physical recovery after critical illness
13. Further notes on regression models
14. Requested data
1. Description of study sample
Details of study recruitment and follow-up will be provided in a flow diagram
(figure 1). Baseline characteristics of recruited patients will be presented.
Baseline variable that will be included will be:
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• Age (mean (SD))
• Gender (M/F (%F))
• Functional comorbidity index (mean (SD))
• Functional comorbidity index subcategories (n (%))
• ICU admission diagnosis (n (%))
• APACHE II score (mean (SD))
• ICU LOS (mean (SD))
• Hospital LOS in days (mean (SD))
• Ventilator days (mean (SD))
• Inotropes at any time (n(%))
• Days of inotropes (median (IQR))
• RRT at any time (n(%))
• Days on RRT (mean (SD))
• Worst SOFA score (median (IQR))
• SOFA subcategories (median
(IQR))
• CAM ICU positive (n(%))
• RMI at randomisation (median (IQR))
4
Z




Reasons why no sampling
at 3 months
Reasons why no follow
up at 6 months
4
Figure 1 - study flow
Number of patients
followed up at 6 months
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To allow assessment of selection and attrition bias, comparison will be made
with patients that declined consent, and those that were lost to follow up.
2. Prevalence of systemic inflammation in ICU survivors
In health CRP concentration rarely rises above 3mg/L even in elderly cohorts.
In a young adult cohort, a CRP concentration of greater than 10mg/L
represents the 99th centile, and 3mg/L the 90th centile. Persistent
inflammation as therefore defined according to these 2 definitions. The
following time points of interest are arbitrarily defined:
• ICU discharge (study entry)
• Closest sample to hospital discharge (variable time after ICU
discharge)
• Community sample (3 month follow up visit)
The number and proportion of surviving patients with evidence of systemic
inflammation for the 3mg/L and 10mg/L threshold at each of these time points
(CRP >3mg/ L or >10mg/L) will be reported.
3. Characterisation of the inflammatory and inflammatory resolution profile
during recovery from critical illness
Blood markers of systemic inflammation and inflammatory resolution (CRP,
IL1 beta, IL6, IL8, C3A, C4A, C5A, MPO, elastase, TGF beta and SLPI), will
be reported at 2 time points - ICU admission and at the 3 month follow up
period. Serum concentrations of all biomarkers are anticipated to be non-
parametric in distribution and will be presented as median (IQR). Serum CRP
concentration will also be reported at an additional time point (hospital
discharge).
For patients surviving to the 3 month follow up visit, CRP concentration will
also be measured at each in-hospital sampling point. Median values of CRP
with interquartile ranges will be presented as a line chart to depict the
inflammatory resolution trajectory.
4. Physical and psychological outcomes of ICU survivors
Physical and psychological outcome measures will be presented for the whole
cohort at both 3 months and 6 months.
Mobility: Rivermead mobility index will be reported as median (IQR).
Hand strength: Using age and gender stratified population norms, handgrip
strength (HGS) measurements will be converted into percentage predicted
HGS and reported as mean (SD). In addition, 3 outcome groups will be
identified to identify patients with particularly poor physical recovery. Patients
with a HGS that falls more than 2 standard deviations below mean predicted
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HGS for age and gender will be considered 'very weak*. Patients with HGS
between 1 and 2 standard deviations below the predicted HGS will be
considered 'weak'. All other patients will be considered 'normal'. The number
and proportions of patients falling into these categories will be reported.
Quality of Life: Total, physical component and mental component scores of
the Medical Outcomes Study Short Form 12 (SF-12) will be presented as
median (IQR).
Anxiety and Depression: Total Hospital Anxiety and Depression Scale
(HADS) will be reported as median (IQR). Patients scoring more that 8 points
on the anxiety component will be considered to have a positive screening test
for anxiety. The same threshold will be used for the depression component.
The number and percentage of patients with a positive screening test for
anxiety or depression will be reported.
Post-traumatic stress disorder: Davidson's trauma scale (DTS) will be
reported as median (IQR). PTSD will be defined as DTS > 40. Number and
percentage of patients with PTSD will be reported.
Falls risk: Number of seconds take to complete the timed up and go (TUG)
test will be reported as median (IQR).
5. Association of systemic inflammation with indices of physical and
psychological recovery
A cross-sectional analysis of CRP concentration at indices of physical
recovery at 3 months will be performed. Scatter plots will be drawn
representing the relationships between CRP concentration and the outcome
measures detailed in section 5. Pearson's correlation coefficients will be
reported with p values. Kendall's tau-b correlation coefficients will be
calculated for non-parametric correlation.
In addition, to explore the association of systemic inflammation and diagnostic
subgroups (depression, anxiety, and PTSD) and patients with particularly poor
physical recovery (lower quartile of RMI, weak HGS category), CRP
concentration will be reported in binary groups and presented as boxplots.
Comparisons will be made with Wilcoxon rank-sum tests.
6. Evidence of previous CMV exposure and CMV reactivation
The number and percentage of patients with previous CMV exposure will be
reported. Previous CMV exposure will be defined as a positive test for CMV
IgG antibody at ICU discharge.
The number and percentage of patients with evidence of CMV reactivation will
be reported. CMV reactivation will be defined as the number of patients with
previous CMV exposure that have detectable CMV DNA in plasma at ICU
discharge.
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7. Investigation of factors associated with evidence of CMV reactivation at
ICU discharge
Baseline data will be presented for each patient with evidence of CMV
reactivation at ICU discharge. Comparison will be made with patients that do
not have evidence of CMV infection at this time.
8. Duration of CMV infection
In those patients who have evidence of CMV infection at ICU discharge, the
number and percentage of patients of those patients that still have CMV DNA
in plasma at 3 months will be reported.
9. Association of prior CMV exposure I CMV reactivation and inflammatory
Box plots of CRP concentration at 3 months grouped according to previous
CMV exposure and active CMV infection will be presented. In addition the
median (IQR) for these comparisons will be reported. The results of Wilcoxon
rank-sum tests will be reported for each of the 2 comparisons.
10. Association of prior CMV exposure / CMV reactivation and indices of
physical and psychological recovery
The outcome measures described in section 4 will be compared according to
previous CMV exposure group. In addition the outcome measures will be
compared according to CMV reactivation group.
Box plots for each comparison will be presented and comparisons will be
performed using Wilcoxon rank-sum tests.
11. Prediction of physical recovery using clinical information available at ICU
discharge
Linear regression analysis (bivariate) will be carried out using RMI as a
continuous outcome variable. Factors considered potentially important in
predicting physical outcome are age, pre-existing frailty, severe and
prolonged illness, multiple organ failures, and physical function at ICU
discharge. The following 6 variables will therefore be tested:
• Age
• Functional comorbidity index
• APACHE 2 score
• Worst SOFA score in ICU
• Length of stay in ICU
• Rivermead mobility index at baseline
resolution
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Variables with predictive potential (p<0.25 on bivariate testing) will be entered
into a multivariable linear regression model using a stepwise approach. Non¬
significant variable (p >0.1) will be discarded from the final model.
12. Addition of inflammatory biomarkers to clinical information to predict
physical recovery after critical illness
A further 8 variables will be subjected to bivariate testing. These variables
represent markers of persistent inflammation and inflammatory resolution.
Variables with predictive potential (p < 0.25 on bivariate testing) will be
entered into a multivariable linear regression model using a stepwise
approach. Non-significant variables (p > 0.1) will be discarded from the final
model.








13. Further notes on regression models
Power It is anticipated that 150 patients will have complete follow up for this
analysis. A maximum of 15 variables (10 variables per case) will be
permitted.
Model assumptions All linear model assumptions will be tested. Collinearity of
variables will be tested by correlation prior to model fitting. Where collinearity
is detected (correlation coefficient > 0.7), only one of the collinear variables
will be tested in the regression model.
14. Requested data fields
Details of blood sampling
Date of randomisation
Date of follow up visit
Date of ICU discharge
Consent to blood sampling (yes/no)
Baseline sample taken (yes/no)
Reason if baseline sample not taken
Survival to 3 month follow up visit (yes/no)
Date of death
Follow up completed at 3 months (yes/no)
Reason if no follow up at 3 months
Follow up blood sample taken (yes/no)
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Reason if no follow up blood sample
Survival to 6 month follow up (yes/no)
Follow up completed at 6 months (yes/no)








ICU length of stay
Hospital length of stay
Ventilator days
Inotropes at any time (yes/no)
Days of inotropes
Renal replacement therapy at any time (yes/no)
Days on renal replacement therapy
Worst SOFA score (and worst score in each category)
CAM ICU score at randomisation
Rivermead mobility index at randomisation
Handgrip strength at 1 week after randomisation (first HGS)
In hospital




SF-12 - total score, PCS, and MCS
HADS score - total score, depression score, anxiety score
DTS - total score
Timed up and Go
6 months
RMI
SF-12 - total score, PCS, and MCS
HADS score - total score, depression score, anxiety score
DTS - total score
Signed: Page 8 of 8
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